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ABSTRACT 
Experimental autoimmune thyroiditis (EAT) can be induced in mice after 
challenge with thyroglobulin (Tg) in complete Freund's adjuvant (CFA). EAT 
resembles Hashimoto's thyroiditis (HT) in humans and is characterized by 
mononuclear cell infiltration of the thyroid gland leading to hypothyroidism. 
In the first part of this study, we attempted to delineate pathogenic Tg 
peptides that encompass dominant epitopes in order to study immunoregulation 
mechanisms in EAT. Since susceptibility to EAT is under the control of H-2Ak 
genes, we utilized an algorithm-based approach that predicts peptides with Ak-
binding potential. Five Tg peptides were found to induce EAT in CBA/J (H-2k) 
mice. In addition, all five peptides were immunogenic at the T cell level and 
induced production of IL-2 and IFN-y by peptide-primed LNCs. Although none 
of these Tg peptides encompass dominant epitopes, they will allow us to study 
mechanisms involved in the immunoregulation of EAT. Furthermore, one of the 
five new Tg peptides (a.a. 2596-2608), was pathogenic in H-2k strains of diverse 
non-H-2 background but not in mice of q, s, d, and b haplotypes. The above 
findings provide important information regarding the influence of H-2 and non-
H-2 genes in the thyroiditogenic potential of the Tg peptides. 
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In the second part of this study, we showed that TNF-a-treated, semi-
mature DCs pulsed with Tg, but not with OVA antigen suppressed Tg-induced 
EAT in CBA mice, through the induction of Tg-specific CD4+CD25+ T cells. 
These CD4+CD25+ Treg cells produce high levels of IL-10 and inhibit the 
proliferation of Tg-specific effector cells in vitro. Suppression was shown to be 
cytokine-independent but cell-cell contact dependent. Additionally, adoptive 
transfer of the CD4+CD25+ Treg cells into CBA hosts suppressed Tg-induced EAT 
confirming the suppressogenic potential of this cell subset. The induction of 
antigen-specific Treg cells will contribute to understand the mechanisms 
involved in the immunoregulation of autoimmune diseases. 
Finally, we describe the generation of transgenic mice specific for the p2496 
pathogenic Tg epitope. The a and~ chain of a p2496-specific l-As-restricted T cell 
hybridoma were identified and inserted into TCR expression vectors. Linearized 
fragments containing the a and ~ chain genes and the constant chain regions 
were injected into fertilized oocytes of (SJLxC57BL6) mice and integration of the 
transgene was monitored by PCR. The p2496-specific TCR transgenic mice will 
provide an excellent source of p2496-specific naive T cells that will be used to 
answer questions on the maintenance of self tolerance. In addition it allow the 
study of parameters that lead to activation of the autoractive T cells and initiation 
of EAT. 
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CHAPTERl 
INTRODUCTION 
1.1 The thyroid gland 
·The thyroid gland is located in the neck and secretes hormones necessary 
for growth and proper metabolism. The thyroid gland consists of two lobes 
joined together by the isthmus and is organized into spherical cyst-like structures 
called follicles. The thyroid follicle is the primary unit of the gland in terms of 
structure and function. It consists of a lumen surrounded by a single monolayer 
of epithelial cells (follicular cells) and is enclosed by a thin basal membrane. The 
lumen is filled with a viscous solution, the colloid, that contains a mixture of 
proteins, mainly thyroglobulin (Tg), which is the precursor of thyroid hormones, 
as well as other lower molecular weight proteins and albumin (DeGroot 1984). 
The basic function of the thyroid is the production of two hormones, 
thyroxine (T4) and triiodothyronine (T3). Abnormalities of thyroid hormone 
production and release result in thyroid disorders. Thus, excessive or insufficient 
release of thyroid hormones leads to the pathological conditions of 
hyperthyroidism and hypothyroidism, respectively. 
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1.2 Autoimmune thyroid disease 
Diseases in which the pathology is caused by immune responses to self 
antigens are called autoimmune. They are classified as systemic or organ-specific 
depending on the distribution of the antigen to which the autoimmune response 
is directed. Autoimmune thyroid disorders (AITD) belong to the second 
clasification because the immune response is directed against the antigens within 
the thyroid. The AITDs include: Hashimoto's thyroiditis (HT), Graves' disease 
(GD), post-partum thyroiditis, idiopathic myxoedema and atrophic asyptomatic 
thyroiditis (Volpe 1991). Since the present study focuses on the experimental 
autoimmune thyroiditis (EAT), the murine model of HT in humans, I will briefly 
discuss the general features of the disease in man. 
1.3 Hashimoto's Thyroiditis 
HT is the most common of the various forms of AITDs, affecting people of 
all ages and both sexes. HT appears more frequently in women of age 40-60 (9-25 
times higher) than in men of the same age group (Tunbridge et al. 
1977;Vanderpump et al. 1995). In terms of histopathology, the disease is 
characterized by the presence of inflammatory cells (lymphocytes, plasma cells 
and macrophages) within the thyroid gland, distorted follicles, and fibrosis 
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(Volpe 1991). Germinal centers are also present, similar to those observed in 
secondary lymphoid organs (mainly accumulation of B cells). Thyroid follicles 
become necrotic and large-size mitochondria are accumulated (Volpe 1991). 
Among the intrathyroidallymphocytes, both CD4+ and CDS+ T cell populations 
have been observed (Canonica et al. 1984); In some studies, immune complexes 
formed between Tg and its Abs were demonstrated around the basement 
membrane of the follicular cells (Kalderon and Bogaars 1977). Finally, the 
intrathyroidal cytokine expression profile in HT revealed expression of a mixed 
Th1 and Th2 response (Ajjan et al. 1996;Paschke et al. 1994). Antibodies against 
Tg (anti-Tg) and against TPO (anti-TPO) have been demonstrated in the sera of 
HT patients by a variety of methods (Weetman and McGregor 1984). However, 
the antibody levels do not always correlate with the thyroid pathology, since 
several patients with HT have been found with no circulatory anti-Tg antibodies 
(Baker, Jr. et al. 1988). In addition anti-Tg antibodies have been detected in 38% 
of healthy individuals (Kohno et al. 1988). 
1.4 Thyroid antigens 
1.4.1 Thyroglobulin (Tg) 
Tg is a large (660-kDa) homodimeric glycoprotein that serves as a 
prohormone for the synthesis of T4 and T3. It is composed of two identical 
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subunits, 330-kDa each, joined together through disulfide bonds. Tg is the most 
abundant protein of the thyroid gland, comprising the bulk of the follicular 
colloid as well as a part of the thyroid's intracellular material. It is not a 
sequestered antigen since it is present in the circulation with an average 
concentration of 5, 10 and 133 ng/ml in humans, mice and rats respectively 
(Carayanniotis and Rao 1997). 
In humans, the Tg gene has been localized in the long arm of the 
chromosome 8 (Brocas et al. 1985), in mice on chromosome 15 (Taylor and Rowe 
1987), whereas in rats on chromosome 7 (Brocas et al. 1985). The complete 
primary eDNA sequences of human (Malthiery and Lissitzky 1987;van de Graaf 
et al. 1997;van de Graaf et al. 2001), mouse (Caturegli et al. 1997;Kim et al. 1998), 
rat (Musti et al. 1986) and bovine (Mercken et al. 1985) Tg have been deduced 
from their respective mRNAs. Partial sequences of the goat (Van Ommen et al. 
1989) and rabbit (Dunn et al. 1987) Tg have also been published. Among these 
species there is a >70% homology in the primary a.a. sequence (Carayanniotis 
and Rao 1997) with a high degree of conservative substitutions (Malthiery and 
Lissitzky 1987;Mercken et al. 1985). Specifically, the first 1177 residues of hTg, 
comprise of a domain repeated 10 times. Another domain of 14 to 17 residues 
occurs three times between residues 1417 and 1464 and another repetitive 
domain occurs five times between residues 1584 and 2167 (Malthiery and 
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Lissitzky 1987). The C-terminus of the molecule shows no repetitive domains but 
is homologous to acetylcholinesterase (Malthiery and Lissitzky 1987). 
Tg is synthesized on rough endoplasmic reticulum by thyroid follicular 
cells. It is subsequently transported to the Golgi apparatus where it undergoes 
several post-translational modifications such as glycosylation, sulfation, and 
phosphorylation, (Consiglio et al. 1987;Herzog 1986;Malthiery and Lissitzky 
1987). Finally the molecule is secreted into the follicular lumen for iodination and 
storage. Tg has 140 tyrosyl residues of which about 40 can be iodinated and 7 are 
hormonogenic sites: 4 major designated A-D and 3 minor designated as G, N, 
and R (de Vijlder and Den Hartog 1998;Lamas et al. 1989). The iodine content of 
Tg in vivo varies depending on the iodine intake by the thyroid, the species and 
the physiological condition. In most mammals, it ranges from 0.2 to 1% per 
molecule, which corresponds to 10-50 atoms of iodine per 660-KDa dimer. The 
normal physiological range of Tg-iodine content in humans is 0.25-0.5% per 
molecule (Charreire 1989). 
Thyroid hormone synthesis and secretion follows a multistep cascade. 
Transport of iodide (I-) into the thyroid is the first step, which is catalyzed by the 
sodium-iodide symporter (Na+ji- S) (Carrasco 1993). In the next step TPO, 
oxidizes I- and intramolecular coupling of iodinated tyrosine residues results in 
the formation of monoiodotyrosine (MIT) and diiodotyrosine (DIT) (Dunn et al. 
20 
1983). Iodinated Tg is then phagocytosed by thyrocytes and proteolysed to yield 
thyroxine (T4) and triiodothyronine (T3) which are released into the extracellular 
fluid (Dunn 1995). Synthesis and release of thyroid hormones is basically under 
the control of thyroid stimulating hormone (TSH), secreted by the anterior 
pituitary (Van Heuverswyn et al. 1985). 
Tg undergoes other post-translational modifications such as glycosylation, 
phosphorylation and sulfation (Charreire 1989;Spiro and Bhoyroo 1988). Tg is 
also highly glycosylated with carbohydrate moieties making up ~ 10% of its mass 
(Charreire 1989). A variety of biological roles have been attributed to 
oligosaccharides i.e. they have been shown to affect iodination and hormone 
synthesis. The role of sulfate residues in the physiological function of Tg is not 
known. 
1.4.2 Other thyroid antigens 
TPO is involved in two important steps in the biosynthesis of the thyroid 
hormones: iodination of Tyr residues on Tg, and intramolecular coupling of 
iodotyrosines, leading to the formation of T3 and T4. TPO is a transmembrane 
glycoprotein, of 107 kDa in size and 933 a.a. in length, that is expressed on the 
cell surface (apical membrane) of the thyrocytes. It is encoded by a gene on 
chromosome 2 and 12 in man and mouse, respectively (Kimura et al. 1987;Kotani 
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et al. 1993). The TPO expression is regulated by TSH and involves cyclic AMP 
production. 
Several functions of the thyroid cells are regulated by the binding of the 
TSH to its receptor (TSH-R). The deduced 764 amino acid sequence of the TSH-R 
showed that is a G-protein-coupled receptor (Nagayama et al. 1989). The first 415 
amino acids encode a large extracellular domain while the remaining 349 
constitute the 7-transmembrane domain and the intacellular cytoplasmic tail 
(Misrahi et al. 1990). 
The TSH-R is the major autoantigen in GD, where autoantibodies against 
the receptor compete with TSH for binding and stimulate cAMP production 
(Vassart and Dumont 1992). That activates the thyrocytes continuously and leads 
to excess of thyroid hormone production and hyperthyroidism. 
1.5 Animal models of EAT 
Animal models have been extensively used to address questions on the 
mechanisms involved in EAT pathogenesis. The mouse model provides a system 
whereby both the immunologic and pathogenic features of thyroid disease can 
be studied. Mice can be manipulated by experimental procedures that cannot be 
employed in humans such as thymectomy, thyroidectomy or adoptive transfer of 
cells or serum. Finally inbred mouse strains allow the use of large numbers of 
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virtually identical animals, leading to valid statistical analysis. Both spontaneous 
and induced experimental models exist for HT, and their features will be 
described in the following paragraphs. 
1.5.1 Spontaneous animal models of thyroiditis 
Spontaneous autoimmune thyroiditis (SAT) has been reported in Obese strain 
(OS) chicken, non-obese diabetic (NOD) mice as well as in Bio-breeding (BB) and 
buffalo (BUF) rats (Charreire 1989). A few of the studies performed on these 
spontaneous thyroiditis models are described below. 
The best studied spontaneous model of thyroiditis that closely resembles the 
human autoimmune disorder, in clinical, histopathological endocrinological and 
immunological aspects, is the OS chicken (Wicket al. 1982). The thyroids of OS 
chickens exhibit mononuclear cell infiltration, and the presence of germinal 
centres after 3 weeks of age (Wicket al. 1974). More than 90% of OS chickens 
have antibodies to thyroid antigens including Tg (>65% ), TPO and thyroid 
hormones (26%) (Wicket al. 1971). 
The NOD mouse model exhibits lymphocytic infiltration of both Langerhans 
islets and thyroid within the 1st and 2nd month of life (Many et al. 1996). The 
incidence and severity of the disease were shown to be age-dependent and to 
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vary from colony to colony, from about 18% to> 77% (Bernard et al. 1992). 
Thyroiditis and autoantibodies to TPO develop in 35% of the mice but the Ab are 
not reactive to Tg. Recently a NOD MHC congenic strain (designated as NOD.H-
2h4) was developed that expresses I-Ak on the NOD background (Braley-Mullen 
et al. 1999). Thyroiditis developed in 60-70% of 7-10 month old mice drinking 
normal water, and developed in 100% of mice upon receiving Nal in their 
drinking water (Braley-Mullen et al. 1999;Rasooly et al. 1996). 
Two spontaneous models of autoimmune thyroiditis have been described in 
rats. The first one was identified by Hajdu and Rona, who observed that inbred 
Buffalo male rats at 36 weeks of age exhibited spontaneous histopathological 
changes of their thyroids comparable to those of HT (Hajdu and Rona 1969). 
Thyroid pathology was similar to that observed in OS chickens. Further studies 
indicated that the thyroid damage of BUF rats was associated with elevated and 
decreased levels of TSH and T4 respectively (Kieffer et al. 1978;Silverman and 
Rose 1971). A second spontaneous model of autoimmune thyroiditis in rats is the 
Bio-breeding/Worcester (BB/W) model. Lymphocytic infiltration of the thyroid is 
observed at the age of 8-10 months in both sexes and in almost 60% of the 
animals (Stemthal et al. 1981). However the serum levels of T3, T4 and TSH in 
BB/W rats were found to be at normal values suggesting that thyroid infiltration 
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by mononuclear cells is not extensive enough to result in thyroid failure 
(Stemthal et al. 1981). 
1.5.2 Induced models of autoimmune thyroiditis 
EAT was first described in 1956, by Witebsky and Rose (Rose and 
Witebsky 1956;Witebsky and Rose 1956). They challenged rabbits intradermally 
with homologous thyroid extract in CF A and the animals developed a 
mononuclear cell infiltration of the thyroid gland as well as autoantibody 
production. EAT was later induced, in a variety of animal species such as guinea 
pigs (Paget et al. 1976), rats (Lillehoj et al. 1981;Rose 1975), monkeys (Pudifin et 
al. 1977), and mice (Tomazic and Rose 1976) by injection of homologous or 
heterologous thyroid extract in adjuvant. Subsequent studies in rats 
demonstrated that more severe thyroid destruction developed in immunized 
animals when highly purified Tg, prepared by ultracentrifugation on sucrose 
density gradient, was used for immunization instead of whole thyroid extract 
(Roitt et al. 1965). 
Another method that has been used for EAT induction was based on 
repetitive injections of homologous Tg or thyroid extract in large doses and in 
the absent of adjuvant (Elrehewy et al. 1981). Almost 60% of highly susceptible 
strains of mice (CBA) developed thyroiditis and significant antibody titers were 
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also determined with Tg specificity (Elrehewy et al. 1981). The same protocol 
resulted in no thyroiditis when tested in poor responders. Finally, several groups 
have successfully induced EAT by immunizing susceptible mice with Tg 
synthetic peptides in CF A (Carayanniotis and Rao 1997). Tg-peptide induced 
EAT will be described in the following section. 
Other approaches of EAT induction: In the mouse model several studies 
have documented thyroiditis induction, following transfer into naive syngeneic 
recipients, of lymph node cells (LNC) primed in vivo and boosted in vitro with 
Tg (Braley-Mullen et al. 1985;Simon et al. 1986). According to another study, in 
vivo Tg-sensitized T-cells further activated in vitro with concanavalin A (con A), 
were also able to transfer EAT (Okayasu 1985). Moreover, several studies have 
shown that peptide-primed-LNC after restimulation in vitro with the 
immunizing peptide were able to transfer EAT in syngeneic naive recipients 
(Carayanniotis and Rao 1997). Another approach that has been used to induce 
EAT is by transferring Tg-specific T-cell clones or lines into naive mice (Maron et 
al. 1983;Romball and Weigle 1987). Similarly, Tg-specific T lymphocytes 
generated by coculture of Tg-primed spleen cells with syngeneic thyroid 
epithelial cells (TECs) were able to mediate EAT when injected i.v. into syngeneic 
recipients (Charreire and Michel-Bechet 1982). 
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A more severe form of EAT, called granulomatous thyroiditis, is induced 
in naive recipients by adoptive transfer of mTg-primed spleen cells activated in 
vitro in the presence of either an antibody specific for the IL-2 receptor (anti-IL-
2R mAb) or anti-IFN-y mAb. As in lymphocytic EAT, CD4+ cells are required for 
the transfer of granulomatous EAT (Braley-Mullen et al. 1991;Stull et al. 1992). 
Induction of EAT in mice has been also demonstrated by transfer of 
syngeneic dendritic cells (DCs) either pulsed in vitro with Tg or isolated from 
animals that have been primed with Tg in CFA (Knight et al. 1988). Similarly, 
DCs that were purified from high responder mice were pulsed in vitro with 
porcine Tg (pTg). Transfer of the Tg-pulsed DCs into syngenic mice resulted in 
thyroiditis induction and development of IgG2a antibodies indicating that Th1 
cells are mainly activated by pTg-pulsed DCs (Watanabe et al. 1999). 
In our laboratory, EAT was induced by immunizing mice with conjugates 
of Tg and mouse class II MHC-specific mAb (Balasa and Carayanniotis 1993). 
While the priming of mice with mAb-Tg conjugates in the absence of adjuvant 
was successful in breaking self tolerance to Tg, as demonstrated by the host IgG-
responses against Tg, this method failed to induce mononuclear infiltration of 
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the thyroid, thereby suggesting lack of activation of Tg-specific autoreactive T 
cells with pathogenic potential in EAT (Balasa and Carayanniotis 1993). 
Another method of EAT induction was developed via the manipulation of 
T-cell subsets in Wistar rats. Following thymectomy and sublethal total body 
irradiation (200 rads x 5 times at 2 weeks intervals) the animals developed 
thyroiditis and Tg-reactive Abs (Penhale et al. 1973). Furthermore they 
demonstrated that EAT can be prevented by reconstitution of thymectomized 
rats with viable lymphoid cells from syngeneic rats (Penhale et al. 1976). 
Among the models for induction of thyroiditis, the Tg-induced EAT 
mouse model is the most extensively studied. It is an excellent model for 
immunogenetic studies due to extensive characterization of the MHC locus. Mice 
can be easily handled and maintained in large numbers and at a lower cost than 
any other animal developing EAT. Moreover, there is an enormous variety of 
mouse-specific reagents such as mAbs specific for surface markers expressed in 
several cell subsets, which can be used to characterize the phenotype and the 
function of those cells during the autoimmune response. 
EAT induction by direct challenge of mice with Tg requires the 
optimization of various parameters such as Ag dose, route of Ag administration, 
28 
adjuvant, immunization protocol and the time of thyroiditis assessment 
(Charreire 1989;Shulman 1971). 
1.6 Immunogenetics of EAT in mice 
1.6.1 MHC genes 
The fundamental role of MHC genes in EAT susceptibility was first 
described by Vladutiu and Rose in 1971 (Vladutiu and Rose 1971). In their study 
they used 33 inbred mouse strains representing 11 different haplotypes. EAT was 
induced by immunization with thyroid extract in CF A, and mouse strains were 
classified based on the existence of mononuclear cell infiltration within the 
thyroid and the extent of its follicular destruction. Specifically, mice carrying the 
H-2kshaplotypes were designated as excellent responders, the H-2q strains were 
good, strains with the H-2a, m, P were fairly good whereas mice of H-2b, d and H-2v 
were poor and very poor responders respectively. In the same study, congenic 
strains such as C3H.SW (H-2h) and C3H/HeJ (H-2k), that share the same 
background genes but have different H-2 alleles were classified as low and high 
responders, respectively. From those studies it was evident that EAT induction 
in mice is under the genetic influence of MHC genes. 
In an attempt to localize the susceptible locus within the MHC complex, 
intra-H-2 recombinant mouse strains were challenged with mTg and genes 
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located at the centromeric side of the H-2 region were shown to influence the 
high anti-Tg response (Tomazic et al. 1974). However, the lack of suitable intra-
H-2 recombinant strains, at that time, did not permit precise localization of the 
gene(s)that predispose to susceptibility. Further studies based on new intra-H-2 
recombinant congenic strains of B10 background with various combinations of k, 
b, q alleles at the K and/or I-A regions, localized the disease susceptibility to the 
I-A locus of the H-2 complex (Beisel et al. 1982a). The significance of the I-A locus 
in EAT susceptibility was confirmed when mice that have been treated with anti-
I-A mAbs either before or at the time of antigenic challenge with Tg in CF A were 
unable to develop EAT (Vladutiu and Steinman 1987a). 
Although the I-A is the major locus conferring susceptibility in mouse 
EAT model, K and D gene regions have been shown to influence the severity of 
EAT. Using several recombinant strains expressing s, k, d and b alleles at the I-A 
locus, and the same or different alleles at the D locus, it was shown that the D-
end genes have a regulatory effect on the disease process (Kong et al. 1979). Like 
the D-end, the K- end has also been shown to influence the severity of the 
disease. Experiments performed using strains of mice with point mutations at the 
H-2K gene showed that a low responder mouse can become a high responder 
upon the introduction of the mutation (Maron and Cohen 1979). A second line of 
evidence implicating the K-end locus in regulating the severity of EAT was 
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shown in studies of intra-H-2 recombinant mice (Beisel et al. 1982a). In these 
studies it was shown that expression of Kk reduces, whereas the presence of Kq or 
Kb increases the incidence of thyroiditis in mice. 
In contrast to the strong association of EAT susceptibility with the H-2 
locus, studies on HLA association with HT in patients have resulted in 
controversy (Weetman and McGregor 1994). Family studies have failed to 
establish a linkeage of HT and HLA (Roman et al. 1992). That was primarily due 
to the serologic typing of only DR antigens following the identification of linkage 
disequilibrium between certain DR and DQ genes. Other parameters that 
contributed in this controversy wre the differences among populations, the 
multiple epitopes that possibly exist on Tg, and the involvement of other thyroid 
antigens during HT development (Weetman and McGregor 1984). However, 
other studies demonstrated an association of goitrous HT with HLA DRS (Farid 
et al. 1981) and atrophic HT with HLA DR3 (Moens et al. 1978). Recently, in an 
attempt to define the HLA class II molecules associated with autoimmune 
thyroiditis, transgenic mice have been generated to express several HLA 
molecules in the absence of other class II genes (Kong et al. 1997). EAT was 
induced by immunization of transgenic mice with human or mouse Tg in 
adjuvant. Based on these studies it has been shown that DR3 and DQ8 alleles 
influence susceptibility whereas DR2, DR4 and DQ6 alleles influence resistance 
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to EAT induction with hTg (Kong et al. 1996;Kong et al. 1997;Wan et al. 2002). 
Immunization with mTg resulted in EAT only in DR3 mice but not in DQ8. In 
order to examine the effects of multiple class II genes as seen in humans, a more 
recent study used class II negative strain of mice that co-express DR3 and DQ8 
HLA molecules (Flynn et al. 2002). Upon mTg challenge, EAT severity was 
significantly reduced in DR3/DQ8 mice compared with the single DR3 mice 
(Flynn et al. 2002). The mechanisms involved in this regulation remain to be 
determined. In summary, the use of single and double HLA transgenes may help 
in addressing questions associated with the HLA contribution to susceptibility or 
resistance in thyroid autoimmunity. 
1.6.2 Non-MHC genes 
The contribution of the non-MHC genes to development of thyroiditis has 
been studied using congenic mouse strains carrying the same H-2, but different 
background genes. The mice were immunized with mTg and 3 hours later they 
received LPS (Beisel et al. 1982b ). In this study it was found that genes outside 
the MHC locus influence the severity and the incidence of thyroiditis, as well as 
the levels of the Tg-specific antibodies. For example, when the BlO, BALB.B, 
C3H.SW and A.BY mice (all of those carry the H-2b haplotype) were compared it 
was shown that C3H.SW and A.BY mice developed higher mTg-specific 
antibody levels and higher incidence of thyroiditis than BlOor BALB.B mice. It 
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was suggested that the non-MHC genes of the C3H strain favored EAT 
development. Similar results were obtained when the B10.BR, BALB.K and 
C3H/ An£ strains that carry the high responder haplotype (H-2k) were compared. 
Another study, using recombinant inbred strains, suggested that genes from the 
Igh locus have an effect on the levels and the subclass of anti-Tg antibodies 
(Kuppers et al. 1994). Following immunization of CBA-Tu (Ighi) and CBA-Ighh 
recombinant strains with mTg in CF A, it was shown that the Ighh haplotype 
produces very low levels of IgG2a mTg-specific antibody compared with the Ighi 
haplotype (Kuppers et al. 1994). 
In a more recent study it was demonstrated that Tg gene is a major 
susceptibility gene in human autoimmune thyroid disease (Tomer et al. 2002). 
This study was based on the analysis of 102 families by using Tg microsatelites 
and provided strong evidence for the association of Tg gene locus with the 
susceptibility to thyroid disease. 
1.7 Mapping of pathogenic Tg T-cell epitopes 
1.7.1 Overview of the existing knowledge of Tg T-cell determinants 
Although a large body of evidence supports the crucial role ofT cells in 
both the inductive and the effector stages of Tg-induced EAT, very little is 
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known about the exact mechanisms involved in the development of the disease. 
A major obstacle in this direction has been the large molecular size of Tg. Tg, as a 
large macromolecule, is likely to encompass several pathogenic T-cell 
determinants that are recognized by distinct T -cell populations that may be 
involved in EAT development. In addition, Tg circulates at low levels in the 
bloodstream (Torrigiani et al. 1969) and it has been hypothesized that 
participates in tolerogenic mechanisms established to protect against 
autoreactivity (Lewis et al. 1987;Lewis et al. 1992;Rayner et al. 1993). Therefore, in 
order to study mechanisms leading to EAT development, it was necessary to 
develop a simplified model in which T -cell subsets of several specificities would 
be eliminated, and disease induction by pathogenic Tg T-cell subsets could be 
easily followed. As a result, interest was focused on the mapping of pathogenic 
T -cell sequences of Tg. 
T -cell determinants have been classified as immunodominant, 
subdominant or cryptic (Sercarz et al. 1993). An immunodominant determinant 
strongly stimulates the in vitro proliferation ofT cells activated in vivo with 
intact antigen whereas a cryptic determinant fails to do so (Moudgil and Sercarz 
1993). Both immunodominant and cryptic determinants can successfully 
stimulate T cells isolated from mice that have been immunized with the 
respective determinant in adjuvant. On the other hand, an epitope can be 
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classified as subdominant when it can induce proliferative cells that respond in 
vitro to both the determinant itself and to the native antigen. T cells induced by 
immunization with the native antigen respond inconsistently in vitro to the 
subdominant determinant. 
Several investigators from different laboratories have focused on 
identifying pathogenic, Tg epitopes within the large Tg molecule. Diverse 
strategies have been employed for the mapping of pathogenic epitopes. One of 
them is based on the generation of Tg-specific T-cell hybridomas and subsequent 
use of these clones as tools for screening for Tg T-cell epitopes with 
thyroiditogenic potential (Champion et al. 1991;Texier et al. 1992). A second 
strategy uses computerized algorithms to predict potential T-cell epitopes within 
the Tg sequence and the subsequent testing of the candidate sequences for their 
ability to induce disease in animals (Carayanniotis et al. 1994;Chronopoulou and 
Carayanniotis 1992). 
Following the first approach, two T-cell epitopes have been identified; the 
first epitope is a 9-mer peptide corresponding to a.a. (2551-2559) of hTg and 
containing T4 at position 2553 (Champion et al. 1991). Its identification was 
based on the use of two CH9 and ADA2 hybridoma clones that were activated by 
the Tg fraction carrying T4 and their activation was dependent on the iodination 
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level of that fraction (Champion et al. 1987). Since there are only four 
hormonogenic sites on Tg at residues 5, 2553,2567 and 2746 (Malthiery and 
Lissitzky 1987) an array of 5 to 12-mer overlapping synthetic peptides covering 
the four hormonogenic sites was synthesized and each peptide was tested for its 
capacity to activate the two hybridomas. In this way the minimal T cell epitope 
was mapped to the C-terminus of Tg including the 2553 residue (Champion et al. 
1991). The (2551-2559) peptide did not induce thyroiditis in CBA/J mice after 
direct challenge with CF A. However, lymph node cells (LNC) isolated from mice 
that had been primed either with intact Tg or with the (2551-2559) peptide 
activated effector cells that successfully transfered thyroiditis to naive syngeneic 
recipients following in vitro stimulation with (2551-2559) peptide (Hutchings et 
al. 1992). An obvious question arising from this study was whether the presence 
of iodine atoms was critical forT cell activation. To address this Kong and co-
workers tested three hTg 12mer peptides (1-12, 2549-2560, and 2559-2570), 
carrying T4 at the other three hormonogenic sites 5, 2553 and 2567 (Kong et al. 
1995). Peptides carrying thyronine (TO, lacks the four iodine atoms) were 
synthesized and used as controls. It was found that (2549-2560) peptide 
containing either T4 or TO was immunogenic at T -cell level and splenocytes 
isolated from CBA mice primed either with mTg or with the respective peptide 
and re-stimulated in vitro with peptide, were able to adoptively transfer disease 
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to syngeneic nai:ve mice. These data suggested that the presence of iodine was 
not necessary for activation of the autoreactive T cells and disease development. 
On the other hand, both T4(5) and T4(2567) peptides were slightly immunogenic 
and only the T4(5) was able to generate mild thyroiditis (Kong et al. 1995). 
Similarly, the peptide 2737-2748 that contains the T4 at position 2746 was not 
found to be immunogenic suggesting that the presence of iodine molecules 
within the peptide structure is not sufficient to render the peptide immunogenic 
(Carayanniotis and Kong 2000). 
The second Tg T-cell epitope identified using the hybridoma-based 
strategy, was a 40-amino acid sequence localized between residues 1672 and 1711 
of hTg (F40D) (Texier et al. 1992). Initially it was found that a <10kDa porcine Tg 
tryptic fragment was able to induce thyroiditis in CBA mice (Salamero et al. 
1987). By using an MHC class !-restricted cytotoxic T lymphocyte (CTL) 
hybridoma (HTC2) that was generated by immunization of mice with pTg it was 
shown that syngeneic macrophages, pulsed with pTg tryptic fragments, were 
lysed in a dose-dependent manner. To identify the sequence(s) responsible for 
the activation of HTC2 cells the <10 kDa fraction of pTg was separated by 2D-gel 
electrophoresis. Those products of electrophoresis that could successfully 
activate the HTC2 cells were collected and further purified by high-performance 
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liquid chromatography (HPLC). HPLC fractions coresponding to the major peak 
that could activate the HTC2 cells were used for N-terminal sequencing. 
Following this procedure the F40D sequence was defined that could induce 
lymphocytic thyroiditis in 4 out of 5 mice, after direct subcutaneous challenge 
(Texier et al. 1992). It is possible that this 40-mer fragment contains more than 
one pathogenic sequence but complete epitope mapping has not been carried 
out. 
Our laboratory made use of computerized algorithms (Margalit et al. 
1987;Rothbard and Taylor 1988) to scan the rTg (mTg sequence was unknown at 
that time). A 17mer peptide (2495-2511) was identified to be pathogenic in H-2k 
(B10.BR, C3H) and H-25 (SJL) but not in H-2d (BALB/c) or H-2b (B10) strain of mice 
(Chronopoulou and Carayanniotis 1992), indicating that the MHC susceptibility 
to EAT induced by this peptide was similar to the pattern of the mTg-induced 
EAT (Vladutiu and Rose 1971). The Tg epitope(s) in this peptide was not 
dominant because: a) it failed to stimulate Tg-primed LNCs in vitro; and b) 
peptide-primed LNCs were not activated in the presence of Tg in culture. Amino 
acid (a.a.) truncation analysis revealed two pathogenic T-cell epitopes within 
(2495-2511) (Rao et al. 1994). The first one was a 9-mer rTg (2946-2504) epitope 
that elicited T-cell proliferative responses as well as severe EAT in both H-2k and 
H-25 mice. The second one was a 8-mer rTg (2499-2507) that induced mild EAT in 
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both k and s strains of mice but was not able to activate peptide-primed LNCs in 
vitro (Rao et al. 1994). 
Via the same algorithm approach, a second peptide on rTg (2695-2713) 
was identified and tested for EAT induction in several mouse strains 
(Carayanniotis et al. 1994). The peptide elicited EAT in SJL (H-25) but not C3H or 
B10.BR (H-2k), BALB/c (H-2d) and B10 (H-2h) mice (Carayanniotis et al. 1994). 
These findings suggested a new genetic pattern of susceptibility to EAT 
(different from that ofTg-induced EAT). This peptide was also non-dominant 
since priming of SJL mice with rTg was unable to elicit T-cell responses to the 
respective peptide in vitro (Carayanniotis et al. 1994). 
Recently, a 20-mer hTg peptide (2340-2359) was identified to contain 
multiple £k- binding motifs (Altuvia et al. 1994;Leighton et al. 1991). Initially, the 
peptide had been identified to be recognized by Tg-reactive autoantibodies in 
sera from patients with Graves' disease (Thrasyvoulides et al. 2001). The peptide 
was shown to contain multiple I-Ek binding motifs upon scanning using a 
computer algorithm (Altuvia et al. 1994) and, therefore, it was tested for 
pathogenicity in H-2k mice. The peptide was immunogenic at both the T- and B-
celllevel and peptide-specific T cells mediated EAT in AKR/J mice (H-2k) (Karras 
et al. 2003). Blocking studies using anti-I-£k mAbs confirmed I-Ek binding-motifs 
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in the pathogenic sequence whereas anti-l-Ak mAbs failed to block the 
proliferation of peptide-primed T cells. 
A third approach used for the identification of pathogenic Tg peptides 
was based on earlier findings by McLachlan and Rapoport (McLachlan and 
Rapoport 1989) that hTg and hTPO share B-cell epitopes and it was hypothesized 
they may also share T-cell epitopes. Based on this study Hoshioka and co-
workers (Hoshioka et al. 1993) identified two 14-mer peptides, the hTg(2730-
2743) and hTP0(118-131), which share 5 identical consecutive a.a. However, 
direct challenge of CBA mice with the hTg peptide failed to induce EAT and 
similar result was obtained after adoptive transfer of peptide activated T cells. 
Extensive lymphocytic infiltration of the thyroid was observed only by adoptive 
transfer of cells that were primed in vivo with mTg and boosted in vitro with 
hTg(2730-2743). The reasons for this discrepancy were not discussed in the 
paper. 
Based on the above discussion it is evident that mapping of pathogenic Tg 
epitopes it is a difficult task. One of the projects in the current study focuses on 
the identification of pathogenic Tg epitopes through an algorithm approach. I 
will proceed therefore to discuss how algorithms that predict T cell epitopes or 
MHC ligands have been formulated and used. 
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1.7.2 Algorithm based prediction ofT-cell epitopes 
In order for T cell activation to take place the T cell receptor must recognize 
antigenic peptides presented in the context of the MHC on the APC. It was 
therefore important to discover specific features of antigenic sequences (T -cell 
epitopes) that facilitate their binding to certain MHC molecules. It was initially 
proposed that the hydrophobic portions of the antigenic determinant interacts 
with the APC whereas the hydrophilic portion confers specificity on the 
interaction with the TCR (DeLisi and Berzofsky 1985). In this way the antigenic 
site postulated to form an amphipathic helical structure characterized by both 
hydrophilic and hydrophobic portions. Considering the predisposition of 
antigenic sites to form amphipathic structures, Margalit and colleagues 
developed an algorithm that could predict potential T cell epitopes within a 
protein (Margalit et al. 1987). In another study, Rothbard and Taylor analyzed 
the primary sequence of 57 known helper and cytotoxic T cell determinants in an 
attempt to delineate common motifs (Rothbard and Taylor 1988). Two motifs 
described; the first consists of four residues whereas the second consists of five 
residues. Within the 57 T -cell epitopes tested the tetramer motif was identified in 
46 (81%) and the pentamer in only 18 (32% ). Both approaches described above 
can be used either to search for antigenic sites in any protein sequence regardless 
of their MHC restriction or to identify determinants that bind to limited MHC 
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alleles. It was necessary therefore, to identify specific motifs that allow peptides 
to bind to certain MHC molecules. For MHC class II ligands the prediction of 
peptide binding motifs was found to be more difficult due to the variable length 
of the ligands that can be accommodated in the MHC groove as well as the more 
degenerate anchor positions. 
To date several algorithms have been developed with the ability to predict 
epitopes that can bind to various MHC class I and II molecules, based either on 
the analysis of natural MHC ligands or on the binding properties of synthetic 
peptides (Chicz et al. 1992;Falk et al. 1994;Hunt et al. 1992a;Hunt et al. 
1992b;Leighton et al. 1991;Rudensky et al. 1992). In that regard, structural motifs 
have been described for non-self sequences that can activate T cells in the context 
of MHC class II alleles and for self-peptides that have been eluted from purified 
MHC class II molecules. On the basis of those studies MHC class II-binding 
motifs have been reported for 1-Ak, 1-Ek, l-Ad, l-Ed, l-As, 1-Eb, l-Ab, DR1, DR2, DR3, 
DR4, DR7, DRll, DQ2, and DQ8 (Rammensee et al. 1999;Rammensee et al. 1995). 
Since susceptibility to Tg-induced EAT is controlled by genes in the H-2A 
region and mice bearing the k haplotype are characterized as "excellent 
responders", we were interested in performing a more systematic search for 
peptides that can bind to 1-Ak molecules. In the next paragraphs I will focus on 
algorithms that describe 1-Ak binding motifs. 
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The first direct evidence for anI-Ak binding motif was described on studies 
with the hen egg lysozyme (HEL) (Allen et al. 1987). The authors utilized two I-
Ak-restricted T cell hybridomas specific for the (46-61) peptide of the HEL (Allen 
et al. 1984). Epitope mapping study revealed that the minimal epitope was 
encoded by the residues 52-61 (Allen et al. 1985;Babbitt et al. 1985). Amino acid 
substitution analysis within the minimal epitope determined that I-Ak -binding 
required three a.a. residues (at positions 1, 7 and 10). Subsequent alignment 
between several naturally processed peptides extracted from I-Ak molecules on 
APC and the HEL peptide revealed a pattern for the three anchor positions 
described above (Allen et al. 1987;Nelson et al. 1996). 
In another study, the crystal structure of the I-Ak molecule in combination 
with the dominant epitope HEL (50-62) was published (Fremont et al. 1998). 
Structural analysis of the peptide-l-Ak complex, revealed that the peptide is 
bound deep into the Ak groove and it extends upward at the C-terminal end. Five 
peptide binding pockets at positions 1,4,6,7 and 9 as well as the residues that 
each pocket can accommodate were delineated (Fremont et al. 1998). 
Combination of this information resulted in a more restrictive motif for peptide 
binding to I-Ak molecule. Moreover, the description of the I-Ak anchor residues 
and the TCR contacts described in this study are in agreement with those 
delineated in previous studies (Allen et al. 1987). 
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Following another approach, Altuvia and co-workers developed a 
computerized algorithm that describes peptide properties for binding to Ak and 
£k molecules (Altuvia et al. 1994). The algorithm was constructed by taking into 
account shared features of peptides that were known to bind to Ak or £k 
molecules and elicit T cell responses. Peptides that could not bind to those 
molecules were also analyzed as controls. The motifs were based on the physical-
chemical and structural properties, such as size, hydrophobicity, charge, 
hydrogen bonding capability etc., of the a.a. that could be accommodated in a 
specific position within the peptide sequence. Similar to previous studies (Itoh et 
al. 1996;Nelson et al. 1996), certain positions critical for peptide binding to the 
MHC were also described (Altuvia et al. 1994). 
1.8 TCR transgenic mice 
In the past, studies of organ-specific autoimmunity have been limited to 
those animals that spontaneously developed disease or to those diseases that 
occur in animals following the injection of autoantigens in adjuvant. With the 
generation of TCR transgenic mouse technology, new opportunities for studying 
autoimmune mechanisms were provided. Specifically, T cell receptor (TCR)-
transgenic mice have been used to address questions in basic mechanisms of self-
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tolerance and to understand the roles of immunological, environmental and 
genetic factors in the generation, activation and expansion of self-reactive T cells. 
The major advantage of TCR-transgenic mice is that one can isolate large 
numbers of homogeneous na"ive T cells with a unique specificity (von Boehmer 
1990). Several TCR transgenic lines have been generated that recognize self-
antigens involved in T -cell mediated autoimmune diseases such as EAE 
(Goverman et al. 1993), type I diabetes (Katz et al. 1993) and autoimmune 
gastritis (Alderuccio et al. 2000). In the next paragraphs, I will discuss how such 
TCR transgenic mice have been utilized to address mechanisms that lead to the 
breakdown of tolerance in the periphery and trigger the initiation of 
autoimmune disease. 
1.8.1 TCR transgenic mice as models of autoimmune disease. 
EAE is one of the best-characterized models of an organ-specific T-cell 
mediated autoimmune disease (Zamvil and Steinman 1990). The disease is 
induced in susceptible animals upon immunization with antigens normally 
presented in the central nervous system (CNS), such as myelin basic protein 
(MBP), proteolipid protein (PLP), and myelin olygodendrocyte glycoprotein 
(MOG), in adjuvant. About one to two weeks after immunization, the animals 
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are characterized by perivascular infiltration followed by demyelination in the 
brain and the spinal cord (Goverman 1999). The chronic form of the disease bears 
some resemblance to multiple sclerosis in humans (Goverman 1999). 
Two laboratories have produced TCR transgenic mice in order to study 
the development, tolerance induction and pathogenic potential of CD4+ T cells in 
EAE (Goverman et al. 1993;Lafaille et al. 1994). These mice (H-2u haplotype) 
express the a and~ chains of an MHC class-II restricted MBP (1-11)-specific TCR 
transgene on >90% of their T cells. The fact that large numbers of mature CD4+ T 
cells expressing the transgenic TCR developed in mice of the H-2u haplotype 
indicates that MBP (1-11 )-specific T cells are not negatively selected despite the 
fact that MBP is a self-antigen. The transgenic T cells were able to proliferate and 
secrete IL-2 in response to exogenously added MBP peptide indicating that the T 
cells are not anergic (Goverman et al. 1993). 
One of the most interesting observations made in this model was that 
spontaneous EAE was seen only in mice that were housed under conventional 
conditions and was not observed when the TCR transgenic mice were housed 
under specific-pathogen-free conditions (Brabb et al. 1997;Goverman et al. 1993). 
This observation suggests that exposure to microbes or other environmental 
factors may trigger the initiation of the disease. It is also indicates the presence of 
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a regulatory mechanism that prevents the activation of the transgenic cells in 
mice kept in pathogen-free conditions. 
To exclude the participation of non-transgenic T cells or other components 
of the immune system in this regulation, Lafaille et al. crossed the MBP 
transgenic mice (T/R+) with RAG-1-deficient mice (T/R-) (Lafaille et al. 1994). In 
this model all mice developed spontaneous EAE. The authors concluded that 
EAE can be mediated by MBP-specific CD4+ T cells in the absence of other T cells 
and also that in T/R+ mice an undefined lymphocyte population can protect 
against spontaneous EAE (Lafaille et al. 1994). To define this cell population, two 
groups systematically examined several lymphocyte populations by crossing 
T/R+ mice with mice that lack B cells (IgM-f..l KO), CDS+ T cells, NKT cells and y8 
T cells (~2m KO) (Olivares-Villagomez et al. 1998;Van de Keere F. and Tonegawa 
1998). In all the transgenic-KG mice described above, the incidence of 
spontaneous EAE was low as it was in T/R+ mice. In contrast, when T/R+ mice 
crossed with CD4 KO mice or a~ KO mice, significant EAE was developed. This 
indicates that CD4+ T cells must be responsible for the protection observed in 
TCR transgenic mice. The ability of CD4+ T cells to protect against EAE was 
confirmed by adoptive transfer of such cells, purified from normal mice, into 
transgenic RAG-1 deficient mice (Olivares-Villagomez et al. 1998;Van de and 
Tonegawa 1998). 
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In the field of diabetes, a TCR transgenic line was created using TCR 
genes derived from a CD4+ clone that was islet-antigen-specific, H-2g7 restricted 
and diabetogenic (Katz et al. 1993). The transgenic mice (termed BDC2.5) were 
utilized to study the activation and effector function of autoreactive T cells that 
lead to destruction of pancreatic ~ cells. Transgenic T cells in these mice were not 
clonally deleted in the thymus or in the periphery (Katz et al. 1993). In addition, 
T cells from the TCR transgenic mice were not anergic, as they could respond 
quite well to islet cells in vitro and infiltrated the pancreatic islets in vivo. For 
example, the authors observed that T cells ignore the islet for the first 3 weeks 
after birth. At that time, T cells up-regulate the expression of co-stimulatory 
molecules and other mediators involved in lymphocyte homing resulting in a 
massive infiltration of the pancreas and induction of insulitis (Andre et al. 1996). 
Me Devitt and coworkers generated another TCR transgenic line from an 
I-Ag7-restricted GAD65 286-300-specific T-cell hybridoma (Tarbell et al. 2002). By 
using GADp286 /I-Ag7 tetramer stainings they showed that p286-specific CD4+ T 
cells responded to the peptide in vitro indicating that the cells were not anergic 
(Tarbell et al. 2002). Although the p286 mouse cell line was generated in the 
NOD strain, no diabetes was observed and insulitis was only observed 
occasionally. This was a strong indication for a regulatory role of the GAD65-
specific T cells. In a follow up study, adoptive transfer of GAD65-specific 
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transgenic T cells along with diabetogenic T cells delayed the diabetes 
development in NOD.scid mice supporting the above hypothesis for the 
tolerogenic role of the p286-specific T cells (Kim et al. 2004). 
The above studies highlight the importance of TCR-transgenic mouse in 
studying mechanisms that are ivolved in the initiation and progression of 
autoimmune diseases as well as in identifying immunoregulatory protocols that 
can lead to disease suppression. In chapter 6, I describe the generation of a Tg 
peptide-specific TCR transgenic mouse that will allow us to study parameters 
that can influence the activation of Tg peptide-specifc T cells. 
1.9 Dendritic cells 
Dendritic cells (DCs) are specialized APCs considered the main subset of 
cells involved in T cell priming. DCs are produced from hematopoietic stem cells 
within the bone marrow and migrate to nonlymphoid tissues where they become 
resident cells (Bell et al. 1999). At this stage, DCs are unable to activate T cells 
since they present an immature phenotype by expressing low levels of MHC 
class II molecules (MHC'ow) and co-stimulatory molecules (CD80/CD861ow) and 
neither CD40 nor CD54, two additional important molecules required during T 
cell activation (Banchereau et al. 2000). However, they are well equipped to 
capture antigens by several pathways; (i) macropinocytosis (Sallusto et al. 1995), 
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(ii) receptor-mediated endocytosis through C-type lectin receptors (DEC205) or 
Fey receptors type I and II, (Jiang et al. 1995) and (iii) phagocytosis of particles, 
apoptotic bodies, viruses, bacteria etc (Banchereau et al. 2000). 
Upon recognition and internalization of the antigen, the immature DCs 
undergo phenotypic and functional changes. The DCs are now able to migrate 
from the peripheral tissue to the draining lymphoid organs where they lose their 
ability for antigen capture. During maturation, DCs assemble large numbers of 
MHC-peptide complexes on their surface and upregulate the expression of 
CD80/CD86 as well as CD40 co-stimulatory molecules that are necessary for T 
cell activation (Banchereau et al. 2000;Turley et al. 2000). Moreover, upon 
stimulation, DCs produce cytokines that depend on the nature of the stimulus. 
For example, IL-12 a critical Thl-polarizing cytokine, is elicited by most 
pathogens but is not induced by stimuli such as TNF-a, IL-l or cholera toxin 
(Kalinski et al. 1999). 
1.9.1 Dendritic cells and tolerance induction 
A large body of literature provides evidence for the DCs as regulators of 
autoimmune responses (Jonuleit et al. 2001;Steinman et al. 2003). The major 
question regarding the DCs and their influence in tolerance is how the same 
APCs are able to initiate an autoimmune response and also suppress 
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autoimmune diseases? Moreover, what are the factors influencing the ability of 
DCs to activate or suppress an autoimmune response? 
The mechanisms that are involved in the induction of peripheral tolerance 
by DCs are still poorly defined. Evidence has been provided to support three 
mechanisms that may be involved in the tolerogenic properties of the DCs; (i) 
induction of anergy by immature DCs, (ii) deletion of effector T cells and (iii) 
induction or expansion of regulatory T cells. 
It has been shown that T cells encountering antigen presented by APCs, 
which express low levels of co-stimulatory molecules, become anergic. In the 
absence of inflammatory signals, DCs are immature and express very low levels 
of MHC and low or no co-stimulatory molecules such as CDB0/86 and CD40 
(Inaba et al. 1994;Mommaas et al. 1995) and therefore are not able to prime na'ive 
T cells. One factor that has been shown to inhibit DC maturation is IL-10 (Lutz 
and Schuler 2002;Steinbrink et al. 1997). Several groups have demonstrated that 
treatment of DCs with IL-10 suppresses their abilty to secrete pro-inflammatory 
cytokines such as IL-l, IL-6 and IL-12 (Buelens et al. 1997;De Smedt et al. 
1997;Koch et al. 1996), and also results in the downregulation of MHC class II 
and costimulatory molecules expression on their surface (Buelens et al. 
1995;Chang et al. 1995;Steinbrink et al. 1997). Experimental evidence for the 
induction of anergic T cells by IL-10-treated DCs was provided by Enk and co-
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workers (Enk et al. 1993). DCs were isolated from the skin and treated with IL-10. 
Cytochrome C-pulsed IL-10-treated DCs were used to activate cytochrome C-
specific Th1 T cell clone. T cells were rescued after 1 day of coculture with IL-10-
pretreated DCs and restimulated with untreated DCs in the presence of Ag. T 
cells incubated with IL-10-pretreated DCs were found to be anergic, whereas T 
cells incubated with untreated DCs proliferated normally after further 
stimulation (Enk et al. 1993). In another study, human IL-10-treated DCs, from 
peripheral blood, induced alloantigen-specific anergy in alloreactive CD4+ T cells 
in vitro, and anergic T cells were characterized by reduced proliferation that 
could be restored in the presence of IL-2 (Steinbrink et al. 1997). 
As mentioned above, DCs may influence tolerance induction via deletion of 
antigen-specific T cells. Steinman's group demonstrated that presentation of 
antigen by immature DCs leads to deletion of antigen-specific CD4+ T cells 
(Hawiger et al. 2001). The authors utilized a mAb specific for the DEC-205 
(Swiggard et al. 1995), an endocytic receptor that is highly expressed on DCs, in 
order to target HEL peptides to DC. When the peptide was delivered in the 
absence of stimulatory signals, to exclude maturation of DCs, HEL peptide-
specific T cells were deleted from the challenged mice leading to tolerance 
induction. However, injection of anti-CD40 mAb (that causes DCs maturation), 
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along with DC-targeted antigen led to development of IFN-y-secreting T effector 
cells and immunity (Hawiger et al. 2001). 
In a parallel vein, OVA conjugated to the DEC-205 mAb was injected 
subcutaneously into C57BL/6 mice and 48 h later DCs isolated from the draining 
lymph nodes were examined for their ability to stimulate OVA-specific CDS+ T 
cells from a TCR transgenic mouse model (OT-I) (Bonifaz et al. 2002). It was 
shown that T cells were able to divide for 4-7 cycles and were then deleted. When 
OT-I T cells were adoptively transferred in vivo along with the OVA-DEC-205 it 
was demonstrated that T cells were deleted after few cycles of proliferation. The 
mice were subsequently immunized with OVA in CF A but they were completely 
unresponsive indicating the induction of tolerance (Bonifaz et al. 2002). The 
above findings suggest that DCs in a steady state induce deletional tolerance, but 
following their maturation they are able to induce immunity. 
The third mechanism accounts for participation of DC in tolerance 
induction is via generation of regulatory T cells (Tregs). In the next paragraphs I 
will focus on the regulatory T cells and how DCs have been shown to participate 
in their induction in vitro and in vivo. 
1.10 Regulatory T cells (Tregs) 
There is now compelling evidence for the existence of T cell 
subpopulations that are involved in the suppression of immune responses and 
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play an important role in the immune regulation (Shevach 2000). These cells have 
been termed Treg cells and are characterized as naturally occurring or inducible. 
It was initially shown that transfer of CD4+ T cells depleted of CD25+ cells in 
na"ive mice, induced multi-organ autoimmunity, such as thyroiditis, gastritis and 
insulitis (Sakaguchi et al. 1995). Reconstitution of CD25+ cells a short period after 
the CD25- cell transfer prevented the development of the autoimmune diseases 
(Sakaguchi et al. 1995). This finding suggested the existence of a natural-occuring 
population ofT cells that might play a role in the maintenance of self-tolerance. 
CD4+CD25+ T cells have since been shown to inhibit autoimmune diabetes in 
mice (Salomon et al. 2000), and cure inflammatory bowel disease (Mottet et al. 
2003;Read et al. 2000). Several studies also support an important role of the 
CD4+CD25+ T cells in transplantation tolerance (Hara et al. 2001) and the control 
of graft-versus-host disease (GVHD) following BM transplantation (Trenado et 
al. 2003). 
Several groups have provided evidence that naturally-occuring Treg cells 
are generated in the thymus with the ability to recognize self-antigens (Asano et 
al. 1996;Itoh et al. 1999;Suri-Payer et al. 1998). The signals that are involved in the 
generation of the CD4+CD25+ T cells in the thymus are not completely defined. 
However, interactions between TCRs with self-peptide/MHC complexes 
expressed on the thymic stromal cells have been shown to play a critical role in 
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the positive selection of CD4+CD25+ T cells (Bensinger et al. 2001;Jordan et al. 
2001;Kawahata et al. 2002). Upon selection, CD25+ T cells constitute 5-10% of 
peripheral CD4 + T cells and less than 1% of peripheral CDS+ T cells in normal 
na'ive mice (Sakaguchi et al. 1995). Several other markers are expressed by the 
CD4+CD25+ T cells. One of the most important markers is the forkhead 
transcription factor FOXP3 (Fontenot et al. 2003;Khattri et al. 2003). Gene 
expression analysis also showed that CD25+ T cells, but not CD25- cells express 
high levels of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) (Gavin et al. 
2002) and glucocorticoid-induced TNFR-related protein (GITR) (McHugh et al. 
2002). 
In terms of the suppressive function of the natural Treg cells it has been 
shown that they require TCR stimulation in order to exert suppression and the 
antigen concentration can be 10- to 100- fold lower than that required to activate 
CD4+CD25- T cells (Takahashi et al. 1998). Additionally, in vitro suppression by 
natural Treg cells requires direct cell contact with responding T cells and/or 
APCs and is cytokine independent (Bluestone and Abbas 2003;Sakaguchi 
2004;Thornton and Shevach 1998). 
Apart from the CD4+CD25+ T cells, other CD4+ subpopulations have been 
described with the ability to inhibit autoimmune responses (Roncarolo and 
Levings 2000). These cells are usually generated from na'ive CD4+ T-cell 
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populations under certain conditions. One subset of the inducible Treg cells has 
been generated in vitro upon culture of naive CD4+ T cells in the presence of 
exogenous IL-10 (Barrat et al. 2002;Groux et al. 1997). These cells termed Tr1 and 
have been shown to produce high levels of IL-10 as well as TGF-~, IFN-y and IL-
5 in the presence of antigen (Cottrez et al. 2000;Levings and Roncarolo 2000). 
Another population of CD4+ T cells that exert inhibitory activity is the Th3 cells 
(MacDonald 1998) that can be generated upon antigen administration via the oral 
or intranasal route (MacDonald 1998;Weiner 2001). This populaion is 
characterized by high levels of TGF-~ secretion (Chen et al. 1994;Faria and 
Weiner 1999) and has been shown to suppress autoimmune responses (Chen et 
al. 1994). Both Tr1 and Th3 cell populations are characterized by a cytokine-
production profile rather than the expression of cell-surface markers. In contrast 
to CD4+CD25+ T cells, inducible regulatory cells mediate suppression through a 
cytokine-dependent mechanism since their suppression function can be reversed 
in the presence of anti-IL-10 and/or anti-TGF-(3 (Kitani et al. 2000;Kitani et al. 
2003). 
1.10.1 Dendritic cells and regulatory T cells (Treg) 
As mentioned above, DCs play an important role in tolerance induction 
through the induction of regulatory T cells. Although the exact DC profile that is 
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required to activate or expand the Treg cells has not been determined, several 
lines of evidence support that the maturation stage of DCs is distinct from those 
that participate in the activation of Th1 and Th2 cells (Lutz and Schuler 
2002;Mahnke et al. 2003a). 
Some studies have suggested that immature DCs (iDCs) control the 
differentiation of na·ive T cells into Treg cells (Akbari et al. 2001;Jonuleit et al. 
2000;Mahnke et al. 2003b;Wakkach et al. 2003). Jonuleit and colleagues 
demonstrated that repetitive stimulation of human naive CD4+ T cells with 
allogeneic immature DCs results in the generation of alloantigen-specific Treg 
cells (Jonuleit et al. 2000). Those Treg cells secreted high levels of IL-10 and were 
able to inhibit antigen-specific proliferation and cytokine production by Th1 cells 
(Jonuleit et al. 2000). The induction of Treg by immature DCs, was further 
supported by in vivo administration of immature DCs pulsed with influenza 
matrix peptide (MP) into healthy individuals. It was found that, CDS+ T cells 
isolated from the DC-immunized individuals 7 days later could inhibit antigen 
specific proliferation ofT cells isolated before injection (Dhodapkar et al. 
2001;Dhodapkar and Steinman 2002). Although, iDCs show phenotypic 
similarities with the IL-10-modulating DCs that induce anergic T cells (see 1.10 
paragraph), the induction of Treg cells requires repetitive stimulation by iDCs. 
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In another study, a subpopulation of DCs has been described as tolerogenic 
and termed "semi-mature" DCs (Lutz and Schuler 2002). Addition of TNF-a in 
DC cultures has been shown to enhance DC maturation as assessed by increased 
expression of MHC class II and costimulatory molecules (Lardon et al. 
1997;Yamaguchi et al. 1997) but functionally were different from DCs matured in 
the presence of LPS (Menges et al. 2002). Specifically, EM-derived DCs that have 
been cultured in vitro in the presence of TNF-a but not LPS were able to 
suppress EAE in an antigen specific fashion (Menges et al. 2002). It was initially 
shown that TNF-a treated DCs were mature in terms of the MHC class II and 
B7.1/2 expression but the same cells were not secreting pro-inflammatory 
cytokines, such as IL-12 and TNF-a, essential for efficient activation of naive T 
cells. When MOG-peptide pulsed-DCs were injected into susceptible mice, 
inhibition of MOG-induced EAE was observed. A population of IL-10-secreting 
CD4+ T cells was found in the spleens of MOG/DC-treated mice but not in mice 
receiving OV A/DCs (Menges et al. 2002). This indicates the Ag-specific induction 
of a Treg cell population with the ability to down-regulate autoimmune 
responses (see below). 
A recent study provides evidence for the capacity of antigen-bearing DCs 
to expand CD4+CD25+ Treg both in vivo and in vitro (Yamazaki et al. 2003). More 
importantly, it was shown that not only mature but also immature DC 
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populations were able to expand the Treg cells. Expansion of CD4+CD25+ cells 
requires DC-T cell contact and the presence of co-stimulation through the B7 
molecules. When steady state or mature DCs were adoptively transferred in vivo 
along with the CD4+CD25+ T cells, a robust antigen-specific proliferation of the 
later subset occured (Yamazaki et al. 2003). Although in most studies mature 
DCs (as well as immature DCs) induce the expansion of this particular Treg 
subset, it is still unclear what determines when mature DCs will activate 
CD4+CD25- T cells (effector cells) or the CD4+CD25+ T reg subset. 
In the field of EAT, it was recently shown that susceptible mice immunized 
with Tg in CFA and also injected with GM-SCF (induces iDCs) for 5 consecutive 
days did not develop thyroidits. In contrast, mice immunized similarly with Tg 
but received fms-like tyrosine kinase receptor 3ligand (Flt3-L; promotes 
maturation of DCs) instead of GM-CSF, developed severe EAT (Vasu et al. 2003). 
The authors observed an increase of the CD4+CD25+ population in spleens of 
mice treated with GM-CSF and not with Flt3-L. Since this T cell sub-population 
was able to suppress the proliferation of mTg-specific T cells in vitro they 
hypothesized that GM-CSF treatment generates a DC population capable of 
expanding Treg cells (Vasu et al. 2003). However, no direct evidence was 
provided for the participation of specialized subset of the DCs in the 
proliferation of the CD4+CD25+ T cells after GM-CSF injection. In a follow up 
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study by the same group, adoptive transfer of CD4+CD25+ T cells isolated from 
GM-CSF-treated mice into mTg-challenged mice reduced the proliferation of 
mTg-specific T cell responses (Gangi et al. 2005). It was also shown that IL-10 
secreted by CD4+CD25+ T cells was critical for the suppression of the effector 
cells, since administration of IL-10 mAb in vivo reversed the suppressive 
function of the CD4+CD25+ T cells (Gangi et al. 2005). In another study, in vivo 
depletion of CD25+ T cells abrogatedartificially induced tolerance to mTg (Morris 
et al. 2003). Mice treated with anti-CD25 mAb developed significantly higher 
degree of thyroid infiltration than mice treated with isotype control mAb (Morris 
et al. 2003). Additionally, CD4+CD25+ T cells isolated from rnTg-tolerized mice 
had the ability to suppress the proliferation of mTg-specific T cells. These data 
indicate the important role of CD4+CD25+ T cells in the immunoregulation of 
EAT. 
In conclusion, there is strong evidence that DCs play a role in peripheral 
tolerance. Therefore, further understanding of the factors that generate DCs with 
the ability to induce antigen-specific tolerance will be useful in designing 
therapeutic methods for autoimmune diseases. 
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2 CHAPTER2 
2.1 MATERIALSANDMETHODS 
2.2 Animals 
Female CBA/J (H-2k), C3H/HeJ (H-2k), B10.BR (H-2k), AKR/J (H-2k), 
C57BL/6 (H-2h), DBA/1J (H-2q), DBA/2J (H-2ct), and SJL/J (H-25 ) mice were 
purchased from the Jackson Laboratories (Bar Harbor, ME USA), and used in 
experiments between 6 to 8 weeks of age. All experimental procedures were 
reviewed and approved by the institutional animal care committee. 
2.3 Antigens and synthetic peptides 
Tg was extracted from thyroids of outbred ICR mice (Bioproducts for 
Science, Indianapolis, IN) as previously described (Chronopoulou and 
Carayanniotis 1992). In detail, frozen glands were homogenized in phosphate 
buffered saline (pH 7.0) and the supernatant was centrifuged three times at 
16,000 x g. The clear supernatant was passed through a Sepharose CL-4B column 
(Pharmacia, Quebec, Canada). The fractions of peak II (Figure 2.1), were pooled, 
dialyzed in 1 X PBS, concentrated in ultra-filtration cells (Amicon, Danvers, MA), 
filter-sterilized, and stored at -20 oc at a final concentration of 2-3 mg/ml. 
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Figure 2.1 Tg isolation from thyroid glands 
About 100 thyroid glands were homogenized in 5 ml ice-cold PBS. The 
homogenate was centrifuged 3x at 16,000g for 10 min at 4°C. The supernatant 
was then loaded on Sepharose CL-4B column. Tg was eluted with PBS. Fractions 
(- 4 ml/tube) were collected after sample loading. Fractions from 24 to 40 within 
peak II were pooled and concentrated. The Tg preparation was filter sterilized 
and stored at -20°C. 
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Ovalbumin (OVA) was purchased from Sigma (St. Louis. MO, USA). 
Tuberculin purified protein derivative (PPD, Seruminstitut, Copenhagen, 
Denmark) was purchased from Cedarlane (Ontario, Canada). 
Peptides designated pllO (VQCDLQRVQ), p226 (LAETGLELLLDEIY), 
p306 (YQTVQCQTEGMCWCV), p1579 (LVQCLTDCANDEA), p1826 
(GDMATELFSP), p2026 (GSEDTEVHTYP), p2102 (SMAQDFCLQQCSRHQ) and 
p2596 (YGHGSLELLADVQ) were synthesized by Sigma-Genosys (The 
Woodlands, TX). The Tg peptide p2495 (GLINRAKA VKQFEESQG) and the 
truncated Tg peptide p2496 (LINRAKA VK) were synthesized at the Alberta 
Peptide Institute (Edmonton, Alberta, Canada). All peptides were blocked with 
an acetyl group at theN-terminal and an amide group at the C-terminal end. The 
thiol group of internal Cys residues was blocked by acetamide. Mass 
spectrometry and HPLC analysis were performed on each peptide to verify 
composition and confirm >80% purity. 
2.4 Algorithm-based search for Ak-binding peptides in Tg 
A computerized algorithm that predicts peptides with Ak-binding 
potential was described by Altuvia et al. (Altuvia et al. 1994). Two motifs were 
used to scan the mTg molecule for peptides that may bind to Ak molecule (Table 
2.1). The "Pole Bio-Informatique Lyonnais: Network Protein Sequence Analysis" 
website (http://npsa-pbil.ibcp.fr I cgi-bin/npsa automat. pl? page=npsa_pattin 
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prot.html) was used to scan the entire Tg molecule. Among the sequences that 
were found to fit motif A and B we chose for our study only those in which 
motifs completely overlapped. 
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Table 2.1 I-Ak-binding motifs A and B (Altuvia et al. 1994) 
Position# Characteristic of a.a. [Includes ]/{Excludes} a.a. 
Motif A 1 Hydrogen acceptor, non- [DEHNQ] 
hydrophobic, not small, not 
aliphatic 
2 Not an amide {NQ} 
3 Any amino acid [Any a.a.] 
4 Medium-sized, aliphatic, [ILTV] 
hydrophobic, no charge, not 
aromatic or amide 
5 Any amino acid [Any a.a.] 
6 Not aromatic {FHWY} 
7 Hydrophobic, no charge, not [ ACFILMPTVWY] 
an amide 
[DEHNQ]- {NQ}-X-[ILTV]-X-{FHWY}-[ACFILMPTVWY] 
MotifB 1 Hydrogen acceptor, not [CDEHNQY] 
small, polar, not aliphatic 
2 Not negatively charged {DE} 
3 Any amino acid [Any a.a.] 
4 Medium-sized, aliphatic, [ILTV] 
hydrophobic, no charge, not 
aromatic or an amide 
5 Hydrogen acceptor, non- [DEHQN] 
hydrophobic, not small, not 
aliphatic 
[CDEHNQY]- {DE}-X-[ILTV]- [DEHQN] 
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2.5 Culture Media and Cell Lines 
All tissue culture media including Dulbecco' s Modified Eagle's Medium 
(DMEM) and RPMI-1640 (GibcoBRL, Burlington, ON, Canada) were 
supplemented with 10% heat-inactivated (1 hour at 56°C with moderate stirring) 
fetal bovine serum (FBS) (Cansera, ON, Canada), 2mM L-glutamine, 100 U/ml 
penicillin, 100 f.!g/ml streptomycin (all from Gibco) and 5 x 10-5 M2-ME (Sigma 
Chemical Co., StLouis, MO). DMEM was also supplemented with 20mM HEPES 
buffer (Gibco ). 
The BW5147a-~- variant (White et al. 1989) was a kind gift of Dr. P. 
Marrack (National Jewish Centre, Denver, CO, USA). The antigen-presenting cell 
line LS 102.9, a B-cell hybridoma expressing H-2Ad/sand H-2Ed (Kappler et al. 
1982), and the IL-2-dependent CTLL-2 cell line (Gillis and Smith 1977) were 
purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). 
The HB 65 (H16-L10-4R5) clone secreting IgG2a MAb specific for nucleoprotein 
of influenza type A virus (Yewdell et al. 1981), the TIB 92 (10-3.6.2) clone 
secreting IgG2a MAb, specific for I-Akmolecules (Oi et al. 1978) as well as the HB 
32 (14-4-4S) clone secreting an IgG2a MAb that specifically reacts with 1-Ek 
determinants (Ozato et al. 1980) were also purchased from ATCC. 
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The X63Ag8 cell line, secreting mGM-CSF (Zal et al. 1994) was a kind gift 
from Dr. B. Stockinger (Department of Molecular Immunology, National 
Institute for Medical Research, London, United Kingdom). 
2.6 EAT induction 
2.6.1 Immunization 
Mice were immunized subcutaneously (s.c.) under ether anesthesia at 2 
sites (base of the tail and along the back) with 100 nmol of Tg peptide in 100 1-11 of 
1:1 PBS:CF A (with Mycobacterium butyricum, Difco Laboratories Inc., Detroit 
MI, USA). Three weeks later, they were boosted s.c. with 50 nmol of Tg peptide 
in Incomplete Freund's Adjuvant (IF A) (Difco ). Five weeks from the initial 
challenge mice were bled to obtain sera for ELISA assays and the thyroid were 
removed and fixed in 10% buffered formalin for histological examination. In 
some experiments EAT was induced by immunizing animals s.c. with 100 1-1g Tg 
in CF A once. Thyroids were collected 21 days from Tg injection. 
2.6.2 Adoptive transfer 
Adoptive transfer of peptide-primed LNCs were performed as previously 
described (Rao et al. 1999). Briefly, CBA/J mice were immunized s.c. with 100 
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nmol of Tg peptide in CFA, and 9 days later, draining LN were collected and 
single cells suspensions were prepared. Cells were cultured in the presence of the 
immunizing peptide (25 f.!M). Three days later, the cells were washed 3x with 
PBS and transferred intraperitoneally (i.p.) into naive syngeneic recipients at 2 x 
107 cells/animal. Fourteen days after transfer, mice were sacrificed and their 
thyroid glands were collected in 10% buffered formalin for histological 
examination. 
2.6.3 Evaluation of thyroid histology 
Fixed thyroid glands were embedded in methacrylate and sectioned 
serially (approximately 21 sections were obtained/gland). Thyroid sections were 
stained with hematoxylin and eosin. The mononuclear cell infiltration index (I.I.) 
was scored as follows: 0 = no infiltration, 1 = interstitial accumulation of cells 
between two or three follicles, 2 = one or two foci of cells at least the size of one 
follicle, 3 =extensive infiltration 10-40% of total area, 4 =extensive infiltration 40-
80% of total area, and 5 = extensive infiltration >80% of total area. 
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2.7 Proliferation assays 
2.7.1 LNC proliferation assay 
Mice were immunized s.c. with peptide (100 nmol) in CF A as described 
above, and 9-10 days later, draining LN were collected. A single cell suspension 
was prepared and cells were centrifuged, washed and adjusted at 4 x 106 cells/ml 
in complete medium (DMEM + 10% FCS). The cells (100~1) were then cultured in 
the presence or absence of antigen in flat-bottomed 96-well plates (total final 
volume 200 ~1) for 72 hat 37 oc in a 10% C02 90% air-humidified incubator. 
Eighteen hours before harvesting, 1 ~Ci of (3H]-thymidine (6.7 Ci/mmol, DuPont, 
Mississauga, ON, Canada) was added to each well in 25 ~1 of complete medium. 
The cells were harvested using a Harvester 96® Mach III M (Tomtec, Hamden, 
CT, USA) and incorporated radioactivity was measured using the TopCount 
NXT™ microplate counter (Canberra Packard Canada, Mississauga, ON, 
Canada). Stimulation index (S.I.) is defined as (cpm in the presence of 
antigen/cpm in the absence of antigen). 
2.7.2 CTLL-2 proliferation assay 
In flat-bottomed wells of microtiter plates, 105 hybridoma T cells and an 
equal number of antigen presenting cells were cultured for 24 h with or without 
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antigen in total volume of 200 f-1.1/well. Then 100 f-1.1 of supernatant was harvested 
from each well, transferred into a new plate and kept frozen for longer than 2 h 
at -70°C. Upon subsequent thawing, 104 CTLL-2 cells were added per well and 18 
h later, 1 fJ.Ci of (3H]-thymidine (6.7 Ci/mmol, DuPont) was added to each well in 
25 f-1.1 of complete medium. The cells were harvested 6 h later and incorporated 
thymidine was measured, as described above. 
2.8 Enzyme-linked immunosorbent assay (ELISA). 
2.8.1 Detection of IgG antibody. 
Polyvinyl chloride microwell plates (Dynatech Laboratories, Chantilly, 
VA, USA) were coated with 0.2 f-lg of peptide or 1 f-lg of mTg in 100fJ.l of 
carbonate buffer pH 9.6, and were incubated overnight at 4°C. The plates were 
washed 3x with 200 f-1.1 of PBS and then blocked overnight at 4 oc with PBS 
containing 1% BSA. The serum samples were added to the well (100 f-1.1/well), 
were serially diluted and incubated for 1 h at room temperature. The wells were 
then washed 3x with 200 f-1.1 of PBS-Tween (PBS-T) and 100 f-1.1/well of alkaline 
phosphatase-conjugated goat anti-mouse IgG (Sigma) diluted in 1% BSA PBS-T 
(1:2000) was added. After one hour incubation at room temperature, the plates 
were washed 3x with PBS-T followed by the addition of 100 f-1.1 of p-
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nitrophenylphosphate substrate (Sigma) solution (1mg/ml substrate in 10 % 
diethanolamine, pH 9.8, 100 11-l/well) and were incubated for 1 hat room 
temperature. Absorbance of the p-nitrophenylphosphate product was measured 
at 405 nm using an automated microplate reader (Molecular Devices, Sunnydale, 
CA, USA). 
2.8.2 Detection of cytokines in culture supernatants. 
Cytokine production was determined in culture supernatants harvested 
following 48 h stimulation of antigen-primed LNCs with the respective antigen 
(8-20 11-M). Detection of IL-2, IL-4, IL-10 and IFN-y was performed by sandwich 
ELISA based on non-competing pairs of capture and detection (biotinylated) 
mAbs as follows: IL-2, JES6-1A12 and JES6-5H4; IFN-y, R4-6A2 and XMG1.2 (all 
from BD PharMingen, San Diego, CA); IL-4, llBll (ATCC) and DVD-6-24G2 (BD 
PharMingen). IL-10 was detected via the use of affinity purified polyclonal rabbit 
Ab 500-P60 and 500-P60Bt (PeproTech, Inc., Rocky Hill, NJ, USA). In brief, 96-
well polyvinyl chloride microwell plates (Dynatech Laboratories) were coated 
overnight with 1 11-g/ml of the IL-2, IL-4 and IL-10 capture mAb and 4 11-g/ml for 
the IFN-y capture mAb. The wells were then washed and blocked with 1% BSA 
for 1 h at room temperature. Both cytokine standards and the LNC supernatants 
were then added (100 11-l/well) and the plates were incubated at 4 °C overnight. 
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The biotinylated anti-cytokine secondary Ab was added in the wells (100 1-1-llwell) 
at a concentration of 2 1-1-g/ml for IL-2 and IL-10 and 1 1-1-g/ml for IL-4 and IFN-y. 
Following one hour incubation at room temperature, alkaline phosphatase-
conjugated streptavidin and its substrate (Sigma) were added as described 
above. Absorbance at 405 nm was measured by using a microplate reader 
(Molecular Devises). The amount of cytokine in each supernatant was 
extrapolated from the standard curve for the respective cytokine. Standard 
curves were generated for each individual cytokine using known amounts of 
murine riL-2 and riFN-y (BD PharMingen), or riL-4 and riL-10 (PeproTech). The 
detection limits were 4 pg/ml for IL-2 and IFN-y, 10 pg/ml for IL-4, and 17 pg/ml 
for IL-10. 
In some experiments, detection of IL-2, IL-4, IL-10, IL-12p70, IL-1f3, IL-6 and 
IFN-y in culture supernatants, was performed by sandwich ELISA using the BD 
OptEIAhn mouse ELISA set (BD Biosciences), following the manufacturer's 
recommendations. TGF-f31 was measured by the TGF-f3 Emax ImmunoAssay 
System (Promega, Madison WI). Light absorbance at 450 nm was measured 
using a Vmax plate reader (Molecular Devices, Sunnyvale, CA). 
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2.9 Fluorescence-activated cell sorting (F ACS) analysis 
Expression of the V~4 chain gene on the surface of the 9.13 T-cell 
hybridoma was determined by Fluorescence Activated Cell Sorting (F ACS) 
analysis. Cells grown in log-phase were washed once and re-suspended in PBS 
buffer containing 1% BSA and 0.1 % NaN3 (F ACS buffer) and finally were 
adjusted to 107 cells/mi. The BW5147 a-~- cell line that was utilized for the 
generation of the 9.13 T-cell clone, was used as control. 107 cells/ml from both cell 
lines (106 cells per 100 ~1) was incubated with 10 ~g/ml of the I-A5-specific HB4 
mAb (IgG2b) (ATCC). Following 30 min incubation on ice, the cells were washed 
3x with F ACS buffer and were labeled with 1 ~g of anti-mouse CD4 mAb labeled 
with fluorescein isothiocyanate (FITC) and 1 ~g of anti-mouse V~4 TCR mAb or 
1~g of anti mouse a~ TCR mAb both coupled with R-phycoerythrin (R-PE) (all 
from PharMingen). Cells were subsequently incubated at 4°C in the dark for 30 
minutes, were washed 3x with F ACS buffer, and were suspended in 500 ~1 of 1x 
PBS buffer containing 1% paraformaldehyde (Sigma Chemicals). The 
fluorescence of 104 cells was measured by F ACStar Plus analyzer and the results 
were analyzed using Cellquest software (Becton-Dickinson Inc., Franklin Lakes, 
NJ, USA). 
To determine the phenotype of DCs, F ACS analysis was performed as 
described above. PE-labeled hamster anti-CDllc (clone HL3), and rat anti-l-Ak 
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(clone 10-3.6), hamster anti-CD80 (clone 16-10A1), rat anti-CD86 (clone GL1), rat 
anti-CD11b (clone M1/70), rat anti-CD40 (clone 3/23), rat anti-CD45R (clone RA3-
6B2), rat anti-CD8a (clone 53-6.7), all labelled with FITC, were purchased from 
PharMingen. 
The surface phenotype of the CD4+CD25- and CD4+CD25+ T cell subsets was 
characterized by using the following antibodies: rat anti-CD103 (clone M290), 
hamster anti-CD69 (clone Hl.2F3), rat anti-CD137 (clone 1AH2), and rat anti-
CD62L (clone MEL-14), all labelled with FITC (PharMingen). Appropriate 
isotype-matched PE-or FITC-conjugated mAbs were purchased from 
PharMingen. Rat anti-GITR (clone# 108619) and isotype control both FITC-
labeled were purchased from R&D Systems (Minneapolis, MN). Purified hamster 
anti-CD152 (clone 9H10) and isotype-matched FITC-labeled mAb were 
purchased for Pharmingen. 
2.10 Generation of bone marrow-derived dendritic cells (BM-DC). 
Dendritic cells were generated from bone marrow (BM) progenitors as 
previously described (Lutz et al. 1999). Briefly, BM was prepared from femurs 
and tibias of CBA/J mice, and RBC cells were lysed with NH4Cl. For cell culture, 
sterile petri dishes with 100 mm diameter (Corning Incorporated, Coming, NY 
USA) were used. At day 0, BM cells were seeded at 2 x 106 per 100 mm dish in 10 
ml RPMI 1640 medium supplemented with 10 % GM-CSF supernatant. At day 3, 
74 
another 10 ml of media containing 10% GM-CSF were added to the plates. At 
days 6 and 8, half of the culture supernatant was collected, centrifuged and the 
cells were resuspended in 10 ml fresh medium containing 10 % GM-CSF 
supernatant, and given back into the original plate. At day 10, non-adherent cells 
were collected and used for further study. Semi-mature DCs (sm-DCs) or mature 
DCs (m-DCs) were generated by the addition of 40 ng/ml tumor necrosis factor a 
(TNF-a, Peprotech) or 1 1-1g/mllipopolysaccharide (LPS, Sigma) at day 9 of 
culture. Twenty-four hours later non-adherent cells were gently dislodged and 
harvested for further study. 
2.11 Adoptive transfer of sm-DCs and EAT induction. 
On day 9 of DCs generation, cells were pulsed with Tg (100 1-1g/ml) or 
OVA (100 1-1g/ml) for 6h and were subsequently treated with TNF-a (40 ng/ml) 
for 24h. TNF-a-treated DCs (sm-DCs) were then washed with PBS and adjusted 
at 2.5 x 107 cells/mi. Cells were intravenously (i.v.) injected into CBA/J mice (100 
J.!l/mouse) at days 1, 3 and 5. As a control, a third group of mice received PBS i.v. 
on days 1, 3, and 5. On day 7 from the initial injection, all mice were immunized 
with Tg (100 1-1g/mouse) in CFA, and 21 days later, thyroid glands were removed 
to assess pathology. Spleens were also collected for further study. 
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2.12 Isolation of CD4+CD25+ and CD4+CD25-T cells. 
Spleen tissues from CBA/J mice were passed through a sterile stainless 
steel mesh (Sigma), and single cell suspensions were prepared. CD4+CD25+ and 
CD4+CD25-T cells, were purified using a magnetic cells sorting (MACS) 
CD4+CD25+ regulatory T cell isolation kit (mouse) according to the 
manufacturer's protocol (Miltenyi Biotec, Auburn, CA, USA). Briefly, CD4+T 
cells were isolated by depletion of magnetically labeled non-CD4+ T cells. CD4+ T 
cells labeled with PE-conjugated anti-CD25 and were then magnetically labeled 
with anti-PE MicroBeads provided with the kit. The magnetically labeled cells 
were passed through a column placed in the magnetic field of MACS separator. 
The CD4+CD25+ T cells retained in the column and the flow through was shown 
to be >90% of CD4+CD25- T cells. Following elution, the CD4+CD25+ T cells were 
shown to be >90% by flow cytometric analysis. 
2.13 Mixing and transwell experiments 
CBA mice were immunized subcutaneously (s.c.) with 100 !lg of Tg in CF A 
and 9 days later, draining lymph nodes were isolated and single cell suspension 
was prepared. CD4+CD25- T cells (effector cells), purified as described above, 
were cultured (1 x 105 cells/well) in the presence or absence of Tg (100 !lg/well) in 
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flat-bottom 96-well plates for 4 days at 37 oc in a 10% C02, 90 air-humidified 
incubator. Splenocytes (2 x 105 cells/well) isolated from syngeneic nai:ve mice and 
treated for 15 min with 50 !lg/ml mitomycin C (Sigma) were used as APC. Mixing 
experiments were performed by the addition of equal numbers (1 x 105 cells/well) 
of CD4+CD25+ T cells, isolated from DC-treated CBA mice and syngeneic 
CD4+CD25· T cells. Eighteen hours before harvesting, 1!lCi of (3H] thymidine was 
added to each well in 25 Ill of complete medium. 
Transwell experiments were performed in 24 -well plates (0.22 11m pore size; 
Costar). 6 x 105 CD4+CD25· effector T cells (isolated from Tg-challenged mice as 
described in the previous paragraph) were cultured with 1.2 x 106 APC in the 
presence of 100 11g/ml Tg and 6 x105 CD4+CD25+ T cells were placed in the same or 
in the top chamber. When CD4+CD25+ T cells cultured in the top chamber, APC 
and Tg were added at the same chamber. After 3 days of culture, the transwell 
chamber was removed and lJ-tCi of (3H] thymidine was added to the lower well. 
2.14 Suppression of Tg-induced EAT 
CBA/J mice were challenged with Tg- or OVA-pulsed DCs as described above 
and 21 days later spleens were collected. CD4+CD25+ T cells were prepared and 5 
x 105 cells/mouse were administered i.p. into syngeneic nai:ve recipients. Control 
mice received one i.p. injection of PBS. One day later, some mice were 
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immunized s.c. with 100 Jlg of Tg in CFA and 21 days after Tg challenge, all mice 
were sacrificed and thyroid glands were collected. Thyroid pathology was 
assessed as described above. 
2.15 RNA isolation 
Total RNA was extracted using the TRizol reagent (Gibco-BRL, 
Burlington, ON, Canada) following the manufacturer's protocol. Briefly, 5x106 
cells were lysed in 1 ml of TRizol reagent. Addition of 200 !J.l chloroform (Sigma 
Chemicals) followed by centrifugation separates the solution into an aqueous 
phase, that contains the RNA, and an organic phase. The aqueous phase (600 !J.l) 
was transferred in a new diethyl pyrocarbonate-treated (DEPC) tube and RNA 
recovered by precipitation with isopropyl alcohol (500 !J.l). The isolated RNA 
washed with 70% ethanol (1 ml), air-dried and resuspended in 20 !J.l of RNAase-
free water (Sigma Chemicals). The RNA yield as well as its purity was measured 
using a spectrophotometer at the optical densities of 260 and 280 nm. 
2.16 First-strand eDNA synthesis and Genomic DNA extraction 
First-strand eDNA synthesis was performed using a kit from Amersham 
Pharmacia Biotech Inc. (Uppsala, Sweden). Briefly, 5 !J.g of total RNA was heated 
78 
in 65°C for 10 min to remove any RNA secondary structure, and then chilled on 
ice. The RNA was then added in a mixture containing 11 ~1 first-strand bulk mix, 
1~1 dithiothreitol (DTT) solution and 0.2 ~g (1 ~1) Not I-d(T)1s primer, all 
provided with the kit. The enzyme that catalyzed the reaction contained in the 
First-strand Bulk mix is Moloney Murine Leukemia Virus (M-MuL V) reverse 
transcriptase. The mixture was then incubated for 1 hour at 37°C and the 
resultant product was heated at 75 oc for 10 min to terminate the reaction. The 
eDNA was stored at -20°C. 
Genomic DNA was extracted from 5 x 106 cells by using the "DNeasy 
Tissue Kit" (Qiagen) and following the manufacturer's instructions. 
2.17 Polymerase Chain Reaction (PCR )for gene amplification 
First strand eDNA was amplified by PCR in a reaction mixture containing 
1x PCR buffer, 2 mM MgCh, (both from Invitrogen, Carlsbad, CA, USA), 0.2 mM 
of each dNTP (Gibco-BRL), 20 pmoles of each primer (forward and reverse, 
Operon Technologies, Inc. Alameda, CA, USA), 1 ~1 of eDNA and 2.5 U of Taq 
polymerase (Invitrogen) in 100 ~1 final volume of RNAase-free water. A 35-cycle 
step program was conducted using the Perkin Elmer DNA thermocycler (Cetus, 
Norwalk, CT, USA) with 1 min denaturation at 95 °C, 1 min annealing at 55 °C, 
and 1 min extension at 72 °C preceded by a 5 min denaturation step at 94 °C. The 
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amplified PCR product was subjected to agarose gel electrophoresis containing 
ethidium bromide (0.5 ~g/ml) for product visualization. 
2.18 RNA ligase-mediated rapid amplification of 5' eDNA ends (RLM-RACE) 
The GeneRacer Kit (Invitrogen) was used in order to identify the 5' end of 
the TCR a chain gene of a Tg peptide-specific T cell hybridoma. Briefly, total 
RNA was extracted from the 9.13 T-cell hybridoma as described above and was 
treated with calf intestinal phospatase (CIP- provided with the kit) to remove 
the 5' phosphates, followed by treatment with tobacco acid pyrophosphatase 
(TAP-- provided with the kit) to remove the 5' cap structure from full-length 
mRNA. The GeneRacer RNA Oligo (provided with the Kit) was ligated next to 
the 5' end of the mRNA using T4 RNA ligase. The mRNA was then reverse-
transcribed to eDNA using an oligo dT primer (supplied with the kit). 
Amplification of eDNA was performed with an oligo-specific forward primer 
(GeneRacer™ 5' primer Table 2.2) and a reverse primer, specific for the a 
constant chain (Ca-R Table 2.2). Material from the first round PCR was subjected 
to nested PCR using, as forward primer a nested oligonucleotide of the RNA 
oligo (GeneRacer™ 5' nested primer Table 2.2) and as reverse primer, a nested 
Ca oligonucleotide (either Cal-R or Ca2-R Table 2.2). The amplified products 
were subjected to agarose gel electrophoresis, and the band containing the a 
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chain gene was cut and purified using the QIAquick Gel Extraction Kit (Qiagen) 
in order to be cloned. 
2.19 Cloning of the 9.13 TCR a chain gene 
In order to sequence the a chain segment, the amplified PCR product was 
gel extracted and cloned into the TOPO TA cloning kit (Invitrogen). According to 
this method, Topoisomerase I from Vaccinia virus is covalently bound to a 
plasmid vector (pCR®4-TOPO), which is supplied linearized. The enzyme binds 
to double-stranded DNA at specific sites and cleaves the phosphodiester 
backbone after 5' -CCCTT in one strand, generating single, overhanging 3' 
deoxythymidine (T) residues. Taq polymerase has a nontemplate-dependent 
terminal transferase activity, which adds a single deoxyadenosine (A) to the 3' 
ends of PCR products. This allows the PCR inserts to ligate efficiently with the 
vector. TOPO cloning reaction was performed for 5 min at room temperature, 
and 2 11-l of the mixture were transferred to a vial containing TOP10 One Shot 
Chemically Competent E.coli (Invitrogen). Upon incubation on ice for 30 min, the 
cells were heat-shocked for 30 seconds at 42 oc, and transferred immediately to 
ice where 250 11-1 of SOC medium (Invitrogen) were added. After 1 h incubation 
at 37 oc with moderate shaking (200 rpm), 100 11-1 from the reaction were spread 
on a pre-warmed Luria Bertani (LB) agar plate containing 100 11-g/ml of ampicillin 
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(Sigma Chemicals, St. Louis, MO, USA) and incubated for 12-16 hat 37 oc. 
Plasmid DNA purification was performed with the plasmid mini-prep DNA 
extraction kit (Mississauga, ON, Canada). Purified plasmid DNA was then 
subjected to PCR amplification by using a forward vector-specific primer (T7-F, 
Table 2.2) and the Ca.-R2 reverse primer. Positive plasmids were sequenced in 
order to identify the entire gene sequence. 
2.20 Amplification of the 9.13 TCR a. chain gene segments from genomic DNA. 
Genomic DNA that was extracted from the 9.13 T-cell hybridoma, was used 
as template in order to amplify the Leader(L)-Variable(V)-Joining(J) segment of 
the TCR a. chain by PCR. The amplified segment was ligated into the pTa. 
cassette vector kindly provided by Dr. D Mathis (Joslin Diabetes Center Harvard 
Medical School, MA, USA). Two forward primer sequences, that contain an 
overlapping region, were designed to engineer a unique Xmal restriction site 20 
bp 5' of the ATG starting codon and a pTa. vector-specific sequence. The first 
primer amplifies the beginning of the leader Va.l.1 sequence (LVa.l.1-F, Table 
2.2), and the second primer, contains an overlapping sequence with the first 
primer and also introduces the Xmal restriction site (Xmal-pTa.-F, Table 2.2). A 
sequence located 30 bp within the intronic region downstream of Ja49 segment 
(EMBL/GenBank data libraries accession number 15795314) was used to design 
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reverse primer. The oligonucleotide was designed to introduce the Not-I 
restriction site for subsequent cloning (Ja49-inton-Notl-R Table 2.2). 
The length of the intronic region between the L and the V region of the 
gene was calculated based on the published genomic sequence of the mouse TCR 
a locus (EMBL/GenBank data libraries accession number 15795314). Resolution 
of the PCR reaction product by 1.5% agarose gel was performed and the band 
contained the L VJ a gene was gel-extracted, purified and cloned into pCR4-TOPO 
vector as described above. TOP 10 E. coli competent cells were transformed with 
the cloned product and plasmid DNA was purified and sequenced. 
2.21 Cloning of the 9.13.TCR [3 chain gene. 
The variable region of the TCR [3 chain expressed by the 9.13 T cell 
hybridoma belongs to Vf34 family (Rao et al. 1997). In order to amplify and clone 
the entire [3 chain gene, a forward primer specific for the beginning of the leader 
Vf34 gene sequence (Kpnl-V[34-F, Table 2.2) and a reverse primer specific for the 
3' of the Cf3 region (Xbal-C~1-R Table 2.2) were used. The primers were designed 
to introduce the unique Kpn-I and Xba-I restriction sites, in order to facilitate 
subsequent cloning. Upon amplification, the PCR product was subjected in 
agarose gel (1.5%) electrophoresis and the expected band was cut and purified 
using the QIAquick Gel Extraction Kit (Qiagen). 
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The purified ~ chain gene was digested with Kpnl and Xbal restriction 
enzymes (Promega, Madison, MI, USA). Briefly, 5 ~1 of the PCR product were 
mixed with 1 ~1 of each restriction enzyme (10 U/~1 each), 0.5 ~1 of BSA 
Acetylated (1 mg/ml) and 5 ~1 of MULTI-CORE buffer lOX (all from Promega) in 
a total volume of 20 ~1 of nuclease-free water (Sigma). After incubation for 1 hat 
37 °C, the digested product was gel purified and re-concentrated by ethanol 
precipitation for subsequent ligation reaction. The pcDNA3.1/zeo+ mammalian 
expression vector (Invitrogen) was similarly digested, gel purified and mixed 
with the DNA insert in two different vector: insert (1:1 and 1:2) ratios, in order to 
identify the optimum ratio for efficient ligation. The ligation reaction was 
performed in the presence of T4 DNA ligase (Invitrogen) for 30 min at room 
temperature. TOP10 One Shot Chemically Competent E.coli were transformed as 
described above and 100 ~1 from the reaction were spread on a pre-warmed LB 
agar plate containing 100 ~g/ml of ampicillin and incubated for 12-16 h at 37 oc. 
Positive colonies were identified by PCR with a vector specific forward primer 
(from the T7 promoter priming site) and an insert specific reverse primer (the 
C~l-R primer). DNA plasmids were purified with the plasmid mini-prep DNA 
extraction kit, and those that were found to contain the ~ chain gene were 
sequenced in order to identify the entire ~ chain sequence. 
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2.22 Amplification of the 9.13 TCR B chain gene segment from genomic DNA 
The L-V-Diversity(D)-J ~chain segment was amplified from genomic 
DNA of the 9.13 T cell hybridoma by PCR for ligation into the pT~ cassette 
vector (also provided by Dr. D. Mathis). Primers were designed to introduce a 
unique Xhol restriction site 7 bp 5' of the starting codon (Xhol-pT~-F, Table 2.2), 
and a novel Apai-Sacll 35 bp 3' within the intronic sequence of JB2.1, (J~2.1-Apai­
Sacii-R, Table 2.2). The length of the intronic region between the Land the V 
region of the gene was calculated based on the published genomic sequence of 
the mouse TCR B locus (EMBL/GenBank data libraries accession number 
2358100). The PCR product was visualized in 1.5% agarose gel, and the 
respective B chain gene was cut and gel purified as described above. To ensure 
fidelity during amplification, the B chain gene was digested with Xhol and Apal 
and was cloned into the multi-cloning site of the pcDNA3.1/zeo+ mammalian 
vector, which had previously digested with the same restriction enzymes. Upon 
transformation of TOP 10 E. coli competent cells, several colonies were 
identified. Colonies were tested by PCR amplification for the presence of the 
insert. For this reason a vector specific primer (T7, same as above) and a gene 
specific primer (JB2.1-R, same as above, for the B chain) were used. DNA 
plasmids were extracted from positive colonies as described above and were 
sequenced. 
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2.23 Preparation of the pTa and pT[3 constructs that contain the 9.13 TCR a and 
[3 chains 
To generate the constructs that contain the a and [3 chain of the 9.13 T cell 
hybridoma, we used the pTa and pT[3 cassette vectors (Kouskoff et al. 1995), 
kindly provided by Dr. D. Mathis. To confirm the correct profile of the cassette 
vectors several restriction enzyme digestions were performed. The following 
restriction enzymes were used: BamH1, Sali and Sali/Noti for pTa and EcoR1, 
Kpn1 and Xhoi/Sacii for pT[3 (all from Promega) and the digestion reactions 
were performed according to the manufacturer's protocol. 
Sequenced a and [3 chain segments that were found to be in frame upon 
comparison with the genomic sequences, were excised from the pCR4-TOPO and 
pcDNA3.1/zeo+ vectors respectively. Excision of the TCR a chain gene was 
performed with the enzymes Xma1 and Notl, and TCR [3 chain gene with the 
Xho1 and Sacii restriction enzymes. The resulting products were quantified using 
the 2-Log DNA Ladder (New England Biolabs Beverly, MA, USA). The TCRa 
and TCR~ expression cassette vectors were also digested with Xma-I/Not-1 and 
Xho-1/Sac-II enzymes respectively and were quantified using the same DNA 
ladder. Ligation of the L VJa and L VDJ[3 into the cassette vectors was performed 
in equimolar (1:1) ratio at room temperature for 12h. Upon transformation of XL-
10 Gold Ultracompetent cells (Stratagene, La Jolla, CA, USA) with the pTa or 
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pT~ constucts, several colonies (-50) were obtained. DNA plasmids were 
purified and were screened with restriction enzyme digestion reactions to 
identify the vectors with the correct profile and also with PCR to verify the 
presence of the desired genes. For amplification of the a chain the LV a1.1-F 
(Table 2.2) forward primer was used in combination with a reverse primer from 
the unique VJa-R region (VJa-R, Table 2.2). For the ~ chain amplification, a 
forward primer within the V~4 sequence (V~4-F, Table 2.2) and a reverse primer 
from the unique VDJ~ region (VDJ~-R, Table 2.2) were used. 
2.24 Genotyping for identification of 9.13 TCR transgenic mice. 
9.13 TCR transgenic mice were identified by a PCR screening strategy using 
primers specific for 9.13TCR a and~ chain. Briefly, mice tail biopsies were 
performed at age of 4 weeks and genomic DNA was extracted as described in 
Materials and Methods. A duplex PCR which contains two pairs of primers was 
set up to examine the presence of 9.13 TCR transgenes. For detection of 9.13TCR 
a-chain-gene 5' GATTTTCCTGAATACATCTCCCG-3' and 5'-
CCAAAATAGAAGTTCTGGTAACC-3', as well as PCR internal control primers 
which amplifies TCRd exon 1 gene, 5' -CAAATGTTGCTTGTCTGGTG-3' and 5'-
GTCAGTCGAGTGCACAGTTT-3', were used. Similarly, 9.13TCR f3 gene-
specific primers 5' -CTCACCAAAGAGACCAGTATCTC-3' and 5'-
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CACACACAAACCCGCGGACT-3', in addition to PC:R internal control primers, 
were used to identify 9.13 TCR [3 transgene. Approximately 100 ng DNA was 
added to each 50 !J.l PCR reaction which contains 2 mM Mg2+, 0.4 !J.M primers, 
200 mM dNTPs and 1 U Taq polymerase. Cycling was performed in a PTC-100 
thermal cycler (MJ Research, Waltham, MA) with 35 cycles of 94 QC 15s, 57 QC 
15s, 72 QC 45s, which was followed by a extension step at 72 QC for 5 min. In each 
run, a no-template control and a plasmid control were included. Final PCR 
products were analysed by agarose gel eletrophoresis. 
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Table 2.2 Primer list 
Denotation 5'Sequence3' 
Kpnl-V~4-F CCCCTACCATCCCCTCCATTTTC 
Xbai-C~l-R CCCCTCTACATCACCAATTTTTTTTC 
Xhol-V~4-F ACTCTCCACACCAACCATCCCCTCCA 
Val.l-F ACCTCCACCACACCCCACAA 
L-Val.l-F CTCACTCCCTACCCATCAAATCCTTC 
Ja49-intron-Noti-R CTCCCCCCCCCACAATTCTACAC 
J~-2.1-R CACCCCCCCCCCACTCTCCTACCTT 
J~-2.1-Apal-Sacii-intron-R CTCCCCCCCCGCTCACTCTCCTACTT 
Xmal-pTa-F CACCCCCCCTTCTCACTCCCTAC 
Xhol-pT~-F CACTCCACACCAACCATCACCT 
Ca-R AAA TCC CCC TAC TTT CAC CA 
Ca-Rl CCA ACC TCT GAA CTC CCC TA 
Ca-R2 CAC TTT TCT CAC TCA TC 
VJa-R CTC CTA ACC CCT CTT ACC TCC AC 
V~4-F CCT CAA CTC GCT TCC AAC C 
VDJ~-R CAA CAC CCC CAC TCT TCC CTC CT 
CeneRacer ™ 5' primer CCACTCCAGCACCACCACACTCA 
CeneRacer™ 5' nested primer CCACACTCACATCCACTCAACCACTA 
T7-F TAATACCACTCACTATACCC 
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3 CHAPTER3 
Delineation of five thyroglobulin T-cell epitopes with 
pathogenic potential In experimental autoimmune 
thyroiditis 
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3.1 Abstract 
Experimental autoimmune thyroiditis (EAT) is a T -cell mediated disease 
that can be induced in mice following challenge with thyroglobulin (Tg) or Tg 
peptides. To date, five pathogenic Tg peptides have been identified, four of 
which are clustered toward the C-terminal end. Because susceptibility to EAT is 
under control of H-2Ak genes, we have used an algorithm-based approach to 
identify Ak-binding peptides with pathogenic potential within mouse Tg. Eight 
candidate synthetic peptides, varying in size from 9 to 15 a.a., were tested and 
five of these (p306, p1579, p1826 p2102 and p2596), were found to induce EAT in 
CBA/J (H-2k) mice either after direct challenge with peptide in adjuvant or by 
adoptive transfer of peptide-sensitized lymph node cells (LNC) into naive hosts. 
These pathogenic peptides were immunogenic at the T -cell level eliciting specific 
LNC proliferative responses and IL-2 and/or IFN-y secretion in recall assays in 
vitro but contained non dominant epitopes. All immunogenic peptides were 
confirmed as Ak binders since peptide-specific LNC proliferation was blocked by 
an Ak-specific but not a control mAb. Peptide-specific serum IgG was induced 
only by p2102 and p2596 but these Abs did not bind to intact mTg. This study 
reaffirms the predictive value of Ak-binding motifs in epitope mapping and 
doubles the number of known pathogenic T -cell determinants in Tg that are now 
found scattered throughout the length of this large autoantigen. This knowledge 
91 
may contribute toward our understanding of the pathogenesis of autoimmune 
thyroiditis. 
3.2 Introduction 
Experimental autoimmune thyroiditis (EAT) can be induced in genetically 
susceptible mice after challenge with thyroglobulin (Tg) in adjuvant (Champion 
et al. 1992;Charreire 1989;Rose et al. 1971;Weetman and McGregor 1994). A 
salient feature of the disease is the gradual destruction of the thyroid gland by 
infiltrating mononuclear cells, a process which also takes place in Hashimoto's 
thyroiditis in humans, leading to hypothyroidism (Weetman and McGregor 
1994). There is strong evidence that CD4+ T cells are both sufficient and necessary 
in EAT induction because the disease can be transferred into nai:ve recipients by 
CD4+ T cell lines or clones (Maron et al. 1983;Romball and Weigle 1987), does not 
develop in nude mice (Vladutiu and Rose 1975), and is under the control of H-
2Ak genes in mice bearing the susceptible H-2k haplotype (Beisel et al. 
1982a;Kong et al. 1997;Vladutiu and Rose 1971). 
Evidence supporting the view that Tg is a major autoantigen in clinical or 
experimental thyroiditis dates back to 1956 (Roitt et al. 1956;Rose and Witebsky 
1956). The molecule is quite abundant in the thyroid gland representing 75-80% 
of the total protein in the thyroid extract (Shulman 1971), and it can be easily 
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isolated by gel filtration chromatography. These features, however, did not aid in 
the identification of pathogenic T -cell epitope sites by biochemical methods as 
this was hampered by the large size of the molecule (homodimeric mass = 660 
kDa). In addition, previous T -cell epitope mapping efforts could not avail 
themselves of the mouse Tg (mTg) gene sequence information and utilized either 
the human (Malthiery and Lissitzky 1987), or the partial rat (DiLauro et al. 1985) 
Tg sequence data in EAT studies, relying on the high sequence homology among 
Tg from different species. Despite these difficulties, over the last decade, and via 
a variety of methods, five immunopathogenic Tg peptides have been identified, 
encompassing at least six distinct T-cell epitopes (Carayanniotis and Rao 1997). 
The use of Tg peptides as model antigens in EAT generated an impetus for 
studying the immunoregulation of the disease (Carayanniotis and Kong 2000). At 
the same time, the emerged map of the pathogenic Tg epitopes focused attention 
on new issues that remain unresolved. First, none of the known pathogenic Tg 
peptides appears to comprise an immunodominant epitope, since these peptides 
cannot be generated following processing of intact Tg by antigen presenting cells 
in vitro (Carayanniotis and Kong 2000;Carayanniotis and Rao 1997). The 
experimental evidence, however, clearly suggests the presence of dominant Ak-
binding epitopes(s) within Tg as supported by the known genetic control of the 
Tg-mediated EAT by the 1-Ak locus (Beisel et al. 1982a;Kong et al. 1997), and the 
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prevention of EAT by treatment of mice with Ak-specific antibodies (Vladutiu 
and Steinman 1987b). Second, four out of the five known pathogenic peptides are 
clustered toward the C-terminal end of Tg, raising the question whether the rest 
of this large molecule can contain additional EAT -causing epitopes. 
In this study, we proceeded to do a systematic search of the complete mTg 
sequence (Kim et al. 1998) for the detection of dominant and/or additional EAT-
causing T-cell epitopes by utilizing an algorithm (Altuvia et al. 1994) that 
searches for Ak-binding motifs within a protein sequence. This algorithm takes 
into account the physicochemical characteristics and structural properties of 
amino acids within motifs that are shared among immunogenic Ak-binding 
peptides. The study was undertaken in the EAT-susceptible strain CBA/J (H-2k) 
but suggests an approach that can be applied equally well to EAT -susceptible 
strains of other H-2 haplotypes or to other thyroid autoantigens. 
3.3 Results 
3.3.1 Prediction ofTg peptides containing 1-Ak- binding motifs 
The complete mTg sequence (Kim et al. 1998) was scanned for the 
presence of two Ak-binding motifs; a heptamer motif A and a pentamer motif B 
(Table 3.1), by using the algorithm described by Altuvia et al. (Altuvia et al. 
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1994). This computerized method was developed following a compilation of an 
extended database of helper T -cell sites and takes into account physical-chemical 
and structural properties of peptides - dictated by the primary a.a. sequence that 
may be responsible for binding to MHC class II antigens. Sixty nine and forty 
seven sites containing motif A orB, respectively, were identified (data not 
shown). To maximize the chances for success, we focused our attention to 
thirteen peptides encompassing completely overlapping motifs A and B flanked 
by four a.a. (Table 3.1). Of these, peptides (224-238) and (228-242) identified an 
overlapping motif-rich site, thus prompting the synthesis of a single peptide 
(226-239) containing this region. The peptides (824-838) with three proline 
residues flanking the motifs, and (837-851) with a proline residue inside a motif 
were not considered for further study, because of concerns that Pro may 
drastically affect the secondary structure. Peptides (2490-2504) and (2543-2557) 
were shown previously to contain EAT-causing T cell epitopes (Chronopoulou 
and Carayanniotis 1992;Rao et al. 1999). With these considerations in mind, we 
proceeded to synthesize the eight motif A and B -containing peptides pllO, p226, 
p306, p1579, p1826, p2026, p2102, and p2596 (Table 3.1) and examine their 
immunopathogenic propepties. 
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Table 3.1 Putative Ak-binding peptides within the mTg sequence. 
a.a Motif-containing Peptide 
coordinatesa sequenceb peptide synthesized denotation 
107-121 YAPVQCDLQRVQCWC VQCDLQRVQ p110 
224-238 RELAETGLELLLDEic LAETGLELLLDEIY p226 
228- 242 ETGLELLLDEIYDTic 
306-320 YQTVQCQTEGMCWCV YQTVQCQTEGMCWCV p306 
824-838 QDVPQVVLEGATTPPd N.D.e 
837-851 PPGENIFLDPYIFWQd N.D. 
1577-1591 SPL VQCLTDCANDEN L VQCLTDCANDEA p1579 
1823- 1837 DFPGDMATELFSPVD GDMATELFSP p1826 
2025-2039 CGSEDTEVHTYPFGW GSEDTEVHTYP p2026 
2102-2116 SMAQDFCLQQCSRHQf SMAQDFCLQQCSRHQ p2102 
2490-2504 PSQDDGLINRAKA VKg N.D. 
2543-2557 YYSLEHSTDDYASFSg N.D. 
2594-2608 ESYGHGSLELLADVQ YGHGSLELLADVQ p2596 
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3.3.2 Identification ofT-cell activating peptides encompassing Ak-binding epitopes 
In order to examine the immunogenicity of the Tg peptides, CBA/J mice were 
challenged s.c. at two sites on the back with 100 nmol of each peptide. Nine days 
later, the inguinal, axillary and brachial LNC were collected and cultured in the 
presence of varying concentrations of the immunizing peptide. Five out of eight 
Tg peptides, p306, p1579, p1826, p2102 and p2596 (Figure 3.1) induced significant 
and specific LNC proliferation since there was no detectable response against the 
control peptide p2495. This reactivity profile correlated well with the capacity of 
the same peptides to elicit IL-2 (Figure 3.1) and/or IFN-y (Figure 3.1) release from 
such activated LNC. IL-4 and IL-10 were undetectable in all culture supernatants 
(data not shown), indicating that these peptides -with the exception of p2102 
which elicited IL-2 but not IFN-y release- activated Thl cells. In all cultures, 
peptide-specific proliferation was significantly blocked by an 1-Ak-specific, but 
not by a control NP-specific mAb (Figure 3.2) strongly suggesting that 
recognition of these five immunogenic peptides occurred in the context of Ak 
molecules. These results confirmed the predictive value of the algorithm and the 
identification of five new Tg peptides encompassing Ak-restricted T-cell epitopes. 
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Figure 3.1 Assessment of peptide immunogenicity in CBA/J mice. 
.l~munlzlng 
peptide 
Cl p24i!B 
A, Recall proliferative responses of peptide-primed LNC in the presence of 25 
~M of the respective peptide or p2495 as a control. Data represent the mean S.l. 
values of triplicate wells that were obtained from full peptide titration curves 
and are representative of four experiments. Background cpm ranged between 
500 and 2000. Band C, Determination of cytokines by sandwich ELISA in 48h 
culture supernatants of peptide-primed LNCs incubated in the presence of 10-20 
J.!M of the respective peptide or p2495 (control). IL-4 and IL-10 were 
undetectable (with detection limits 10 and 17 pg/ml, respectively) under similar 
conditions. Results are representative of two separate experiments. 
99 
p306 
p1579 
p1826 
p2102 
p2596 
0 25 50 
% inhibition 
75 100 
• anti-1-Ak 
D anti-NP 
Figure 3.2 Inhibition of LNC proliferative responses against various Tg peptides. 
LNC were isolated from Tg peptide-immunized CBA mice and cultured in the 
presence of the respective peptide (final concentration 25 f.lM) and mAbs (10 
f.lg/ml) specific for I-Ak or influenza nucleoprotein (control). Antigen specific 
proliferation was measured by (3H] uptake as described in Materials and 
Methods. Data represent mean+/- S.D. of triplicate wells. 
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3.3.3 The immunogenic Tg peptides do not contain immunodominant determinants 
To examine if any of the five immunogenic peptides contains dominant T-
cell determinants, CBA/J mice were s.c. primed with 100 1-1-g of intact Tg in CFA 
as above and 9 days later the draining LNC were cultured in the presence of Tg 
or free peptide. As shown in (Figure 3.3), Tg-primed LNC responded strongly to 
Tg in vitro but failed to respond to equimolar (0.2- 0.9 1-1-M range) concentrations 
of free peptide. This lack of responsiveness was observed even at higher 
concentrations of free peptide (up to 75 f.!M), thus excluding the possibility that a 
narrow range of peptide concentration might influence the results. Conversely, 
LNC primed in vivo with any of the five immunogenic peptides did not respond 
to intact Tg in recall assays in vitro (data not shown). These results do not 
support the view that these immunogenic peptides encompass dominant T -cell 
epitopes. 
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Figure 3.3 Proliferative reponses of mTg-primed LNC to the indicated antigens in 
vitro. 
Mice were injected s.c. with 100!-lg of Tg in CF A and 9-10 days later draining LN 
were collected. Cells were adjusted at 4 x 106 cells/ml and plated in the presence 
or absence of titrated amounts of Tg or Tg peptides. Antigen specific 
proliferation was measured by (3H] uptake as described in Materials and 
Methods. Data show the mean+/- S.D. of S.l. values of triplicate wells and are 
representative of 2 experiments. Background cpm was 2000. 
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3.3.4 The I-Ak binding peptides are thyroiditogenic in CBAIJ mice 
Subsequently, CBA/J mice (6 per group) were immunized with each of the 5 
immunogenic peptides above in CF A and were boosted, 3 weeks later, with the 
same peptide in IF A. Five weeks from the initial challenge, thyroid glands were 
removed for histological examination of EAT development and the infiltration 
index was scored as described in Materials and Methods and representatively 
shown in (Figure 3.4). With the exception of p2102 which did not elicit 
detectable pathology, all other peptides induced mild and variable EAT with 
mean I.I. varying from 0.2 (p1826) to 1.2 (p306) (Table 3.2). On the other hand, 
adoptive transfer of peptide-primed LNCs into syngeneic CBA/J hosts increased 
both the incidence and the severity (I.I. 0.7 -2.2) of EAT in all groups, including 
the one challenged with p2102, (Table 3.2), confirming that all five immunogenic 
peptides have thyroiditogenic potential. Intrathyroidal homing of mononuclear 
cells was specific since analogous infiltration was not observed in liver or kidney 
samples of these mice (data not shown). Peptide pathogenicity did not correlate 
with the presence of peptide-specific IgG in pooled sera of CBA/J mice with EAT 
since only p2102 and p2596 elicited IgG responses (Figure 3.5) In addition, 
peptide- reactive IgG did not appear to bind to intact Tg suggesting that p2102 
and p2596 are either not expressed on the surface of Tg or that they adopt in free 
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form a conformation different from the one they assume within the intact Tg 
molecule. 
Figure 3.4 Histological appearance of mononuclear cell infiltration in mouse 
thyroids following induction of EAT with Tg peptides. 
A, normal gland I.I.=O; B and C interstitial accumulation of inflammatory cells, 
I.I.=1; D and E one or two foci of inflammatory cells, I.I. =2; F, extensive 
infiltration, 10-40% of total thyroid gland, 1.1.=3. Magnifications: A,B,D and F, 
100x; C and E, 200x. 
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Table 3.2 EAT induction by Tg peptides in CBA/J mice. 
Direct induction of EATa Adoptive transfer of EA Tb 
Infiltration index (I. I.) #mice Mean Infiltration index (1.1.) #mice Mean 
antigen 0 1 2 3 with EAT 1.1. 0 1 2 3 with EAT 1.1. 
p306 3 1 0 2 3/6 1.2 ± 1.5 1 0 1 4 5/6 2.2 ± 1.2 
p1579 5 0 1 0 1/6 0.3 ± 0.8 1 0 1 3 4/5 2.2 ± 1.3 
p1826 5 1 0 0 1/6 0.2 ± 0.4 1 2 3 0 5/6 1.3 ± 0.8 
p2102 6 0 0 0 0/6 0 3 2 1 0 3/6 0.7 ± 0.8 
p2596 2 3 1 0 4/6 0.8 ±0.8 1 1 3 1 5/6 1.7±1.0 
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Figure 3.5 IgG responses in pooled immune sera of CBA/J mice. 
IgG responses in pooled immune sera of CBA/J mice (6 mice/group) that were 
primed and boosted with the indicated peptide for EAT development as 
described in Table II. Mice were bled five weeks after the initial challenge. The 
reactivities against the immunizing peptide, mTg or p2495 (control) are 
presented as the mean O.D. values of triplicate wells. 
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3.4 Discussion 
We have conducted an algorithm-based search for pathogenic, I-Ak-
binding peptides within the complete mTg sequence in order to substantiate, at 
the T-cell epitope level, the well known control of Tg-induced mouse EAT by the 
I-Ak region (Beisel et al. 1982a;Kong et al. 1997). Our findings double the known 
number of EAT-inducing Tg sequences from five to ten and map, for the first 
time, four MHC class II-binding pathogenic peptides outside the 534 a.a. C-
terminal acetylcholinesterase-homologous region of Tg (Rachinsky et al. 1990). 
These four peptides (p306, p1579, p1826, and p2102) are scattered throughout the 
2200 a.a. N-terminal segment of the Tg molecule (Figure 3.6) which is known to 
contain three families of homologous domains with cysteine-rich motifs 
(Malthiery and Lissitzky 1987;Mercken et al. 1985). Interestingly, p306 is 
localized within the 1.4 domain with type 1 homology, whereas p1579 as well as 
p2102 are encompassed respectively in the Illa.1 and Illa.3 domains that express 
type 3 homology (Table 3.3). The fifth pathogenic peptide p2596 maps in the 
vicinity of the (2549-2560) epitope which encompasses a thyroxine molecule at 
position 2553 (Champion et al. 1991). 
108 
Table 3.3 Positioning of pathogenic peptides within the repetitive domains of 
mouse Tg 
Domain Amino Acid 
No.a Mouse Tg Seguenceh Coordinatesh 
1.1 F QT VQC QNDGQS CWCVD 29-55 
I.2 y AP VQC DLQRVQ CWCVD 107-123 
1.3 F MP VQC 40 CYCAD 170-220 
I.4 y QT VQC QTEGM CWCVD 306-321' 
I.S y ED IQC YAGE CWCVD 606-620 
1.6 F LP VQC FNSE CYCVD 673--687 
1.7 W RH VQC 124 CWCVD 749-883 
1.8 W EP VQC HAGTGQ CWCVD 1018-1034 
1.9 y VR KQT SGTG TWCVD 1095-1109 
I.10 F SP VQC DLAQGS CWCVL 1157-1173 
Illa.1 DSPLVQ CL TD CA NDEA 1576-1591' 
IIIa.2 EQANLW CL SR CA QEPI 1864-1879 
Illa.3 SMAQDF CL QQ cs RHQD 2102-2116' 
aDomain assignment was as described by Malthiery et al. (Malthiery and 
Lissitzky 1987) for the human Tg sequence. Alignment is shown only for parts of 
the repetitive type I and type III domains according to (Malthiery and Lissitzky 
1987). 
b Amino acid sequence data and numbering are as described by Kim et al. (Kim 
et al. 1998). 
'Peptides used in this study are underlined. Conserved amino acids are shown 
in bold 
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The reasons for the lack of immunogenicity of p110, p226, and p2026 are not 
known but may relate to non H-2 effects on immune responsiveness or 
influences of motif-flanking residues on T -cell recognition (Vacchio et al. 1989). 
In competitive inhibition experiments using a cloned Ak-restricted T cell 
hybridoma specific for the previously identified Tg (2499-2507) epitope (Rao et 
al. 1994), we have not seen large differences in Ak-binding capacity among all 
peptides tested (data not shown). Therefore, collectively, the results confirm the 
predictive value of the algorithm by Altuvia et al (Altuvia et al. 1994) in the 
identification of Ak-binding peptides. This method relies on physical-chemical 
and structural properties of peptides such as hydrophobicity, charge, hydrogen 
bonding capability, etc. that can be extracted from a.a. sequence data. Although 
in this study we concentrated on candidate peptides with completely 
overlapping A and B motifs, it is noteworthy that ninety nine additional Tg sites 
with non overlapping A or B motifs were also revealed by this search (data not 
shown). In contrast, scanning of the complete mTg sequence with a more 
restrictive nonamer Ak-binding motif derived from crystallographic data of the 
Ak molecule complexed with a hen egg lysozyme peptide (Fremont et al. 1998) 
identified only three sequences: (1576-1584) and (1585-1593) partially 
overlapping with p1579 and (2107-2115) partially overlapping with p2102 (Table 
3.1). Thus, it is difficult to predict from such data how many additional Ak-
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binding peptides are harbored within Tg and it is likely that alternative 
approaches might still identify other EAT-causing determinants. Interestingly, 
none of the five pathogenic Tg peptides described herein overlap with seven 
putative I-Ek-binding peptides uniquely expressed in murine Tg, as identified by 
the EpiMer algorithm (Caturegli et al. 1997). In contrast, p306 and p2102 are 
being indicated as sites that contain one out of five Ek-binding motifs according 
to the algorithm of Altuvia et al. (Altuvia et al. 1994). 
The current data also bring into focus the fact that none of the seven 
known Ak-restricted pathogenic Tg peptides -five from the present study, plus 
the (2499-2507) and (2549-2560) epitopes (Champion et al. 1991;Rao et al. 1994)-
can be classified as immunodominant since they cannot be generated following 
processing of intact mTg in vivo and/or in vitro. This is a rather paradoxical 
finding in view of the fact that Tg-induced EAT is under control of the I-Ak locus 
(Beisel et al. 1982a;Kong et al. 1997), implying the presence of dominant Ak-
restricted T-cell epitopes in this large autoantigen. The following explanations 
can be proposed to account for this apparent discrepancy: First, one could 
maintain that immunodominant T-cell epitopes in Tg exist but remain 
unidentified because: a) the sheer size of Tg prevents their easy detection, b) such 
epitopes do not contain hormonogenic sites but are normally iodinated, c) 
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detection is precluded by limitations of algorithm-based approaches in epitope 
mapping (here and in (Carayanniotis et al. 1994;Chronopoulou and 
Carayanniotis 1992) or inherent restrictions in using cloned Tg-reactive T-cell 
hybridomas for screening the antigenicity of overlapping Tg peptides- a method 
followed by Champion et al. for the discovery of the pathogenic (2549-2560) 
sequence (Champion et al. 1991). Second, the theoretical possibility exists that all 
Ak-restricted Tg peptides interact with MHC with similar affinity and activate T-
cell precursors of low frequency, thus not allowing a clearcut hierarchy of 
immunodominance to emerge. In this case, Ak-controlled susceptibility to EAT or 
reactivity to mTg in vitro would be detected as a result of additive or synergistic 
effects of Tg peptide-specific T cell clones which, nevertheless would remain 
individually undetectable due to their low frequency. Third, and most likely, the 
conventional criteria for the definition of immunodominance might not apply to 
Tg. This is an explanation we have previously elaborated on (Carayanniotis and 
Rao 1997), as it is conceivable that in vitro processing of this large autoantigen 
does not normally generate enough of any given epitope to activate peptide-
specific lymphoid cells. For example, optimal processing of 100 flg/ml (150 nM) 
of intact dimeric Tg would not generate more than 0.6 flg/ml (300 nM) of any 
given 2 kDa peptide. 
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For most Tg peptides tested in this study, the adoptive transfer protocol 
led to EAT with higher incidence and severity than that induced following direct 
challenge of hosts with peptide in CF A. These data might be explained on the 
basis of a peptide dose constraint on direct EAT induction- (100 nmol of peptide 
may be a relatively low dose given the non dominant nature of these antigens) -
vis-a-vis the capacity of preformed peptide-specific effector T cells to home 
selectively to the thyroid following the adoptive transfer protocol. In analogy 
with the peptide (2549-2560) previously identified by Raitt's group (Hutchings et 
al. 1992), the pathogenicity of p2102 was shown only by adoptive transfer of 
p2102-primed LNC to syngeneic na·ive CBA mice, confirming the view 
(Carayanniotis and Rao 1997) that the thyroiditogenicity of candidate peptides 
should not be examined only by direct challenge of host mice with the respective 
epitope. We cannot explain why peptide p2102 does not elicit detectable levels of 
IFN-y in culture. However, its potential to elicit mild EAT via the adoptive 
transfer protocol indicates that p2102 activates a very low number of Th1 cells 
and /or other types of effector cells that can infiltrate the thyroid. Indeed, 
previous studies have shown that mice lacking the IFN-y receptor gene are able 
to develop disease upon challenge with Tg (Alimi et al. 1998a), and adoptive 
transfer of Tg-activated T-cells along with a IFN-y -specific Ab into na'ive hosts 
results in the induction of granulomatous EAT (Stull et al. 1992). 
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The present findings support the notion that Tg encompasses many non 
iodinated T-cell epitopes which can be cryptic but pathogenic under conditions 
that allow their generation and presentation in professional APC. In that regard, 
we have previously shown that processing of highly iodinated Tg (Dai et al. 
2002) or Tg-Ab complexes (Dai et al. 1999) in APC allows selective presentation 
of pathogenic but cryptic Tg peptides. These mechanisms would promote 
epitope spreading (Cibotti et al. 1992;Lehmann et al. 1992) and rapid emergence 
of thyroiditogenic T cells since it is unlikely that peripheral tolerance would have 
been pre-established against cryptic Tg determinants (Cibotti et al. 1992). Some 
epitopes may even promote expansion of autoreactive T cells via molecular 
mimicry with foreign pathogens as has been shown previously with the 
pathogenic Tg (2695-2706) determinant that exhibits high homology with the 
(368-381) peptide of murine adenovirus type 1 sequence (Rao et al. 1999). On the 
other hand, an immunoregulatory role for peptide-reactive IgG Abs is quite 
unlikely for the Tg sequences described herein, since only p2102 and p2596 
elicited IgG responses and these Abs did not bind to intact Tg. 
In conclusion, the present study has established the immunopathogenic 
potential of five novel Tg peptides in CBA/J mice out of a list of eight candidate 
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sequences that contain Ak-binding motifs. The overall importance of all 
sequences in mouse EAT can be further evaluated in future studies using H-2k 
strains of diverse non H-2 backgrounds and/or strains of other H-2 haplotypes. 
Work with previously identified pathogenic Tg epitopes, such as the 9-mer 
(2496-2504) which binds to non-isotypic I-P and l-As determinants (Rao et al. 
1994) and the 11-mer (2549-2559) which induces EAT in CBA/J but not in DBA/1 
(H-2q) or SJL (H-25) mice (Rayner et al. 1993) suggests that the outcome of such 
studies is impossible to predict. However, our findings demonstrate a promising 
approach for the identification of immunopathogenic Tg peptides with MHC 
class II-binding properties in EAT which can be analogously applied in the 
search of Tg epitopes relevant to human thyroiditis. 
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Figure 3.6 Relative positions of Tg peptides that are known to cause EAT. 
(~) Peptides containing hormonogenic sites and shared between mTg and 
hTg sequence;(-) peptides derived from mTg; (1::::;:;:::1) peptides derived from 
hTg. The a.a. co-ordinates have been assigned according to mTg sequence data 
by Kim et al. (Kim et al. 1998) and the revised hTg sequence data by van de Graaf 
et al. (van de Graaf et al. 2001) 
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4 Chapter4 
Experimental Autoimmune Thyroiditis (EAT) 
Induced by the Thyroglobulin Peptide (2596-2608): 
Influence of H-2 and Non H-2 Genes. 
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4.1 Abstract 
We have previously identified five thyroglobulin (Tg) peptides with Ak-binding 
motifs that induce experimental autoimmune thyroiditis (EAT) in CBA/J (H-2k) 
mice. In this study, we have examined whether H-2 or non H-2 genes can 
influence the immunopathogenicity of peptide p2596 (a.a. 2596-2608), which 
earlier elicited considerable pathology in CBA/J hosts. The p2596 peptide 
induced mild EAT- (infiltration index range= 1-2)- in H-2-compatible AKR/J, 
BlO.BR, and C3H/HeJ mice. Moreover, p2596-primed LNC from these 
mice exhibited peptide-specific proliferative responses and secreted significant 
amounts of IL-2 and IFN-y in recall in vitro assays. Priming and boosting of 
these strains with p2596 resulted in the generation of specific IgG responses five 
weeks after the initial challenge. In contrast, s.c. challenge of H-2-incompatible 
strains such as DBA/lJ (H-2q), SJL (H-25), DBA/2J (H-2d) and C57BL/6 (H-2b) with 
the same peptide dose did not elicit EAT pathology and peptide-specific B- or T-
cell responses. These data demonstrate the thyroiditogenic potential of p2596 in 
H-2k strains of diverse non-H-2 backgrounds but not in mice carrying H-2 b,d,qors 
haplotypes. 
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4.2 Introduction 
Murine experimental autoimmune thyroiditis (EAT), induced with 
thyroglobulin (Tg) in adjuvant, is under the control of H-2 genes (Vladutiu and 
Rose 1971) and studies with intra-H-2 recombinant mice have mapped control of 
disease susceptibility in the H-2A region (Beisel et al. 1982a;Tomazic et al. 1974). 
Non H-2 genes (e.g. from the C3H background) have also been shown to 
influence both the incidence and severity of EAT (Beisel et al. 1982b). Overall, the 
H-2 effects on Tg-induced EAT are demonstrable in a "gradient" pattern: for 
example, H-2k, s mice are susceptible, H-2q mice are moderately susceptible and 
H-2b,d mice are resistant to EAT development (Vladutiu and Rose 1971). 
However, even EAT-resistant strains develop a low degree of thyroiditis 
following challenge with Tg (Beisel et al. 1982a;Vladutiu and Rose 1971), 
suggesting that some pathogenic Tg peptides can be presented in the context of 
"low responder" H-2 genes. 
So far, thirteen pathogenic peptides encompassing T -cell epitopes have been 
identified within Tg, and none of them has been classified as dominant 
(reviewed in (Carayanniotis 2003)). At least six distinct Ak-restricted 
determinants- five of which have been recently mapped (Verginis et al. 2002)-
are contained within these sites. Genetic studies with other Tg peptides, 
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however, have confirmed that it is impossible to predict which MHC class II 
alleles are involved in the presentation of a given epitope despite the known 
genetic pattern of mouse susceptibility to Tg-induced EAT (Carayanniotis and 
Kong 2000). Thus, the p2694 (a.a. 2694-2711) peptide elicits EAT in H-25 but not 
H-2k mice (Carayanniotis et al. 1994), and vice versa, the p2549 (a.a. 2549 -2560) 
causes disease in H-2k but not H-25 strains (Rayner et al. 1993), although both H-2 
haplotypes are susceptible to Tg-induced EAT. No Tg peptides have been yet 
identified that are pathogenic in "low responder" mice. 
In this study, we have examined the pathogenic potential of the recently 
identified p2596 (a.a. 2596-2608) epitope in H-2- and non H-2-disparate strains. 
This determinant was chosen because it carries an Ak-binding motif and it causes 
significant EAT in CBA/J hosts (Verginis et al. 2002). Our goals were: a) to 
determine whether non H-2 genes could influence the p2596-specific response; 
and b) whether p2596 could cause EAT in classical"poor responder" strains. 
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4.3 Results 
4.3.1 Influences of host H-2 and non H-2 genes on the immunogenicity ofp2596. 
Mice from H-2k- haplotype strains (CBA, C3H, B10.BR, AKR), as well as 
mice from strains carrying other H-2 haplotypes C57BL/6 (H-2b), DBA/1 (H-2q), 
DBA/2 (H-2d), SJL (H-25), were s.c. immunized with 100 nmol p2596 in CF A. Nine 
days after the challenge, LNC were collected (2 mice per group) and cultured in 
the presence of titrating amounts of p2596 or equimolar concentrations of 
another pathogenic Tg epitope (p2494), as a control. Significant p2596-specific 
proliferation was only observed in cultures with LNCs isolated from H-2k mice 
(Figure 4.1). In contrast, LNCs isolated from p2596-primed mice carrying the H-2 
b, d, q, s haplotypes were unresponsive in the presence of p2596 in vitro (Figure 4.1). 
LNCs isolated from all eight strains strongly responded to PPD (data not shown). 
Significant amounts of IL-2 and IFN-y- but not IL-4 or IL-10 (data not shown)-
were detected in culture supernatants of p2596-activated LNCs from H-2k strains 
(Figure 4.2) whereas IL-2 or IFN-y were undetectable in culture supernatants of 
peptide-primed LNC from non-H-2k mice. Collectively, these results demonstrate 
the immunogenicity of p2596 in several H-2k strains and the lack of its immune 
recognition in strains carrying other H-2 haplotypes. 
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Figure 4.2 Determination of cytokine content in supernatants of p2596-primed 
LNCs. 
Mice were immunized with 100 nmol of p2596 and 9-10 days later draining LNs 
were collected. Cells were cultured in the presence of 15 J.!M of the indicated 
peptide and 48h later culture supernatants were collected. Presence of IL-2 and 
IFN-y was determined using sandwich ELISA as described in Materials and 
Methods. Data represent mean concentration values of duplicate wells 
extrapolated from standard curves constructed using murine recombinant 
cytokines. IL-4 and IL-10 were not detected in culture supernatants over a 
detection limit of 20 pg/ml. Results are representative of three individual 
experiments. Standard deviations did not exceed 2% of the mean values in all 
groups. 
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4.3.2 The p2596 peptide is thyroiditogenic in H-2k but not in H-2Mq.s mice. 
The profile of p2596 pathogenicity was assessed following s.c priming and 
boosting of mice from all strains (4-6 mice per group) with the emulsified 
peptide, as described in Materials and Methods. The thyroid glands were 
removed 35 days after the initial challenge and examined for signs of 
mononuclear infiltration. All H-2k strains developed mild EAT with infiltration 
indices between 1-2 (Table 4.1). There were no significant differences in the 
frequency or severity of disease among the different groups. On the other hand, 
p2596 did not induce any detectable pathology in the thyroids of H-2 b, d, q, s mice 
in agreement with its lack of immunogenic behaviour in these strains. Analysis 
of serum samples, obtained at the time of thyroid gland removal, indicated the 
generation of strong p2596-specific IgG responses in mice bearing the H-2k 
haplotype (Table 4.1) but these antibodies were not reactive with intact mTg. In 
contrast, p2596-specific IgG responses were very low or undetectable in mice of 
b,d,q, and s haplotypes, in correlation with the LNC response data. 
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a Mice were primed with 100 nmol of p2596 in CF A and boosted three 
weeks later with 50 nmol of peptide in IF A. Mononuclear infiltration of the 
thyroid was assessed five weeks after the initial challenge as described in 
Materials and Methods. 
hPeptide-specific IgG was assessed in pooled sera by alkaline-phosphatase-
based ELISA as outlined in Materials and Methods. The reactivities 
against p2596, mTg and p2494 are presented as the mean OD values of 
triplicate wells and were obtained after full titration of sera. 
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Table 4.1 Immunopathogenicity of p2596 in various strains of mice 
Direct induction of EATa Serum IgG response (O.D. 405 nm)b 
Infiltration Index (1.1.) Target antigen 
p2596 Tg p2494 
Strains 0 1 2 #of mice 
with EAT 
1:30 1:60 1:30 1:60 1:30 1:60 
CBA 1 1 2 3/4 1.13 0.82 0.18 0.19 0.17 0.16 
C3H 3 1 1 2/5 0.90 0.36 0.11 0.07 0.09 0.08 
B10.BR 4 2 0 2/6 1.27 0.70 0.19 0.16 0.22 0.07 
AKR 4 2 0 2/6 1.11 0.48 0.13 0.14 0.17 0.12 
DBA/1 6 0 0 0/6 0.20 0.11 0.20 0.16 0.20 0.15 
DBA/2 6 0 0 0/6 0.16 0.07 0.15 0.15 0.09 0.16 
SJL 6 0 0 0/6 0.33 0.18 0.36 0.16 0.34 0.15 
C57BL/6 6 0 0 0/6 0.14 0.20 0.08 0.20 0.16 0.14 
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4.4 DISCUSSION 
Pathogenic Tg peptides have been increasingly used as model antigens in 
EAT (Carayanniotis 2003;Carayanniotis and Kong 2000) but there is only limited 
knowledge as to how host genes influence the outcome of the peptide-specific 
response. Theoretically, for any individual T-cell epitope in Tg, such influences 
are likely to be more pronounced than those observed against the multi-epitopic 
intact Tg antigen, leading occasionally to a complete abrogation of the immune 
response. For example, the peptide (2549-2559) causes EAT in CBA (H-2k) but not 
DBA/1 (H-2q) strains (Rayner et al. 1993) and (2694-2711) is pathogenic in SJL (H-
25) but not C3H (H-2k) hosts (Carayanniotis et al. 1994), despite the fact that all 
four strains are highly susceptible to Tg-induced EAT (Vladutiu and Rose 1971). 
The peptide p2596 was initially identified as a candidate pathogenic epitope in 
CBA/J hosts because of the presence of two Ak-binding motifs within the 
heptamer HGSLELL segment (Verginis et al. 2002). As shown here, p2596 
retained its mild immunopathogenicity in three other A k-expressing strains 
(C3H, B10.BR and AKR), and this effect was demonstrable at 100 nmol per 
mouse in accordance with its cryptic nature (Verginis et al. 2002). The p2596-
specific proliferative LNC responses and in vitro IL-2 secretion were significantly 
lower in LNC from B10.BR and AKR vs the CBA mice but this did not correlate 
with IFN-y secretion or susceptibility to EAT. Interestingly, C3H non H-2 genes 
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did not enhance EAT severity and p2596-specific IgG titers, as has been observed 
for Tg-specific responses in Tg-induced EAT (Beisel et al. 1982a) suggesting that 
recognition of p2596 does not contribute to this effect in C3H hosts. 
Similarly to (2549-2559) (Rayner et al. 1993), p2596 did not elicit EAT in SJL 
or DBA/1 mice which are very susceptible to Tg-induced EAT. This observation 
is also in accordance with the non dominant nature of p2596 and the fact that this 
peptide does not carry MHC-binding motifs that have been described for the I-
Ab,d,sandqand I-Eb,d molecules (Brand et al. 1994;Kalbus et al. 2001;Rammensee et 
al. 1995;Scott et al. 1998;Zhu et al. 2003). However, the immunogenic behaviour 
of p2596 in these hosts could not have been predicted since the absence of a 
given motif within a peptide is not necessarily associated with lack of its binding 
to the respective MHC. For example, as has been mentioned earlier (Verginis et 
al. 2002), p2596 itself would not have been discovered via an algorithm based on 
the more restrictive nonamer Ak-binding motif of Fremont et al. (Fremont et al. 
1998). In addition, peptides such as the 9mer (2496-2504) are known to bind to 
non isotypic molecules across H-2 haplotypes (Ek and As) (Rao et al. 1994). The 
lack of immunopathogenicity of p2596 in mice of b,d,q and s H-2 haplotypes may 
result from lack of MHC binding and/or the absence of available T cell receptors 
recognizing the appropriate peptide-MHC complex (Dyson et al. 1991;Frankel et 
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al. 1991). It is noteworthy that none of the three pathogenic Tg peptides that have 
been tested so far- (2494-2510), (2694-2711) and p2596- have induced signs of 
EAT pathology in the "poor responder" BALB/c and B10 strains (Carayanniotis 
et al. 1994;Chronopoulou and Carayanniotis 1992). The development of mild 
thyroiditis in EAT-resistant mice after challenge with Tg suggests recognition of 
certain unknown Tg determinants by these strains. Identification of these 
determinants would facilitate the study of thyroiditis in genetic backgrounds 
distinct from those used so far in conventional EAT. As shown here with p2596, 
the established pathogenicity of certain Tg peptides in genetically diverse hosts 
would also allow greater flexibility in the design of future EAT studies 
employing congenic, intra-H-2-recombinant or transgenic mice. 
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5 CHAPTERS 
Tolerogenic semi-mature dendritic cells suppress 
experimental autoimmune thyroiditis by activation of 
thyroglobulin-specific CD4 +CD25+ T cells 
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Figure 4.1 Proliferative LNC response to p2596. 
H-2k (A) or non H-2k (B) mice, were s.c. immunized with 100 nmol of p2596 and 9 
days later LNC were collected (2 mice per group) and cultured in the presence of 
the peptide for 4 days in vitro. (3H]TdR was added during the last 18 h of culture. 
Background S.I. values were obtained following culture with the control peptide 
p2494. Results are representative of three individual experiments. 
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5.1 Abstract 
Ex vivo treatment of bone marrow-derived dendritic cells (BM-DCs) with tumor 
necrosis factor alpha (TNF-a) has been previously shown to induce partial 
maturation of DCs that are able to suppress autoimmunity. Here, we 
demonstrate that i.v. administration of TNF-a-treated, semi-mature DCs pulsed 
with thyrogloblin (Tg), but not with OVA antigen, inhibits the subsequent 
development of Tg-induced experimental autoimmune thyroiditis (EAT) in 
CBA/J mice. This protocol activates CD4+CD25+ T cells in vivo, which secrete IL-
10 upon specific recognition of Tg in vitro and express regulatory T cell (Treg)-
associated markers such as GITR, CTLA-4 and Foxp3. These CD4+CD25+ Treg 
cells suppressed the proliferation and cytokine release of Tg-specific, CD4+CD25-
effector cells in vitro, in an IL-10-independent, cell contact-dependent manner. 
Prior adoptive transfer of the same CD4+CD25+ Treg cells into CBA/J hosts 
suppressed Tg-induced EAT. These results demonstrate that the tolerogenic 
potential of Tg-pulsed, semi-mature DCs in EAT is likely to be mediated through 
the selective activation of Tg-specific CD4+CD25+ Treg cells and provides new 
insights for the study of antigen-specific immunoregulation of autoimmune 
diseases. 
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5.2 Introduction 
Apart from being highly immunogenic (Banchereau and Steinman 1998), 
dendritic cells (DC) have been shown to play an important role in peripheral 
tolerance via various mechanisms, including activation of T regulatory (Treg) 
cells, induction ofT-cell anergy and Th1/Th2 polarization (Jonuleit et al. 
2000;Jonuleit et al. 2001;Steinman et al. 2003). Although the exact mechanisms 
involved in the decision of a DC to become immunogenic or tolerogenic have not 
been elucidated, increasing evidence suggests that DC function is dependent on 
their maturation stage (Lutz and Schuler 2002;Mahnke et al. 2002). While 
immature DCs have been implicated to anergy induction, fully mature DCs are 
efficient activators of naive T cells (Steinman and Nussenzweig 2002). An 
intermediate stage of DC maturation was recently described where DCs express 
high levels of MHC class II and costimulatory molecules but do not secrete pro-
inflammatory cytokines (Menges et al. 2002). This stage of maturation was 
obtained upon exposure of immature DCs to TNF-a ex vivo, and the cells were 
termed "semi-mature" DCs. These DCs were shown to induce tolerance through 
the generation of IL-10-secreting regulatory T (Treg) cells whose profile was not 
characterized (Menges et al. 2002). 
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5.3 Results 
5.3.1 Generation of "semi-mature" DCs. 
In order to generate "semi-mature" DCs, we treated BM-DCs with TNF-a for 
24h. Untreated and LPS-treated DCs were used as immature and completely 
mature DCs, respectively. The surface marker phenotype of the DC populations 
was assessed by flow cytometry. Both TNF-a-treated and LPS-treated DCs 
expressed higher levels of cell-surface MHC class II, CDSO, CD86 and CD40 
molecules, as compared to untreated DCs (Figure 5.1). It has been previously 
shown that TNF-a-treated DCs express low levels of proinflammatory cytokines 
at the mRNA level and do not secrete significant amounts of IL-12 (Menges et al. 
2002). To confirm this finding, we performed sandwich ELISA in DC culture 
supernatants collected upon 24 h TNF-a treatment. Low levels of IL-12, IL-1~, 
and IL-6 were secreted by TNF-a-treated DC, similarly to those secreted by 
immature DCs. In contrast, all cytokines tested were highly produced by LPS-
treated DCs (Figure 5.1). Collectively, these results confirmed the generation of 
"semi-mature" DCs upon TNF-a treatment. 
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5.3.2 Induction of Tg-specific, IL-10-secreting CD4+CD25+ T cells by Tg-pulsed "semi-
mature" DCs. 
To assess a possible tolerogenic role of "semi-mature" DCs in EAT, DCs were 
pulsed with Tg or OVA for 6 hand were subsequently treated with TNF-a for 
additional 24 h. CBA/J mice received three i.v. injections of DCs (2.5 x 106 
cells/mouse) on days 1, 3 and 5 and were sacrificed 21 days after the last 
challenge. Splenocyte-derived CD4+CD25+ and CD4+CD25- T cells were cultured 
with Tg or OVA and mitomycin C-treated syngeneic splenic APCs as described 
in Materials and Methods. Both T cell subpopulations did not proliferate in the 
presence of Ag (data not shown) and they did not produce detectable amounts of 
IL-2 or IFN-y in culture supernatants (Table 5.1). However, CD4+CD25+ T cells, 
isolated from mice challenged with Tg-pulsed DCs (Tg/DC) secreted significant 
amounts of IL-10 in response to Tg stimulation in vitro and this effect was Tg-
specific since it was not detected in response to OVA. Interestingly, OVA-pulsed 
DCs (OVA/DC) were not able to induce OVA-specific CD4+CD25+ T cells with the 
ability to produce IL-10 (Table 5.1). Additionally, no IL-4 was detected in 
supernatants of any of the above cell cultures (data not shown), indicating the 
activation ofT cell subpopulation(s) distinct from Th2. These results 
demonstrate that Tg/DCs have the ability to induce CD4+CD25+ T cells that 
produce IL-10 in response to Tg in vitro. 
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Table 5.1 Induction of Tg-specific, IL-10-secreting CD4+CD25+ T cells following 
challenge of mice with Tg-pulsed "semi-mature" DCs. 
In vivo 
treatment 
DC/Tg 
DC/OVA 
In vitro activation 
CD4+CD25· 
CD4+CD25+ 
CD4+CD25· 
CD4+CD25+ 
CD4+CD25· 
CD4+CD25+ 
CD4+CD25· 
CD4+CD25+ 
Tg 
Tg 
OVA 
OVA 
Tg 
Tg 
OVA 
OVA 
[Cytokine] (pg/ml) 
IL-2 
31 ± 0.3 
33 ± 0.1 
31 ± 0.1 
34± 0.2 
31 ± 0.2 
34 ± 0.2 
32 ± 0.3 
IFN-y IL-10 
105 ± 5.3 39 ± 0.4 
81 ± 2.1 461 ± 0.4 
96 ± 2.1 28±0.7 
97± 7.2 27±4.3 
109 ± 8.4 36 ± 1.8 
119 ± 14.6 28 ± 1.7 
132 ± 20.6 32 ± 0.2 
37 ± 0.4 77 ± 18.2 35 ± 0.8 
CBA/J mice were i.v. injected three times (day 1, 3 and 5) with TNF-a-treated 
DCs pulsed either with Tg or OVA as described in Materials and Methods. 
Twenty-one days later, spleen-derived CD4+CD25· and CD4+CD25+ T cells (1 x 105 
cells/200 J-ll) were stimulated with Tg or OVA in the presence of mitomycin C-
treated syngeneic splenocytes (2 x 106 cells/200 J-ll) as APC. Culture supernatants 
were collected at 48 hand assayed for the presence of IL-2, IL-10 and IFN-y by 
ELISA. Results are representative of two independent experiments. 
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5.3.3 Expression of a Treg phenotype by CD4+CD25+ T cells 
To examine whether the CD4+CD25+ T cells obtained from mice challenged with 
Tg/DC express surface markers associated with Treg, we assessed their 
phenotype by FACS. The CD4+CD25+ T cells were CD62Lhigh and CD691ow 
indicating that the cells were not in an activated stage and their expression of 
GITR, CTLA-4 and CD137 molecules was higher as compared to that of the 
CD25- T cell subpopulation (Figure 5.2). Similarly, Foxp3 expression on CD25+ T 
cells, was 5-fold higher than that in the CD25- population at the transcriptional 
level (Figure 5.2). These data indicated that the CD4+CD25+ T cells isolated from 
Tg/DC-treated mice possess a phenotype similar to that described for Treg cells 
(McHugh et al. 2002). 
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Figure 5.2CD4+CD25+ T cells from Tg/DC-primed mice express the characteristic 
markers of Treg cells. 
CD4+CD25- and CD4+CD25+ splenic T cells were isolated from CBA mice that 
received Tg-pulsed TNF-a-treated DCs as described in Materials and Methods. 
A. Cells were stained and analysed for the expression of CD62L, CD69, CD137, 
CD152 and GITR (filled histograms). Isotype-matched control antibodies are 
indicated with open histograms. B. RNA was extracted from 5 x 105 cells and 
reverse-transcribed to eDNA. Foxp3 was amplified by RT-PCR by using gene 
specific primers. The relative expression of FoxP3 was normalized to the relative 
expression of GADPH gene. 
141 
5.3.4 CD4+CD25+ T cells from Tg!DC-challenged mice suppress Tg-specific T cell 
responses in vitro. 
The functional characteristics of the CD25+ T cell subpopulation were 
subsequently assessed in mixing experiments. CD25- T cells isolated from the 
draining LN of Tg/CFA-immunized CBA mice were used as effector cells. The 
CD25- cells proliferated strongly in the presence of Tg and APC and secreted 
high levels of IL-2 and IFN-y (Figure 5.3). The response was Tg-specific since 
proliferation or cytokine release were not detected upon culture of CD25- cells 
with OVA (data not shown). CD4+CD25+ T cells isolated from mice that received 
Tg/DC, but not OVA/DC, were able to completely suppress the proliferation and 
cytokine production of the CD25- effector cells (Figure 5.3). CD4+CD25+ T cells 
isolated from na1ve mice were also unable to suppress the Tg-specific response in 
vitro. None of the CD4+CD25+ T cell populations proliferated in response to Tg 
and only CD25+T cells from Tg/DCs-treated mice secreted IL-10 upon culture 
with Tg and APC, indicating efficient activation of this subset (Figure 5.3). These 
data highlighted the ability of Tg/DCs to induce a CD4+CD25+ T cell population 
that suppress Tg-specific T cell responses. 
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Figure 5.3 Suppression of proliferative Tg-specific T cells by CD4+CD25+ T cells 
in vitro. 
CBA/J mice were immunized s.c. with 100 !lg of Tg in CF A and 9 days later 
CD4+CD25- T cells were isolated and used as effector cells. CD4+CD25+ T cells 
(Treg) were isolated from spleens from mice that have been injected with <a>Tg-
pulsed TNF-a-treated DCs, (b>QV A-pulsed TNF-a-treated DCs, as described in 
Figure 3 or <c>either isolated from nai:ve mice. Effector cells (1 x 105 cells/well) 
were culture with equal numbers of Treg cell in the presence of Tg. Mitomycin-C 
treated syngeneic splenic cells (2 x 105 cells/well) were used as APC. Data 
represent stimulation index (S.I.= cpm in the presence of Ag/cpm in the absence 
of Ag) values of triplicate wells. Secretion of IL-2, IFN-y and IL-10 was measured 
by cytokine ELISA in supernatants collected after 48 h of culture. Data are 
representative of two independent experiments. 
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5.3.5 CD4+CD25+ T cells mediate suppression in a cell-cell contact-dependent manner. 
To investigate the mechanism by which CD25+ T cell mediate suppression, Tg-
specific CD4+CD25- effector cells were stimulated with Tg and APC in a 24-well 
transwell plate. Tg-specific CD25+ T cells, isolated as above, were placed in the 
same well or in the upper chamber at a 1:1 ratio, in the presence (or absence) of 
Tg. Inhibition of proliferation was observed only when effector cells and CD25+ 
cells were co-cultured in the same well (Figure 5.4), and this inhibition correlated 
well with the suppression of IL-2 and IFN-y secretion by the effector cells. As 
expected, significant amounts of IL-10 were detected only in wells where CD25+ 
T cells were cultured in the presence of Tg and APC. These data also suggested 
that while contact between effector cells and CD25+ cells is required to mediate 
suppression, it is not needed for the production of IL-10 by Tregs. Altogether, the 
results supported the view that CD25+ T cells suppress the activation of Tg-
specific CD25- effector cells via a cell-cell contact-dependent, cytokine-
independent mechanism. 
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Figure 5.4 Cell-cell contact is required for the suppressive activity of the Tg-
specific Treg cells. 
Effector and CD4+CD25+ T cells were isolated as in Figure 3. 6 x 105 effector cells 
were stimulated in 24-well transwell plates with 100 Jlg of Tg and 1.2 x 106 APC 
prepared as described in Figure 4. In addition, 6 x 105 Treg were either added 
directly to the culture or placed in the transwell chamber with Tg and APC. 
Proliferation was assessed after 4 days of culture. Supernatants were collected 
after 48 h of stimulation and cytokine ELISA was performed to measure the 
content of IL-2, IFN-y and IL-10 in the culture. Data are representative of two 
independent experiments. 
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5.3.6 Tg!DCs can suppress EAT induction through the generation of CD4+CD25+ T 
cells. 
To assess the tolerogenic potential of Tg/DC in Tg-induced EAT we challenged 
CBA mice on days 1, 3, and 5 with Tg/DC, OV A/DCs or PBS and two days after 
the last DC challenge, we immunized them with Tg in CF A. Twenty-one days 
later, the thyroids were removed and examined for mononuclear cell infiltration. 
As expected, mice that received PBS and were subsequently challenged with Tg 
showed the highest degree of EAT (I.I. = 2.2), (Figure 5.5) whereas mice that 
received OVA/DCs had a slight decrease of EAT incidence (I.I. = 1.8) that was not 
statistically significant (p = 0.613). In contrast, disease was significantly 
suppressed (1.1.= 0.5, p = 0.006) in mice that received Tg/DCs prior to Tg 
challenge. We did not detect any thyroid pathology in mice challenged with 
Tg/DC or OV A/DCs alone, indicating that the semi-mature DCs themselves did 
not contribute to the development of EAT. Based on these observations, we 
formulated the hypothesis that Tg/DCs but not OV A/DCs are able to expand 
CD4+CD25+ T cells with the ability to suppress Tg-induced EAT. To directly 
address this, we adoptively transferred CD25+ T cells into naive mice and one 
day later, we challenged the mice with Tg in adjuvant. Mononuclear cell 
infiltration of the thyroid was assessed twenty-one days later, as described in 
Materials and Methods. Mice that received CD25+ cells from Tg/DCs-treated 
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donors showed a significant decrease of EAT (I.I. = 0.89, p =0.03) (Table 5.2), as 
compared to the control group (I.I. = 2.5). On the other hand, EAT in mice that 
received CD25+ T cells from OVA/DC-challenged mice was not significantly 
reduced (I.I. =2.13, p=0.50), as compared to that of control mice immunized with 
Tg/CFA alone. Collectively, these data demonstrated the suppressogenic 
potential of CD4+CD25+ T cells derived from mice that have been challenged with 
Tg/DCs, but not OV A/DCs. 
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CD4+CD25+ Treg cells arise normally in naive mice and constitute 
approximately 10% of the peripheral CD4+ T cells. Treg cells are generated in the 
thymus upon high-avidity interactions with self-peptides (Bensinger et al. 
2001;Jordan et al. 2001;Seddon and Mason 1999) and they participate in the 
maintenance of peripheral self-tolerance (Sakaguchi et al. 2001;Shevach 2000). 
Their development has been shown to programmed by the transcription factor 
Foxp3 (Fontenot et al. 2003;Hori et al. 2003;Khattri et al. 2003) and, in addition to 
CD25, they constitutively express CTLA-4 (Takahashi et al. 2000) and GITR 
(McHugh et al. 2002;Shimizu et al. 2002) on their surface. Although accumulating 
evidence suggests a major role of this subset in the maintenance of self-tolerance 
(Sakaguchi et al. 2001), the antigen specificity and the exact mechanism(s) of 
action of the CD4+CD25+ T cells remain unresolved. Meanwhile, ample evidence 
indicates that DCs play an important role in expansion/induction of Treg cells 
(Jonuleit et al. 2001) that could be specific for self antigens (Fisson et al. 2003). 
However, a clear profile of DC involved in this process has yet to be identified. 
EAT, a murine model of Hashimoto's thyroiditis in humans, can be induced 
upon challenge of susceptible animals with thyroglobulin (Tg) in CFA (Charreire 
1989). The disease is mediated by CD4+ T cells and characterized by lymphocytic 
infiltration of the thyroid gland (Weetman and McGregor 1994). Several reports 
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have suggested a major role of the CD4+CD25+ T cells in immunoregulation of 
EAT. First, elimination of Treg cells in mice resulted in development of multi-
organ autoimmune diseases including thyroiditis whereas reconstitution of 
CD4+CD25+ T cells inhibited development of autoimmunity (Sakaguchi et al. 
1995). Second, it was recently reported that CD4+CD25+ T cells, isolated from 
GM-CSF-treated mice, were able to suppress Tg-specific T cell responses in vitro 
(Vasu et al. 2003). The authors suggested differential activation of DCs by GM-
CSF that induces Treg cells. In addition, Kong and coworkers showed that 
CD4+CD25+ T cells from Tg-tolerized mice can suppress mouse Tg-specific 
responses in vitro (Morris et al. 2003). 
In this study, we sought direct evidence for the induction of CD4+CD25+ 
Treg cells, with the ability to suppress Tg-induced EAT. To investigate this, TNF-
a-treated DCs isolated from CBA/J mice were pulsed with Tg and transferred 
into syngeneic mice. Splenocyte-derived CD4+CD25+ T cells were tested for their 
ability to suppress Tg-specific effector T cell responses in vitro as well as 
development of EAT. 
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Figure 5.5 Suppression of Tg-induced EAT by Tg-pulsed smDCs. 
CBA/J mice received three i.v. injections (day 1, 3 and 5) of 2.5 x 106 TNF-a-
treated DCs pulsed with 100 !lg of Tg or OVA. Control mice received three i.v. 
injections of PBS. Two days after the last DC injection some mice were 
immunized with 100 !lg of Tg in CF A. On day 21, all mice were sacrificed and 
thyroid glands were collected. Mononuclear cell infiltration index (1.1.) was 
scored as described in Materials and Methods. Statistical analysis was performed 
using the Mann-Whitney nonparametric test. 
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Table 5.2 Adoptive transfer of CD4+CD25+ T cells from Tg/DC-treated CBA mice 
into na1ve hosts inhibits EAT development. 
Infiltration index (1.1.) 
DC Antigen #of mice Mean 
challenge in vivo 0 1 2 3 with EAT of 1.1. p value 
Tg/DC Tg 5 2 1 0 3/8 0.50 0.006 
OVA/DC Tg 0 3 2 2 7/7 1.86 0.613 
None Tg 0 2 3 3 8/8 2.13 
Tg/DC None 6 0 0 0 0/6 0 
OVA/DC None 6 0 0 0 0/6 0 
5 x 105 CD4+CD25+ T cells isolated from either (aJTg-pulsed DCs- or (bJQV A-
pulsed DCs -primed CBA mice were adoptively transferred i.p. into synjeneic 
na1ve recipients. Control mice received one i.p. injection of PBS. One day after 
the T cell transfer some mice were immunized with 100 )..lg of Tg in CFA. On day 
21 all mice were sacrificed and thyroid glands were collected. Mononuclear cell 
infiltration index (1.1.) was scored as described in Materials and Methods. 
Statistical analysis was performed using the Mann-Whitney nonparametric test. 
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5.4 Discussion 
The present study demonstrates that Tg-pulsed "semi-mature" DCs can 
induce Tg-specific CD4+CD25+ T cells with the ability to inhibit EAT 
development. Our data confirm earlier findings in the EAE model that TNF-a.-
treated DCs, expressing a "semi-mature" phenotype, mediate antigen-specific 
protection against autoimmune disease (Menges et al. 2002), and extend these 
observations by highlighting that this protection is likely to be mediated by 
autoantigen-specific CD4+CD25+ Treg cells. Tg/DC, but not OVA/DC, may 
activate and/or expand pre-existing, naturally occurring, Tg-specific CD25+ T 
cells that have been positively selected in the thymus. This hypothesis is in 
agreement with recent data demonstrating that thymic expression of a self-
antigen facilitates the development of high numbers of antigen-specific Treg cells 
(Jordan et al. 2001;Walker et al. 2003) and that Tg is known to be expressed 
intrathymically (Heath et al. 1998). 
Although the critical factors that determine the tolerogenic potential of 
TNF-a.-treated DCs cells remain unknown, the absence of proinflammatory 
cytokine secretion by this subset has been suggested to contribute to 
tolerogenicity (Lutz and Schuler 2002). This hypothesis is supported by our 
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findings since the TNF-a-treated DCs were found to secrete low levels of IL-12, 
IL-6 or IL-l~. Unlike the immature DC, semi-mature DCs also express relatively 
high levels of costimulatory molecules such as CD80, CD86 and CD40 which 
have been implicated to play an important role in homeostasis and expansion of 
CD4+CD25+ Treg cells. Blockage of CD80/86 molecules has been known to lead to 
autoimmunity (Lohr et al. 2003;Salomon et al. 2000) and CD40-deficient mice 
exhibit a reduced population of CD25+ T cells associated with increased T cell 
autoreactivity (Kumanogoh et al. 2001). In contrast to the above findings, two 
groups have recently reported that mature DCs are able to expand CD4+CD25+ 
Treg cells both in vitro and in vivo (Oldenhove et al. 2003;Yamazaki et al. 2003). 
However, the classification of DCs as mature in both studies was based on their 
surface phenotype expression and not on the cytokines that they secrete. 
Apart from TNF-a, several other factors have been described to induce DCs 
with a semi-mature-like phenotype, including lactobacilli (Christensen et al. 
2002), and cholera toxin (Braun et al. 1999). It has also been proposed that steady-
state migrating DCs in vivo ("veiled" cells) resemble the ex-vivo generated semi-
mature DCs (Lutz and Schuler 2002). Veiled cells circulate through peripheral 
tissues where they pick up apoptotic cells and migrate to the secondary 
lymphoid organs (Huang et al. 2000;Inaba et al. 1998), where they present self-
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peptides in the context of MHC molecules (Scheinecker et al. 2002). In the 
absence of maturation stimuli, however, DCs do not secrete proinflammatory 
cytokines and induce tolerance (Hawiger et al. 2001;Liu et al. 2002;Steinman and 
Nussenzweig 2002). Other types of DCs have been shown to induce tolerance by 
distinct mechanisms (Jonuleit et al. 2001). For example, human IL-10-treated DCs 
were characterized by low levels of MHC class II and costimulatory molecule 
expression and induced antigen-specific anergic T cells (Steinbrink et al. 
1997;Steinbrink et al. 1999). In addition, mouse pulmonary DCs that secrete IL-
10, but not IL-12, upon exposure to antigen, induced tolerance through the 
development of Treg cells (Akbari et al. 2001). Tolerogenic DCs have been 
generated by other methods including treatment with vitamin D3 (Penna and 
Adorini 2000), corticosteroids (Rea et al. 2000), and low doses of GM-CSF (Lutz et 
al. 2000) but it was not clear in these studies how modulated DCs mediated 
tolerance. 
The functional and phenotypic characteristics of the Tg-specific 
CD4+CD25+ T cells are consistent with those described for the naturally arising 
Treg cells (Banz et al. 2003;McHugh and Shevach 2002;Read et al. 2000;Sakaguchi 
2004;Shimizu et al. 2002;Takahashi et al. 2000;Thomton and Shevach 1998). Yet, 
Tg-specific CD25+ Treg cells- maintained presumably by the normal 
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physiological levels of Tg in the periphery- could not be functionally detected in 
the spleen of naive CBA/J mice. This suggests that challenge with Tg/DCs must 
increase the relative number as well as the efficiency of Tg-specific CD4+CD25+ T 
cells in a selective manner, since we did not observe a size difference or 
phenotypic changes in the overall splenic CD4+CD25+ T cell subset between the 
Tg/DC- challenged mice and the controls (data not shown). A similar expansion 
and/or activation of Tg-specific, CD25+ Treg cells, has been proposed to occur in 
the induction of tolerance observed following the elevation of Tg levels in the 
circulation (Morris et al. 2003). 
Our results do not support a role for IL-10 in the suppressive effect of Tg-
specific CD25+ cells in vitro but cannot formally exclude a possible role for this 
and other cytokines in the observed suppression of EAT. Vasu et al.(Vasu et al. 
2003) have recently shown that GM-CSF-treated mice have increased numbers of 
CD4+CD25+ T cells and fail to develop EAT upon challenge with Tg. CD4+ T cells 
isolated from GM-CSF-treated mice did not proliferate in response to Tg in vitro, 
but addition of neutralizing anti-IL-10 mAb increased the Tg-specific T cell 
response, indicating a possible role for IL-10 and an alternative mode of EAT 
suppression in this model. Currently, the reasons for these contrasting findings 
remain unclear; previous studies have provided evidence for (Annacker et al. 
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2001) or against (Suri-Payer et al. 1998;Thornton and Shevach 1998) an 
involvement of IL-10 in CD4+ CD25+ T cell-mediated suppression. 
The observation that CD4+CD25+ T cells from Tg/DC-treated mice mediate 
in vitro suppression by a cell contact-dependent mechanism, and with no 
apparent requirements for secretion of soluble factors agrees well with previous 
findings (Bluestone and Abbas 2003;Hawiger et al. 2001;Sakaguchi 2004;Shevach 
2000;Thornton and Shevach 1998). The CTLA-4 molecule, expressed on the 
surface of Tg-specific CD4+CD25+ T cells, has been shown to contribute to the 
cell-cell contact mediated suppression of effector cells (Takahashi et al. 2000). 
CD4+CD25+ Treg cells are also known to mediate suppression through ligation of 
the cell surface bound TGF-B to TGF-BR on target cells (Green et al. 
2003;Nakamura et al. 2001) and additional costimulatory molecules, such as 
OX40, ICOS and 4-1BB, have been reported to be involved in downregulation of 
immune responses (Croft 2003). Lastly, in our study, the activation and/or 
expansion of Treg cells by Tg/DC, but not OVA/DC, suggests that this 
phenomenon is Tg-specific but it remains to be established whether suppressor 
effector function is completely antigen non-specific, as has been well described in 
other systems (Shevach 2000). 
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The generation of Tg-specific CD4+CD25+ Treg cells by semi-mature 
Tg/DCs raises new questions about their fine specificity and mode of function. 
Currently, thirteen pathogenic epitopes have been mapped within the Tg 
molecule (Carayanniotis 2003) and it will be interesting to test whether effector 
and Treg cells recognize distinct or overlapping regions in mouse Tg as well as 
examine if post-translational modifications of Tg have any role in this process. 
The delineation of physiological processes that promote the generation of 
tolerogenic DC in EAT, similar to TNF-a-treated DCs, would contribute greatly 
to our understanding of the immunoregulation of this disease. Lastly, the 
examination of the effectiveness of CD25+ Treg cells in reversing established 
disease would aid in the development of new therapeutic approaches in this 
field. 
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6 Chapter 6 
Generation of T cell receptor (TCR)-transgenic mice to 
study experimental autoimmune thyroiditis (EAT). 
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6.1 Abstract 
EAT can be induced after challenge of SJL mice with the thyroglobulin peptide 
p2496 in adjuvant. We are in the process of generating TCR transgenic mice with 
TCR-a and-~ chains derived from the p2496-specific l-As-restricted, 9.13 T-cell 
hybridoma clone. By RT-PCR and subsequent cloning and sequencing of the 
amplified product it was revealed that the 9.13 T cell hybridoma expresses a 
rearranged V~4-D~2.1-J~2.1 chain. The 9.13 TCR a chain was identified by "anchor 
PCR". The amplified product was cloned and sequenced to reveal that the 9.13 T cell 
hybridoma utilizes the rearranged Val.1-Ja49 chain. Genomic DNA isolated from 
the 9.13 clone, was PCR-amplified with appropriate primers to introduce unique 
restriction sites for subsequent cloning into pTa and pT~ expression vectors that 
have been engineered to contain TCR regulatory elements, as well as the Ca and C~ 
regions. Following digestion with specific restriction enzymes to remove 
prokaryotic sequences, linearized fragments were injected into fertilized C57 /BL6 x 
SJL oocytes. Integration of the transgene was screened by PCR amplification of 
genomic DNA with VJa and VDJ~ specific primers. Positive mice were backcrossed 
to SJL mice for at least five generations. These mice will be valuable tools to study 
parameters (such as iodination of Tg or high iodine intake) that promote the 
generation of this epitope in vivo and lead to EAT development. 
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6.2 Introduction 
It has been demonstrated that self-reactive T cells are present in the 
periphery of healthy individuals (Markovic-Plese et al. 1995) as well as normal 
animals (Anderson et al. 2000), and their activation is limited by mechanisms of 
peripheral tolerance induction (Kamradt and Mitchison 2001 ). Breakdown of one 
of these mechanisms can lead to activation of self-reactive T cells and 
development of autoimmune diseases (Kamradt and Mitchison 2001). 
Studies on the activation and effector function of self reactive T cells as 
well as on mechanisms that influence tolerance induction were hampered in the 
past by the low frequency ofT lympocytes specific for a self antigen (one in 104 to 
105) that are present in normal mice (Anderton et al. 1999). This obstacle was 
circumvented with the generation of transgenic mice that express TCR specific 
for a given self antigen. The majority of the T cells in TCR transgenic mice are 
na1ve and express TCR with unique specificity for antigen. TCR transgenic mice 
have been described for most models of autoimmunity including experimental 
autoimmune encephalomyelitis (EAE) (Goverman et al. 1993;Lafaille et al. 1994), 
diabetes (Katz et al. 1993;Tarbell et al. 2002), rheumatoid arthritis (Mori et al. 
1992;0sman et al. 1998) and autoimmune gastritis (Alderuccio et al. 
2000;McHugh et al. 2001), and contributed further in our understanding of the 
autoimmune processes. 
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In the field of thyroiditis, transgenic mice expressing TCR specific for a Tg 
peptide or other thyroid antigens have not yet been described. In this study, we 
attempted to generate TCR transgenic mice specific for the p2496 Tg peptide that 
has been shown to be pathogenic in SJL mice (Rao et al. 1994). The a and f3 TCR 
chain genes were derived from the p2496-specific, I-A5-restricted, 9.13 T-cell 
hybridoma clone and inserted into the pTa and pTf3 cassette expression vectors 
(Kouskoff et al. 1995). These vectors contain the natural TCR a- f3-
promoter/enchancer elements allowing specific expression of the receptor on the 
T cell surface (Kouskoff et al. 1995). The 9.13 TCR-transgenic mice will be 
invaluable tools to study parameters that influence the activation and effector 
function of p2496-specific T cells. 
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6.3 Results 
6.3.1 The p2496 peptide specifically activates the 9.13 T-cell hybridoma clone. 
The 9.13 T-cell hybridoma was generated by fusion of LNC obtained from 
p2496-primed SJL mice (H-25), with the BW5147a-(3- (TcR a-(3-) myeloma cell line 
as previously described (Rao et al. 1997). To examine the specificity of the clone, 
T cells were cultured with an H-2A5 -expressing APC cell line (LS102.9) in the 
presence of p2496 or another Tg pathogenic epitope p2695 (control antigen) as 
described in Materials and Methods. After 24 h, culture supernatant was 
collected for assessment of IL-2 release as measured by the proliferation of the 
CTLL-2 line using (3H] thymidine. Only p2496 and not the control peptide was 
able to activate the 9.13 T cell hybridoma as indicated from the proliferation of 
the CTLL-2 cell line (Figure 6.1). 
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Figure 6.1 Activation of the As-restricted 9.13 T-cell hybridoma by the p2496 Tg 
epitope. 
9.13 hybridoma cells (105/well) were cultured with equal numbers of the LS102.9 
antigen presenting cell line in the presence of either p2496 or p2695 (control) 
peptides as described in Materials and Methods. The IL-2 content in culture 
supernatants, collected after 24 hours of culture, was assessed by the 
proliferation of the IL-2-dependent CTLL-2 cell line. 
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6.3.2 Characterization of the a TCR chain gene expressed on the 9.13 T-cell 
hybridoma. 
Total RNA was extracted from the 9.13 T cell clone and the RML-RACE 
technique for the identification of the 5' end of the a TCR chain was performed 
as described in Materials and Methods. Since the a chain sequence was unknown 
we could not estimate the exact size of the expected PCR product. By taking into 
consideration the average length of the published a chain sequences we 
estimated the approximate length of the amplified a chain gene to be between 
600-750 bp or 475-625 bp using the Cal or Ca2 reverse primers, respectively. 
Upon PCR amplification of eDNA using Generacer-F and Cal-R primers, a 
strong band close to 700 bp (lane 2) was detected whereas with the same 
forward primer and the Ca2-R primer a band close to 580 bp (lane 3) was found 
(Figure 6.2). Based on the size difference of the two PCR products we concluded 
that these bands should contain the a chain gene of the 9.13 T cell hybridoma. 
The band amplified with the Cal primer (lane 2) was gel purified and inserted 
into the pCR4-TOPO vector. Plasmid DNA was purified from colonies obtained 
after transformation of competent cells and was sequenced as described in 
Materials and Methods. Analysis of the sequence results revealed that the TCR 
utilizes an a chain gene of the VaLl family rearranged with Ja49 joining 
sequence (Figure 6.3). 
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Figure 6.2 Amplification of the TCR-a chain gene from the 9.13 T cell hybridoma 
clone by RT-PCR. 
RNA was extracted from the 9.13 T cell hybridoma and eDNA was prepared 
using the 5' RACE kit as described in Materials and Methods. RT-PCR was 
performed using reverse primer specific for the a constant region (Ca1lane 2 or 
Ca2lane 3) and an oligo specific forward primer. PCR products were visualized 
in 1.5% agarose gel. The 100 bp DNA ladder is shown in lane 1. 
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ATG AAA TCC TTG AGT GTT TCA CTA GTG GTC CTG TGG CTC CAG GTA 
AAC TGT AAG TTT GGG AAT TCC TTT GGG ATC CAG GTG TGA TAT GTA 
AAG TTA TTG TCT GCT CCA GGC TAA TGG TAC AAA CAC AGA TGT TCT 
TAA TCC CTA GTT AGG GGC GGG AGA CCC ATG GAA ATG CCA TTC TGG 
AAT GTT AGC ATC CAT ACG CAT CCA GTC TTG ATT GTC TGA CCT TTG 
TTT TTC TGT ACA GGC GTG AGG AGC CAG CAG AAG GTG CAG CAG AGC 
CCA GAA TCC CTC AGT GTC CCA GAG GGA GGC ATG GCC TCT TTC AAC 
TGC ACT TCA AGT GAT CGT AAT TTT CAG TAC TTC TGG TGG TAC AGA 
CAG CAT TCT GGA GAA GGC CCC AAG GCA CTG ATG TCA ATC TTC TCT 
GAT GGT GAC AAG AAA GAA GGC AGA TTC ACA GCT CAC CTC AAT AAG 
GCC AGC CTG CAT GTT TCC CTG CAC ATC AGA GAC TCC CAG CCC AGT 
GAC TCC GCT CTC TAC TTC TGT GCA AGC TAA CTC CGC TCT CTA CTT 
CTG TGC AGC TAA CAC GGG TTA CCA GAA CTT CTA TTT TGG GAA AGG 
AAC AAG TTT GAC TGT CAT TCC AAG TAA GTA 
Figure 6.3 Nucleotide sequence of the eDNA encoding the 9.13 TCR a chain. 
Sequencing analysis revealed that the 9.13 T cell hybridoma utilizes an a chain of 
the Val.1 family rearranged with Ja49 (bold sequence). Underlined sequence 
represents the beginning of the constant region Ca. 
164 
6.3.3 Characterization of the~ TCR chain gene expressed on the 9.13 T-cell hybridoma. 
It has been previously found that the~ chain expressed by the 9.13 T cell 
hybridoma belongs to V~4 family (Rao et al. 1997) but the DJ region was 
unknown. Primers from the beginning of the leader sequence of the published 
V~4 gene and also from the 3' of the constant ~ chain were designed to amplify 
eDNA from the 9.13 clone, as described in Materials and Methods. Upon PCR 
amplification, a single band of the expected size (950 bp -Figure 6.4) for the [3 
chain gene was observed. The amplified [3 chain gene was gel purified and 
ligated into the pcDNA3.1/zeo+ mammalian vector. The ligated product was used 
to transform competent cells and plasmid DNA from the resulting colonies was 
isolated and sequenced. From the sequencing results we confirmed the 
utilization of the V~4 gene rearranged with the D2.1-J2.1 gene segments (Figure 
6.5). Additions of N nucleotides were also observed without altering the reading 
frame of the ~ chain gene (Figure 6.5). 
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Figure 6.4 Amplification of the entire TCR-~ chain gene from the 9.13 T cell 
hybridoma clone by RT-PCR. 
RNA was extracted from the T-cell clone, and was reverse transcribed in eDNA. 
RT-PCR was performed using gene specific primers as described in Materials 
and Methods. A single band of the expected size (lane 2) contains the ~ chain 
gene. Amplification of the GADPH gene was used as positive contol (lane 3). 
PCR products were visualized in 1.5% agarose gel. lOObp DNA ladder is shown 
in lane 1. 
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ATG GGC TCC ATT TTC CTC AGT TGC CTG GCC GTT TGT CTC CTG GTG 
GCA GGT AGT CCT AGT CTT GGC CTA TAC ACC TTT GTA TTT TAC ATA 
GAA CAT CCT TCT ACA ATT ATC TTG AGG ATT AAA CTT GTT TTC TTA 
TTT CCA CAG GTC CAG TCG ACC CGA AAA TTA TCC AGA AAC CAA AAT 
ATC TGG TGG CAG TCA CAG GGA GCG AAA AAA TCC TGA TAT GCG AAC 
AGT ATC TAG GCC ACA ATG CTA TGT ATT GGT ATA GAC AAA GTG CTA 
AGA AGC CTC TAG AGT TCA TGT TTT CCT ACA GCT ATC AAA AAC TTA 
TGG ACA ATC AGA CTG CCT CAA GTC GCT TCC AAC CTC AAA GTT CAA 
AGA AAA ACC ATT TAG ACC TTC AGA TCA CAG CTC TAA AGC CTG ATG 
ACT CGG CCA CAT ACT TCT GTG CCA GCA GCC AAG ACT GGG CGT CTT 
CGT CTG AGC AGT TCT TCG GAC CAG GGA CAC GAC TCA CCG TCC TAG 
GTA AGA 
Figure 6.5 Nucleotide sequence of the eDNA encoding the 9.13 TCR b chain. 
Bold sequence represents the leader sequence of the 13 chain rearranged with the 
Vl34 -DI32.1 (italic sequence)-JI32.1 (bold sequence)-CI3 (underlined). The addition 
of N nucleotides is shown (double underlined). 
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6.3.4 High levels ofV~4 chain expression on the surface of the 9.13 T-cell hybridoma. 
To examine if 9.13 T cell hybridoma consists of one T cell population we 
looked at the level of V~4 expression on the surface of these cells. We stained the 
cells with mAbs specific for the V~4 chain as well as anti-TCR and anti-CD3 
mAbs and analysed them with FACS analysis. Since VaLl-specific mAb was not 
commercially available we only assessed ~ chain expression. Upon staining with 
anti-CD4 and anti-TCR, 77% were stained double positive, and 76% were found 
to express the V~4 chain indicating that almost 100% of the T cells were 
expressing the ~4 family (Figure 6.6). No expression of the V~4 chain was 
observed with the myeloma cell line BW5147a-~- that was used for the fusion 
during the generation of the T-cell clone (Figure 6.6). 
168 
9.13 BWa-~-
77 
-.:t l 0 0 
aS-TCR 
-.:t l 0 0 
VS4 
Figure 6.6 Phenotype ofT cells from the 9.13 T cell hybridoma. 
Cells were surface stained with anti-CD4 (y axis) and anti-a~TCR (x axis) or 
with anti-CD4 and anti-V~4 (x axis) specific monoclonal antibodies. As contol, 
cells from the BW a-~- cell line were used. The percentages of double positive cells 
are shown in the upper right boxes. 
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6.3.5 Identification of the appropriate pTa and pT~ cassette vectors upon digestion 
with combination of restriction enzymes 
In order to generate the TCR transgenic mice we used the pTa and pT~ 
cassette vectors (Kouskoff et al. 1995), for expression of the a and~ TCR chains 
respectively. To identify vectors with the correct profile, plasmid DNA was 
purified from several colonies that were obtained upon transformation of XL-10 
GOLD competent cells with pTa and pT[3. Subsequently the plasmids were 
digested with different combinations of restriction enzymes: the pTa vector was 
digested with BamHI, Sail and Sail/Notl, and the pT~ vector with EcoRI, Kpnl 
and Xhol/Sacll. The expected fragments were calculated according to the 
published map of each vector (Kouskoff et al. 1995). Specifically, digestion of the 
pTa vector with BamHI resulted in 5 bands at: 2.3 Kb, 3.0 Kb, 3.3 Kb, 5.2 Kb and 
8.5 Kb whereas digestion with the Sail and Sali/Notl resulted in 2 fragments at 5.2 
Kb and 17.1 Kb or 3 fragments at 2.8 Kb, 5.2 Kb and 14.3 Kb respectively (Figure 
6.7). Similarly, digestion of pT~ with EcoRI resulted in one band at 0.9 Kb, one at 
2.2 Kb, two bands between 3-4 Kb and a fifth band at 10 Kb. Upon digestion of 
pT~ with Kpnl a band at 17.6 Kb and one at 2.9 Kb were obtained, whereas with 
Xhol and Sacll one band at 0.6 Kb and one at 19.9 Kb were found (Figure 6.7). 
Vectors with the correct profile were further used for generation of the a and ~ 
gene constructs. 
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Figure 6.7 Restriction enzyme analysis of the original pTa (A) and pT~ (B) 
cassette vectors. 
The pTa vector was digested with BamHI (B), Sail (S) or Sail and Notl (S/N). The 
pT~ cassette was digested with EcoRI (E), Kpnl (K) or Xmal and Sacll (X/S). 
Undigested vectors are also shown (-). The ;\DNA/Hindll ladder and the 1 Kb 
DNA ladder were used to calculate the size of the digested fragments. 
Electrophoresis in 0.8% agarose gel was performed at 70V for lh 45min. 
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6.3.6 The Vfa and VD]f3 gene segments were amplified from genomic DNA and cloned 
into the pTa and pTf3 cassette vectors respectively. 
To generate the microinjection constructs, genomic DNA was isolated 
from the 9.13 T-cell hybridoma and amplification of the LVJa (~ 650 bp) and 
LVDJ~ (~ 570 bp) segments was performed as described in Materials and 
Methods. The complete LVJa segment was amplified in two sequential rounds of 
PCR (Figure 6.8) and the genomic fragment of the second round was inserted 
into the pCR4-TOPO. Plasmid DNA that contained the a chain gene was 
sequenced in order to ensure fidelity of the a chain gene segment. Genomic L VJa 
fragment that was in frame was excised from the pCR4-TOPO upon digestion 
with Xmal/Notl and its quantity was measured with the 2-Log DNA ladder. The 
VDJ~ segment was amplified using only one round of PCR (Figure 6.8) and was 
digested with Xho-I/Apa-I in order to be ligated into the pcDNA3.1/zeo+ vector. 
Genomic L VDJ~ fragment that was in frame was released upon digestion of 
pcDNA3.1/zeo+ vector with Xhoi/Sacii. The digested genomic LVJa and LVDJ~ 
fragments were ligated into similarly digested pTa and pT~ vectors 
respectivelly, using equimolar quantities, as described in Materials and Methods. 
The pTa/L VJa and pT~/L VDJ~ cassettes with the appropriate profile were 
quantified, and linearized by excising the prokaryotic sequences upon digestion 
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of the pTa cassetteswith Sal!, and the pT~ cassettewith Kpn I. The respective 
17Kb and 17.5Kb fragments were gel-purified, and quantified prior to 
microinjection. 
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Figure 6.8 Amplification of the genomic a and f3 gene segments. 
The VJa (650 bp) gene segment (A) and the VDJf3 (570 bp) gene segment (B) were 
amplified from the 9.13 T cell hybridoma genomic DNA. The a gene was 
amplified in two rounds of PCR as described in Materials and Methods. 
Amplification was performed by PCR in 35 cycles and the products were 
subjected to agarose electrophoresis (1.5% agarose gel). The 100 bp DNA ladder 
is shown. 
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6.3.7 Successful integration of the 9.13 T cell receptor a and~ chain genes. 
To examine if the TCR a and ~ transgenes successfully integrated into the 
germline of founder mice, DNA was isolated from mouse tails and subjected to 
PCR using primers specific for the 9.13 TCR a and~ chain genes. Six mice 
(defined as 2BC.F1-2BC.F6) were screened at the 4th week of age. Using the gene 
specific primers, the expected size for tha 9.13 a chain is 593 bp whereas for the 
9.13 ~chain is 591 bp. Two out of six mice (2BC.F2 and 2BC.F3) were identified to 
contain both 9.13 TCR a and~ chain genes (Figure 6.9). Internal control primers 
which amplify TCRb exon1 gene were also used in each PCR reaction in order to 
confirm the presence of sufficient amount of DNA. The expected size of the 
TCRb exon 1 amplified gene is 206 bp (Figure 6.9). 
175 
a ~ 
1.0 1.0 
tv tv tv ~ tv tv ......... tv tv tv tv tv tv......., IIl t:J:::I t:J:::I t:J:::I t:J:::I t:J:::I w IIl t:J:::I t:J:::I t:J:::I t:J:::I t:J:::I t:J:::Iw 
M~ () () () () () () 'U tv () () () () () ()'U M i-rJ i-rJ i-rJ ~ i-rJ i-rJ t--:3 0 i-rJ i-rJ i-rJ i-rJ i-rJ i-rjt--:3 ......... tv w Vl 0. ....... tv w .c.. Vl 0. 
593bu • 591 bp 
20tibp ... 206bp 
Figure 6.9 PCR demonstration for the identification of p2496-specific TCR 
transgenic mice. 
Mice that have incorporated the 9.13 a and~ TCR chains were identified by 
PCR. DNA was extracted from mice tail and a duplex PCR was performed as 
described at Materials and Methods. Primers specific for the a, ~ as well as the 
TCRb exon 1 gene were used. In each run, a no-template control and a plasmid 
control were included. Final PCR products were analysed by agarose gel 
eletrophoresis (Courtesy by Jinguo Wang). 
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6.3.8 9.13 TCR transgenic T cells specifically activates in response to p2496 in vitro. 
In order to examine if the 9.13 TCR transgenes were expressed on the 
surface of the TCR transgenic mice, spleens were isolated from founder mice and 
single cell suspensions prepared as described in Materials and Methods. As 
control wild type SJL mice were used. The cells were tested for their ability to 
proliferate in the presence of the p2496 Tg peptide or OVA antigen as control. 
Only cells from transgenic mice proliferated in the presence of p2496 Tg peptide. 
Proliferation was antigen specific since was not observed in the presence of OVA 
(Figure 6.10). The above data indicate the successful generation of transgenic 
mice that express a TCR specific for the p2496 Tg peptide. 
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Figure 6.10 In vitro T cell proliferation of p2496-specific TCR transgenic mice 
Splenocytes were isolated either from 9.13 TCR transgenic or SJL mice and were 
adjusted at 4x106 cells/mi. Cells were cultures (200 J.1l/well) in the presence of 
p2496 peptide or OVA antigen as control. Followed 56h incubation, 1J.1Ci 3H TdR 
was added to each well for the last 16h. Cells were harvested and cpm counting 
with a micro-scintillation counter was performed as described in Materials and 
Methods. (Courtesy by Jinguo Wang) 
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6.4 Discussion 
In this study, we focused on the generation of transgenic mice, that carry a 
TCR specific for the cryptic p2496 Tg peptide, on the SJL background. These mice 
will provide an abundant source of na1ve p2496-specific T cells that will be used 
to answer questions on the activation of the autoreactive T cells and their role in 
EAT pathogenesis. In addition, immmunoregulation studies will be performed 
with the aim to identify protocols to suppress the pathogenic potential of the 
p2496-specific T cells. 
For the expression of the 9.13 TCR a and~ chains we utilized the pTa and 
pT~ cassette vectors respectively. Both vectors have been engineered to contain 
natural TCR a and ~ promoter and enchancer elements in order to ensure 
specific expression of the a and~ on the T cell surface. One potential problem 
working with such large vectors (-20 Kd each) was that during cloning 
procedures several short plasmids could be obtained due to false recombination 
events. Therefore, competent cells were transformed with either pTa or pT~ 
vectors and colonies were screened with combinations of restriction enzymes (as 
described in paragraph 6.3.5) in order to identify cassettes with the correct 
profile. Upon screening, 10-20% of the vectors were found to express the 
expected profile and were further used to prepare the 9.13 constructs. Screening 
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for cassettes with the appropriate profile was also performed after the generation 
of 9.13 pTa and pT[3 constructs. 
Most of the TCR transgenic mice that have been described in the literature 
do not develop autoimmunity spontaneously (Alderuccio et al. 2000;Goverman 
et al. 1993;Lafaille et al. 1994), and this finding has been attributed in part to the 
presence of regulatory cell populations in the periphery of those mice (Olivares-
Villagomez et al. 1998;Van de and Tonegawa 1998). For example, when MBP-
specific TCR transgenic mice were crossed with RAG-deficient mice (to remove 
the non-transgenic lymphocytes), 100% of transgenic mice develop 
spontaneously EAE (Lafaille et al. 1994). In contrast to the above findings, all 
transgenic mice expressing a TCR derived from a gastritogenic CD4+ T cell clone 
developed gastritis spontaneously without need for reducing the endogenous T 
cell repertoire (McHugh et al. 2001). So far the 9.13 TCR transgenic mice have 
been backcrossed for five generations to SJL background and are housed in a 
pathogen free environment. No spontaneous development of EAT have been 
noticed in these mice indicating lack of sufficient presentation of the p2496 
peptide in vivo. Additionally, p2496-specific CD4+CD25+ T cells could exist in 
9.13 TCR transgenic mice with the ability to suppress the activation of p2496-
specific effector T cells. Immunization of transgenic mice with p2496 in CF A 
induced robust activation of p2496-specific T cells and massive infiltration of the 
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thyroid gland was observed 10 days post immunization (experiments performed 
by Jinguo Wan g) 
The p2496-specific TCR transgenic mice will provide useful information on 
the pathogenic mechanisms underlying EAT development and will allow the 
testing of various regulatory protocols aimed at the amelioration of the disease. 
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Summary 
Experimental autoimmune thyroiditis induced by Tg and adjuvant in 
mice is considered to be a model for Hashimoto's thyroiditis in man. In this 
study, we did an algorithm-based search to map Tg peptides containing Ak-
binding motifs and we identified five Tg peptides that were pathogenic in CBA/J 
mice (Chapter 3). None of the five peptides encompass dominant epitopes, but 
nevertheless, they will be very useful in the study of mechanisms that promote 
their generation within APC, thus assigning to them a potential role during the 
autoimmune cascade. One of the five peptides, p2596, was tested and found to be 
pathogenic in several H-2k strains but not in mice of b, d, s or q haplotypes 
(Chapter 4). 
The experiments in Chapter 5 describe that TNF-a-treated dendritic cells 
pulsed with Tg induce a Tg-specific CD4+CD25+ T cell population (Treg) that 
suppresses Tg-specific immune responses and Tg-induced EAT. The 
CD4+CD25+ Treg cells secrete IL-10 upon activation with Tg in vitro but 
transwell experiments indicated that soluble mediators are not sufficient to 
mediate their suppressogenic function; instead, cell-to-cell contact between these 
regulatory cells and effector cells is required. These data create a new impetus to 
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study the mechanisms underlying the induction or effector function of Tregs as 
well as to identify molecules that are engaged during this process. Additionally, 
we can investigate whether Tg-specific CD4+CD25+ T cells can revert established 
EAT, significant question from a clinical point of view. 
Finally, Chapter 6 describes the effort to generate TCR- transgenic mice 
whose T cells are specific for the cryptic p2496 Tg epitope. These mice will enable 
the isolation of large numbers of p2496-specific na!ve T cells and they will be 
extremely useful for investigating parameters that can influence: a) the 
generation and presentation of the p2596 cryptic epitope on APC and b) the 
subsequent activation of p2596-specific T cells leading to EAT development. 
Moreover, the availability of na'ive p2596-specific TCR transgenic cells may allow 
us to establish protocols under which they can become Treg with the ability to 
suppress the development of autoimmunity . 
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Chapter 7 
FUTURE DIRECTIONS 
The identification of immunodominant T cell epitopes in autoantigens has 
been critical in the study of organ-specific autoimmunity. This is because 
induction of autoimmune responses has been directed to dominant T cell 
determinants. Therefore, delineation of immunodominant epitopes will allow the 
study of immune effector mechanisms that lead to disease development as well 
as the design of antigen specific therapeutic strategies. When I started this study, 
five pathogenic Tg epitopes had been mapped and classified as non-dominant. 
Therefore, the current work was initiated with the aim to identify 
immunodominant epitope(s) within the Tg molecule. Using an algorith approach 
we discovered five new pathogenic Tg peptides in CBA mice. However, none of 
the five Tg peptides encompass a dominant epitope. Although, knowledge of an 
immunodominant Tg epitope is of great interest, identification of cryptic Tg 
determinants however, generates new questions on parameters that influence 
their generation in vivo and allow the investigation of their role in disease 
immunoregulation (Carayanniotis 2003;Moudgil and Sercarz 2005). 
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Hypothesis 1: cryptic epitopes are involved in EAT pathogenesis due to epitope 
spreading. 
The phenomenon of epitope spreading was first described in EAE 
(Lehmann et al. 1992;Lehmann et al. 1993;Moudgil and Sercarz 1994). It was 
shown that EAE mediated by intact myelin basic protein (MBP) or the 
immunodominant epitope (Ac 1-11) can spread (within 40 days post 
immunization) both inter-molecularly to other autoantigens and intra-
molecularly to other non-dominant determinants (Lehmann et al. 1992). To test 
"determinant spreading" in EAT, susceptible mice will be immunized with Tg in 
CFA. Spleen and thyroid-draining lymph node cells (LNC) will be isolated on 
day 10, 20,30 and 40 after immunization and will be examined for their 
proliferative responses against a panel of cryptic Tg peptides (those identified 
previously (Carayanniotis and Kong 2000) and in this study (Verginis et al. 2002) 
as well as intact Tg in vitro. According to our hypothesis, we should observe 
significant proliferation of Tg-primed splenocytes or thyroid-draining LNC 
against some of the cryptic peptides tested, beyond the 20 days post T g 
immunization. This result will indicate the importance of the cryptic epitopes in 
the evolution of Tg-induced EAT. In addition, it will significantly aid future 
studies on the immunoregulation of EAT studies since one should consider that 
specific immunotherapy would directed not only against the dominant epitopes 
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of an autoantigen but also against epitopes· that appear during the progression of 
the disease. 
In case that no reactivity occurs against the Tg peptides tested it could be 
possible that the autoimmune response is directed against other cryptic Tg 
pathogenic peptides that have not been identified or against epitopes from other 
thyroid autoantigens such as TP A and TSHR (intramolecular spreading). 
Additionally, cryptic peptides could become dominant intrathyroidically after 
disease progression and therefore will not be able to detect them in the draining 
lymph nodes. 
Hypothesis 2: Tg cryptic epitopes must be generated and expressed by intra-
thyroidal APC to exert their immunopathogenic effect. 
To test this hypothesis, we should first establish primary thyrocyte 
cultures, as previously described (Jeker et al. 1999), or isolate thyroid-derived 
dendritic cells that originate from normal EAT susceptible strain of mice. 
Thyrocytes or DCs will be cultured in the presence of IFN-y to up regulate the 
expression of MHC class II molecules and the co-stimulatory molecules that are 
essential for T cell activation. In parallel, we will generate T cell hybridomas or T 
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cell clones specific for the cryptic Tg pathogenic peptides. These clones will be 
cultured in the presence of the thyrocyte or DC cultures in the absence or 
presence (positive control) of exogenously added peptide. According to our 
hypothesis, significant proliferation of peptide-specific T cell clones will occur in 
the absence of the respective Tg peptide and that will indicate the intra-thyroidal 
generation of the cryptic Tg peptides. If peptide-specific proliferation does not 
occur, it could be due to not sufficient presentation of peptide in the thyrocytes 
or DCs in vitro. In this case, only thyrocytes and DCs that pulsed with 
exogenously added peptide should activate the T cells clones. 
Hypothesis 3: Cryptic Tg peptides are involved in mouse model of spontaneous 
thyroiditis development. 
One of the most studied animal models that develop SAT is the NOD.2h4 
mouse (Braley-Mullen et al. 1999). The NOD.2h4 mice develop 100% thyroiditis 
when they drink 0.05 Nai (Braley-Mullen et al. 1999;Rasooly et al. 1996). To test 
the above hypothesis, spleens and thyroid-draining lymph nodes will be 
collected from NOD.2h4 mice at the time or before of disease initiation and 
during disease progression. As negative control, NOD. SWR (H-2q) (Braley-
Mullen et al. 1999) will also be used following the same treatment. Isolated cells 
will be tested for proliferative response and cytokine secretion in the presence of 
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the known pathogenic Tg peptides (mentioned above). According to our 
hypothesis, only T cells isolated from the NOD.2h4 mice, should proliferate in 
response to the Tg peptides and should secrete significant amounts of IL-2 
and/or IFN-y. Identification of pathogenic epitope(s) in NOD.2h4 mice will allow 
us to investigate immunoregulation mechanisms (such as induction of peptide-
specific suppressor cells) in a spontaneously induced thyroiditis model. 
It has been shown that regulatory cells participate in the maintenance of 
tolerance (Sakaguchi et al. 2001;Shevach 2000). My present work demonstrates 
that DCs with semi-mature phenotype are able to induce CD4+CD25+ T cells with 
the ability to suppress Tg-induced EAT. Several questions remain to be answered 
on the induction, function and specificity of the Treg cells as well as how 
tolerogenic DCs can be formed under physiological conditions. 
Hypothesis 1: Upon endocytosis of apoptotic thyrocytes, immature DCs adapt a 
"semi-mature" phenotype similar to that induced in the presence of the TNF-a in 
vitro. 
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There is increasing evidence that immature DCs in steady state can traffic 
through tissues and pick up cells that die through apoptosis due to normal cell 
tum over (Albert et al. 1998;Huang et al. 2000;Inaba et al. 1998). To test the above 
hypothesis we will generate thyrocyte cultures (as described above) and 
apoptosis will be triggered by UV irradiation (Sauter et al. 2000). Immature DCs 
will be prepared from femurs and tibias of CBA mice as described in Materials 
and Methods and will be cultured with the apoptotic thyrocytes at cell 
equivalent ratios of 1:1, 2:1 and 1:2 for 3h at 4°C or 37°C. In order to determine if 
the apoptotic thyrocytes are efficiently phagocytosed by the DCs, both cell 
populations will be labeled with different fluorochromes (such as PKH26-GL and 
PKH67-GL red and green fluorescents respectively- Sigma) before incubation. 
Phagocytosis will be defined by the percentage of the double positive cells using 
F ACS analysis. As controls, non-apoptotic thyrocytes will be used. The DCs will 
be washed to remove the non-endocytosed thyrocytes and will be examined for 
the surface phenotype as well as the cytokines that they secrete. According to our 
hypothesis, we expect only DCs that have up taken apoptotic thyrocytes to 
express high levels of MHC class II and costimulatory molecules and to secrete 
low levels of proinflammatory cytokines such as IL-12, IL-6 and IL-l~. The 
phenotype of DCs/apoptotic thyrocytes will be compared with the phenotype of 
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TNF-a-treated DCs that have been shown to possess tolerogenic properties 
(Menges et al. 2002;Verginis et al. 2005). 
Hypothesis 2: DCs that have internalized apoptotic thyrocytes, are able to induce 
tolerance to thyroid antigens through the generation of antigen-specific 
CD4+CD25+ T cells. 
Following the rationale of the previous hypothesis, we will now examine 
if DCs that have captured apoptotic thyrocytes can induce tolerance. The 
DCs/thyrocytes will be prepared as described above, and will be injected into 
CBA mice intravenously at day 1, 3 and 5. Unpulsed DCs or DCs pulsed with 
non-apoptotic thyrocytes will be used as controls. On day 7, mice will be 
challenged with Tg or thyroid extract (peptides derived from thyroid antigens 
such as TPO could be also presented by DCs) in CFA. EAT will be assessed on 
day 21 after the antigenic challenge. I£ our hypothesis is correct, we expect to see 
a significant decrease of the EAT incidence in the group of mice that received 
DC/apoptotic thyrocytes, compared with the control groups. In parallel, 
CD4+CD25+ and CD4+CD25- T cell populations will be isolated (21 days post 
immunization) from mice that have been injected with DCs but did not receive 
antigenic challenge. Both CD4+CD25+ and CD4+CD25- T cell populations will be 
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tested for their function in cultures with the effector T cells isolated from Tg- or 
thyroid extract-immunized syngeneic mice. According to our hypothesis, only 
CD4+CD25+ T cells from mice challenged with DC/apoptotic thyrocytes should 
suppress the effector T cells. 
In case that the data obtained from these experiments do not support the 
hypothesis it could be due to presence of other antigens that are contained in the 
apoptotic thyrocytes and compete with the Tg peptides for presentation by the 
DCs. 
Hypothesis 3: Suppression of Tg-specific autoreactive T cells, mediated by the 
CD4+CD25+ T cells generated by Tg/DCs, is antigen-specific and is not due to 
bystander effect. 
According to my results, the activation and/or expansion of Treg cells by 
Tg/DC, but not OVA/DC, indicates that the phenomenon is Tg-specific. To 
examine if the suppressor effector function of the Treg is antigen specific, we will 
utilize Tg pathogenic peptides as antigens. Several studies have demonstrated 
the presence of Treg cells specific for dominant self-peptides (Cozzo et al. 
2003;Mukherjee et al. 2003;Picca and Caton 2005;Yu et al. 2005). To test our 
hypothesis, TNF-a-treated DCs will be pulsed with p2596 Tg peptide (randomly 
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selected) and will be injected i.v. into CBA mice on day 1, 3 and 5. On day 7, mice 
will be s.c. immunized with p2596 or p306 in CF A. Control mice will receive PBS 
instead of the DC injections. Twenty-one days later, mice will be sacrificed for 
assessment of thyroiditis. A decrease in EAT incidence is expected in mice that 
receive DC/p2596 and immunized with p2596 but not p306 Tg peptide, as 
compared to the control group. This finding will indicate that DC/p2596 activate 
p2596-specific Treg that suppress p2596-specific T cell responses. Additional 
evidence supporting our findings will be obtained by in vitro experiments. 
CD4+CD25+ T cells will be isolated from splenocytes of mice challenged with 
DC/p2596 (3x as above) and will be used as suppressors. Effector cells will be 
isolated from the lymph nodes of mice that have been challenged with p2596 or 
p306 Tg peptide. Effector cells will be cultured in the presence or absence 
(control) of the suppressor cells (at equimolar ratio) as well as syngeneic APC 
and the respective peptide. If our hypothesis is correct, significant decrease in the 
proliferation of the p2596-effector but not of the p306-effector T cells should be 
demonstrated when compared with cell proliferation in control cultures. 
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Hypothesis 4: Tg-specific CD4+CD25+ T cells can reverse established EAT. 
To test this hypothesis, we will first isolate CD4+CD25+ T cells from 
DC/Tg- and DC/OV A-challenged CBA mice, as described above. Syngeneic mice 
will be immunized with 100 !J.g Tg in CFA. Three weeks later, some mice will be 
sacrificed to assess EAT. Based on our results, at that time point mice develop 
EAT with mean I.I. of 2.2. The remaining mice will be boosted with 50 !J.g Tg in 
IFA and will also be challenged i.p. with CD4+CD25+ T cells from DC/Tg or 
DC/OV A-challenged mice. Control group will receive PBS instead of 
CD4+CD25+ T cells. Two weeks later all mice will be sacrificed and thyroids will 
be assessed for EAT development. According to our hypothesis, mice that 
received CD4+CD25+ Treg cells from DC/Tg- but not DC/OV A-treated mice 
should have decrease EAT incidence compared with the control group. 
Finally, the TCR transgenic line specific for the p2496 Tg peptide, 
described in Chapter 6, provides an invaluable tool to study mechanisms that are 
involved in the precipitation or amelioration of EAT. Although in our TCR-
transgenic model high frequency of p2496 Tg peptide-specific T cells will be 
obtained it is difficult to predict if mice will develop or not EAT. Therefore, we 
hypothesize that the TCR-transgenic mice will not develop spontaneous EAT. 
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Hypothesis 1: In vivo presentation of the p2496 by DC results in the activation of 
p2496-specific Thl cells and induction of EAT. 
To test this hypothesis, BM-DC will be isolated from SJL mice (as described 
above) and will be cultured in the presence of LPS for 24h in order to mature. 
Maturation of DCs will be examined by flow cytometry for upregulation of MHC 
class II and B7.1/B7.2 expression by sandwich ELISA for secretion of IL-12, IL-l 
and IL-6. In the next step, DCs will be pulsed with p2496 for 6h and will be 
adoptively transferred i.p. into TCR transgenic mice specific for the p2496. 
Control mice will receive unpulsed DCs or DC pulsed with another pathogenic 
Tg peptide. Twenty-one days after the DC/peptide transfer, mice will be 
sacrificed and thyroids will be collected and assessed for EAT. According to our 
hypothesis, mice received p2496-pulsed DCs will develop EAT in contrast to 
control mice, which should be free of disease. Based on our results, we can 
conduct a time-kinetic of the EAT induction by collecting thyroids at different 
times after the DC transfer. We can also adoptively transfer peptide-pulsed DC 
for three consecutive days to achieve higher incidence of EAT. Priming of p2496-
specific Thl will be examined by T cell proliferation and cytokine release of cells 
isolated from the spleen of the TCR transgenic mice 10-14 days after DC transfer. 
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These experiments will allow us to develop an EAT induction model without the 
use of adjuvants or in vitro T cell activation. 
Hypothesis 2: Processing of I-Tg by DCs leads to generation of p2496 and 
activation of p2496-specific T cells in vivo. 
Previous work in our lab, demonstrated that processing of I-Tg but not Tg by 
DCs results in the generation of the cryptic p2496 Tg peptide (Dai et al. 2002). 
Using the p2496-specific TCR transgenic mice, we can assess the above 
hypothesis directly in vivo. DCs will be pulsed with I-Tg, Tg or the p2496 Tg 
peptide and will subsequently treated with LPS to mature. Unpulsed mature 
DCs will be used as controls. Antigen-bearing or unpulsed DCs will be 
adoptively transferred i.p. into the TCR transgenic mice. Priming of CD4+ T cells 
will be monitored 12-14 days after cell transfer. Splenocytes will be isolated and 
cultured in the presence of I-Tg, Tg, p2496 and control peptide. According to our 
hypothesis, T cells isolated from mice that challenged with DC/I-Tg and 
DC/p2496 and not with DC/Tg should proliferate and secrete IL-2 and IFN-y 
against the respective antigens in vitro. Moreover, transgenic T cells from DC/I-
Tg- or DC/p2496-challenged mice will proliferate in the presence of p2496 and I-
Tg respectively. Additional evidence to support our hypothesis will be obtained 
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from the histology of the thyroid gland of the above groups of mice. Specifically, 
we expect to observe induction of EAT in mice that received DC/I-Tg and 
DC/p2496. 
Hypothesis 3: presentation of p2496 by smDCs can lead to the expansion of 
p2496-specific CD4+CD25+ Treg cells. 
To test our hypothesis, we will prepare smDCs (as described above) and 
pulse them with p2496 peptide. The smDC/p2496 cells will be adoptively 
transferred on day 1, 3 and 5 into the p2496-specific TCR transgenic mice. 
Control mice will be challenged with unpulsed DCs at the same time points. The 
mice will be divided in three groups, which will be sacrificed on days 10, 15 and 
20 post-transfer, and splenocytes will be collected. CD4+CD25+ and CD4+CD25-
T cells will be prepared and will be tested in vitro by proliferative assays and 
cytokine production in the presence of p2496 or a control Tg peptide. Only 
CD4+CD25- T cells should strongly proliferate in the presence of p2496 in vitro. 
To support our hypothesis, we will conduct a mixing experiment where 
CD4+CD25+ T cells should suppress the proliferation of syngeneic p2496-specific 
CD4+CD25- T cells. If the results support our hypothesis, we will seek additional 
confirmation by transferring p2496-specific CD4+CD25+ T cells (generated as 
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above) into syngeneic mice that have been challenged with p2496 in CF A prior to 
or post T cell transfer and monitor EAT. Control mice will receive CD4+CD25+ T 
cells isolated from mice challenged with DCs alone or with DC that present 
another Tg pathogenic peptide. We expect to observe amelioration of EAT only 
in mice that received p2496-specific CD4+CD25+ T cells. 
If CD4+CD25+ T cells cannot inhibit EAT induction, despite their 
suppressive activity in vitro, it might be due to not sufficient cell numbers that 
were transferred. Therefore, we will perform kinetics to determine the adequate 
number of CD4+CD25+ T cells that have to be transfered in CBA mice to 
ameliorate EAT. 
Hypothesis 4: FoxP3-transduced p2496-specific T cells can suppress EAT. 
Recent studies have demonstrated that expression of FoxP3 on antigen-
specific T cells can revert them to regulatory T cells with the potential to 
suppress autoimmunity (Fontenot et al. 2003;Jaeckel et al. 2005). To test the above 
hypothesis, FoxP3 mRNA will be isolated from SJL mice and eDNA will be 
amplified using gene-specific primers with incorporated restriction sites. The 
amplified eDNA fragment will be cloned into a retroviral vector (Moloney 
murine leukemia virus MML V) as previously described (Fontenot et al. 
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2003;Loser et al. 2005). Empty retroviral vector will be used as control. 
Retrovirus-containing supernatants (encoding FoxP3 or "empty") will be 
collected upon transfection of a packaging cell line (commercial available) with 
retrovirus encoding plasmid DNA. CD4+CD25- T cells isolated from the spleens 
of either from p2496-specific TCR transgenic mice or naive SJL mice will be 
infected with high titers of FoxP3-containing or "empty" retrovirus using 
centrifugation as described (Jaeckel et al. 2005). Sufficient expression of FoxP3 on 
infected cells will be monitored by F ACS analysis. To test our hypothesis, p2496-
specific CD4+CD25- T cells (effectors) isolated from TCR transgenic mice will be 
cultured with p2496 peptide and syngeneic APC as well as equal numbers of 
CD4+CD25- T cells expressing or not FoxP3 (regulators). Only effector cells 
cultured with CD4+CD25- T cells infected with the "empty" retroviral vector 
should proliferate and secrete IL-2 and IFN-y in response to p2496 in vitro 
whereas FoxP3-expressing p2496-specific CD4+CD25- T cells should suppress the 
proliferation of the p2496-specific effector cells. In addition, retroviraly-infected 
CD4+CD25- T cells will be adoptively transferred (3X) to p2496 TCR transgenic 
mice on day 0 and on day 1 mice will be immunized with p2496 in CF A. Another 
group of mice will receive PBS and will be used as additional control. If our 
hypothesis is correct, TCR transgenic mice that received FoxP3-expressing p2496-
expressing CD4+CD25- T cells will shown decreased incidence of EAT compared 
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with control groups. Additional evidence for the suppressogenic properties of 
FoxP3-expressing antigen-specific CD4+CD25- T cells could have a therapeutic 
potential in patients with autoimmune thyroiditis. 
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